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Abstract 
There are currently 30 extracellular proteins known to form pathogenic amyloid 
within the human body. These proteins result in a wide range of diseases described as 
amyloidoses. These amyloidoses can be either systemic, affecting multiple organs, or 
localised to a single tissue. Almost all systemic amyloidoses can have cardiac 
manifestations and cardiac involvement correlates with poor prognosis. Cardiac 
infiltration is most commonly associated with AL amyloidosis, with 50 % of patients 
presenting with heart failure at the time of diagnosis.  
In addition to the myocardium, amyloid deposits are frequently reported in the 
surrounding vasculature. The most common form of localised amyloid – aortic 
medial amyloid (AMA) - is primarily localised to the internal elastic laminae of the 
ascending aorta. It is estimated to be present in 97 % of the Caucasian population of 
50 years of age but despite its prevalence there remains very little information 
available about the structural, biophysical and aggregation properties of the main 
protein component, a 5.5 kDa peptide termed medin. Clinically, it has been 
suggested that AMA may have a role in aortic aneurysm and dissection through 
binding to the elastic structures of the aorta and reducing elasticity.   
 
This work aimed to further our molecular-level understanding of amyloid aggregates 
formed by proteins, known to affect the cardiovascular system; medin, and a model 
peptide for AL amyloidosis, SMA.  
 
Initially, this work investigated the structural and biophysical properties of three 
medin derived peptides with a view to identifying key amyloidogenic regions that 
could be targeted therapeutically. Furthermore, this work established that small 
ii 
medin peptides were not suitable structural models for full length medin. It was 
therefore necessary to develop a reliable method for the production of full-length 
medin. This work describes for the first time a procedure for the expression and 
purification of soluble medin in both unlabelled and 
13
C/
15
N labelled forms in E.coli 
for future biophysical and structural investigations. The recombinant medin was then 
characterised using a variety of techniques commonly used for the characterisation of 
amyloid proteins. These results indicated that medin aggregation proceeds via a 
nucleation dependent mechanism with a lag time of 30 hours and forms amyloid-like 
fibrils visible by transmission electron microscopy. Structural and biophysical 
studies were coupled with computational techniques to generate a structural model of 
medin fibrils, stabilised by a salt bridge between residues D25 and K30. Salt bridge 
mutations gave rise to aggregates with altered aggregation mechanisms and 
morphology. 
 
It is not known what causes some immunoglobulin light chain fragments involved in 
AL amyloidosis to become pathogenic. It is possible that structure underlies the 
differences. This work demonstrates a protocol for producing isotopically labelled 
immunoglobulin light chains, in particular a model protein SMA, and subsequent 
NMR analysis to detect inter-nuclear contacts within aggregates. 
 
Collectively this work has identified key regions and features of medin that could be 
targeted in future for therapeutic or diagnostic purposes. Furthermore, it paves the 
way for further structural studies of aggregates formed by immunoglobulin light 
chains.  
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1 
1. Introduction 
The term amyloid was first used by Virchow in 1857 to describe ‘starch-like’ 
deposits within tissue that stained with iodine and sulphuric acid (Virchow, 1857). It 
is now known that this phenomena is due to accessory components not the fibrillar 
content (Pras, 1968). For approximately the next 100 years the only tools available to 
study amyloid proteins were light microscopy and a variety of dyes (Buxbaum and 
Linke, 2012). In the 1920’s it was established that all amyloid deposits bind the dye 
Congo red (CR) and exhibit apple green birefringence when viewed under polarised 
light (Puchtler et al., 1962, Divrey, 1927). It remains unclear exactly how CR binds 
to amyloid deposits, but it still remains a diagnostic characteristic of amyloid. Later 
developments in biochemistry have greatly increased our understanding of the 
biophysical and structural properties of amyloid deposits and are now included in the 
definition of amyloid. 
The international society for amyloidosis now defines amyloid as insoluble protein 
fibrils, primarily found in the extracellular spaces between organs and tissues that 
result in alternative protein folding and ultimately a condition known as amyloidosis 
(Sipe et al., 2012). Amyloid fibril proteins have characteristic structural and tinctorial 
properties, they occur as non-branching fibrils approximately 10 nm in diameter, 
have a distinguishing cross- pattern when studied by X-ray fibre diffraction 
(XRFD) and bind CR  (Sipe et al., 2012, Divrey, 1927, Puchtler et al., 1962).  
1.1. Amyloid and disease 
Diseases linked with amyloid affect a wide range of tissues and are associated with 
high morbidity and mortality rates. The amyloidoses can be divided into localised 
and systemic diseases. Localised amyloid affects a single tissue type whereas 
systemic amyloid affects multiple tissues and organs.  These can be acquired, as seen 
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in amyloid light chain (AL) and serum amyloid A (AA) amyloidosis, or hereditary in 
transthyretin (ATTR) variant and apolipoprotein A1 (AApoA1) amyloidosis (Table 
1.1).  
The signs and symptoms associated with the amyloidoses are highly variable and 
differ greatly between the different diseases. Several amyloid-associated diseases are 
localised to the brain and result in neurodegeneration and cognitive decline 
(Bredesen, 2009). In systemic amyloidoses, such as AL amyloidosis, symptoms 
include heart failure, hepatomegaly and autonomic or sensory neuropathy 
(Sanchorawala, 2006).  
3 
Table 1.1 Summary of the different types of amyloid with cardiovascular manifestations including examples of specific pathologies and 
the respective protein components, adapted from (Banypersad et al., 2012). Those diseases and proteins italicised comprise the focus of 
this thesis.  
Disease Protein 
Cardiovascular 
involvement 
Other organ 
involvement 
Treatment Prognosis Prevalence 
AL amyloidosis 
Monoclonal light 
chain 
40-50% 
Kidneys, liver, 
soft tissue, PNS 
Chemotherapy or stem 
cell transplantaion 
48 months or 8 if 
cardiac tissue 
involved 
Affects 1 in 130000  
ATTR 
 
wild type 
transthyretin 
>90% 
Carpel tunnel 
syndrome 
supportive 7-8 years 
25 % in people 
over 80 years of 
age 
mutant transthyretin 
mutant 
 
Range from rare to 
>90% depending on 
mutation 
PNS, Carpel 
tunnel 
syndrome 
Liver transplant or 
supportive therapy 
Variable depending 
on mutation and 
treatment 
Variable depending 
on mutation,  
AA amyloidosis serum amyloid A Rare Kidneys 
Treat underlying 
inflammatory disease 
good 
0.5-0.89 % of the 
population 
A2M 2-Microglobulin rare joints kidney transplant variable 
48 % of patients on 
long term dialysis 
but number falling 
 
Aortic medial 
amyloid (AMA) 
 
medin 100% unknown none unknown 
90 % of caucasion 
population over 50. 
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1.1.1. Pathogenicity 
Despite the advances in amyloid research, the pathogenic species and thus the 
causative agent of these devastating diseases remains unclear. The role of fibrillar 
deposits in the pathogenicity of amyloidosis continues to be debated. It is still 
inconclusive whether they represent a causative agent or are merely a secondary by-
product of the pathology. This primarily arises from results indicating that there is no 
correlation between the amount of insoluble plaques of A present in the brain and 
the degree of cognitive decline (Näslund et al., 2000). Conversely, it appears that 
higher concentrations of soluble Aβ correlated with cognitive impairment in patients 
with Alzheimer’s disease (Wang, 1999). The hypothesis that deposits are merely by-
products is further substantiated by evidence that amyloid plaques can be observed 
many years before clinical symptoms appear (Perrin et al., 2009). In vitro studies 
have also shown that  pathogenicity is linked to the level of aggregation. 
Monomeric or highly aggregated fibrils are not toxic, but small oligomeric species 
are in some cases cytotoxic (Kayed et al., 2003, Madine and Middleton, 2010, 
Bucciantini et al., 2002, Fändrich, 2012). The toxicity of oligomeric species has 
focussed attention on the multimeric intermediate species in the amyloidogenesis 
pathway 
5 
 
 
Figure 1.1 Schematic to illustrate some of the possible mechanisms of amyloid 
toxicity caused by multimeric intermediates within the amyloid pathway. 
(Berthelot et al., 2013). 
 
Many of the proposed cytotoxic mechanisms of these oligomers involve disruption 
and destabilisation of the lipid membrane (Figure 1.1) (Stefani, 2007, Berthelot et al., 
2013).  
Many studies have reported accelerated aggregation in the presence of lipids and 
membranes, resulting in carpeting and raft formation, whereby amyloid proteins 
assemble on or within the membrane preventing normal membrane activity. (Necula 
et al., 2003, ChooSmith et al., 1997, Knight and Miranker, 2004). Although these 
interactions are far from fully understood it seems that hydrophobic interactions are a 
key determinant in how different amyloid proteins behave in the presence of lipids 
(Berthelot et al., 2013).   
Amyloid proteins are also capable of interfering with normal membrane physiology 
at different stages of aggregation (Williams and Serpell, 2011). For example, 
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monomeric A can impede the diffusion of metabotropic glutamate receptors 
through binding of the synaptic plasma membranes which results in abnormal Ca
2+
 
mobilization (Renner et al., 2010). A further mechanism involves the formation of 
pores within the membrane resulting in cytotoxicity (Demuro et al., 2011, Butterfield 
and Lashuel, 2010, Milanesi et al., 2012)  
Notwithstanding the confusion surrounding the cytotoxic mechanisms of oligomeric 
species, these are more commonly observed in neurodegenerative amyloidoses. 
The primary pathology associated with systemic diseases is the deposition of 
amyloid within the visceral organs. It remains evident that large quantities of 
amyloid deposits, in sometimes kilogram amounts, can impair organ function and 
damage tissue structure (Pepys, 2001).  
1.1.2. Additional components 
Amyloid deposits are always found associated with other proteins, 
glycosaminoglycans (GAGs) such as heparan sulphate, and proteoglycans (Papy-
Garcia et al., 2011, Pepys, 2001, Ariga et al., 2010). GAGs and other additional 
components are important in the process of fibrillogenesis and understanding their 
role in plaque formation may provide ways of modulating amyloid formation. 
Furthermore they can be useful tools for the development of imaging techniques or 
diagnostics. Several components in particular are well documented to be found in 
amyloid plaques; one such protein is serum amyloid P (SAP) protein (Pepys et al., 
1997). This protein has been shown to bind to amyloid fibrils in vitro in a calcium 
dependent manner (Pepys et al., 1979). Later work has exploited this interaction and 
led to the development of new imaging techniques that use SAP, labelled with iodine 
isotopes 123 or 131, to image deposits within the body (Hawkins et al., 1998, Lovat 
et al., 1998b). This is a very effective method for imaging deposits in patients with 
7 
systemic amyloidoses but it is unclear whether it is sufficiently sensitive to image 
smaller deposits in the brain (Lovat et al., 1998a). 
Many studies have documented the presence of glycosaminoglycans (GAGs) within 
amyloid deposits in vivo e.g. (Stevens  and Kisilevsky, 2000) GAGs are large un-
branched polysaccharides consisting of repeating disaccharide units. Cardiac tissue 
containing amyloid deposits have been shown to have 5-fold increase in GAGs 
(Ohishi et al., 1990) The presence of GAGs has also been shown to increase the rate 
of aggregation (Cohlberg et al., 2002, Madine and Middleton, 2010). The intimate 
relationship between amyloid fibrils and GAGs is currently being exploited for new 
therapeutic options. This is discussed further in Section 1.5.2. 
1.2. Protein folding and mis-folding 
Protein folding is a process whereby polypeptide chains transform into specific three-
dimensional structures. This conversion is prerequisite to the biological function of a 
protein and is an important means of biological control. The current theory 
describing this process utilises the concept of a funnelled energy landscape (Onuchic 
and Wolynes, 2004). This theory assumes that the native fold of a protein 
corresponds to the structure with the lowest free energy. Initially, a polypeptide chain 
samples many possible conformations but as interactions start to occur, lower energy 
structures are selected, and ultimately this results in the native fold. The landscape is 
often described as rugged to account for the multiple non-native local minima and 
may act as kinetic traps along the route to the native fold (Figure 1.2). 
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Figure 1.2 Schematic of the rugged funnel energy landscape of protein folding. 
As a protein interacts and starts to fold, free energy is reduced. The pathways 
highlighted in green indicates possible routes to the native fold, including small 
kinetic traps that can be overcome with the help of chaperones. The landscape 
also features local energy minima that can act as kinetic traps for mis-folded 
proteins (red) that may result in amyloid formation.  
 
Some of these traps can be overcome with the help of chaperone proteins but, in 
some cases the mis-folded protein can aggregate (Dobson, 2003, Dobson, 2006, Chiti 
and Dobson, 2006). The mis-folded protein may form well ordered aggregates that 
act as the precursor to amyloid formation (Figure 1.3) 
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Figure 1.3 Schematic illustrating some possible routes to amyloid formation. 
Green arrows indicate the correct route to the native fold and red arrows 
indicate disadvantageous routes. The large arrows indicate the most kinetically 
favourable route. Degraded fragments can become incorporated into amyloid 
fibrils, indicated by the dashed red line. 
 
1.3. Mechanisms of aggregation 
1.3.1. Destabilisation of the native fold 
There are many different factors that can cause proteins and polypeptides to mis-fold 
and aggregate. In some cases aggregation follows cleavage from a precursor protein 
as in the case of Aβ (Tomita et al., 1998). In other examples, aggregation results 
from destabilisation or conformational change of the intermediates or native fold. 
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These can occur as a result of mutation (Steward et al., 2008), membrane binding 
(Williamson et al., 2009), molecular crowding (Hatters et al., 2002), binding of metal 
ions (Mantyh et al., 1993) or the presence of a seed (further details in section 1.3.4) 
(Paravastu et al., 2009). It is thought that this destabilisation exposes aggregation 
prone regions, which are then able to self-assemble and form amyloid-like structures. 
1.3.2. Non-pathogenic fibril formation 
It has been suggested that fibril formation is a generic property of all polypeptides 
and that under the right destabilising conditions all proteins are capable of forming 
fibrillar species (Pertinhez et al., 2001). This was first noticed fortuitously but has 
since been observed with many plasma proteins with no known disease links (Chiti et 
al., 2001, Sunde and Blake, 1998) . It should be noted that the conditions required to 
destabilise some of these proteins, such as low pH, are frequently non-physiological 
and thus these proteins differ from their pathogenic counterparts which are capable 
of aggregating in vivo. 
1.3.2.1. Functional amyloid 
There is a further sub-class of proteins utilising an amyloid-like protein fold to 
perform a function.  There are many examples in nature, in a wide variety of 
organisms, such as: curlin in E.Coli (Chapman et al., 2002), spidroin in N. edulis 
(Kenney et al., 2002), the intra-lumenal domain of Pmel17 (Berson et al., 2003) and 
the organisation of hormones stored in secretory vesicles (Maji et al., 2009) in 
humans. 
1.3.3. Nucleation dependant polymerisation 
Nucleation dependent polymerisation is the current leading theory for amyloid 
formation and growth. The assembly process is characterised by three distinctive 
features, a lag phase, a nucleation step, and a growth and elongation phase (Figure 
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1.4). Initially a lag time is observed, during which monomeric protein and small 
soluble oligomers associate to form a critical nucleus. During this stage aggregates 
are usually undetectable by electron microscopy (Chiti and Dobson, 2006).  The 
process of nucleation  is kinetically unfavourable and is highly dependent on protein 
concentration and other variables such as pH and salt concentration (Jarrett and 
Lansbury Jr, 1993). It is this nucleus formation that represents the rate limiting step 
in amyloid formation. Once the critical nucleus is formed, amyloidogenesis enters a 
growth and elongation phase. This process is thermodynamically favourable and 
proceeds rapidly resulting in the formation of fibrillar species with amyloid 
characteristics, detectable by electron microscopy (Figure 1.4). The majority of 
aggregation kinetic studies monitor aggregation using the benzothiazole salt 
Thioflavin T (ThT). Upon binding to -rich structures, ThT exhibits enhanced 
fluorescence and a red shift in its emission spectra. Monitoring the fluorescence 
increase allows researchers to observe aggregation, often in real time and 
subsequently calculate kinetic parameters. 
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Figure 1.4 Schematic of amyloid nucleation dependant growth theory. The blue 
growth curve indicates normal amyloid formation and the red curve highlights 
the change upon addition of a seed. The vertical dotted line designates the point 
of nucleation. 
 
1.3.4. Seeding 
Seeding is the term given to the process of adding pre-formed aggregates or a 
‘nucleus’ to monomeric proteins to eliminate the lag phase (Figure 1.4 red growth 
curve) (Come et al., 1993). This phenomenon has been observed both in vitro (Kim 
et al., 2007, Petkova et al., 2005a, Jarrett and Lansbury Jr, 1993) and in vivo (Prado 
and Baron, 2012, Rosen et al., 2012, Jucker and Walker, 2011). Seeding usually 
requires a high degree of similarity between the seed and the elongating species (i.e. 
homologous seed) but there is evidence that cross-seeding can occur between protein 
species. The most notable example of heterologous seeding can be observed in the 
relationship between bovine spongiform encephalopathy and Creutzfeldt-Jacob 
disease, where the bovine protein (93 % sequence identity) has been shown to be 
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able to seed the human protein (Mabbott and MacPherson, 2006). More recently it 
has been shown that one amyloid protein is capable of seeding a protein with a 
different origin (Larsson et al., 2011). A study investigating the effect of sequence 
identity on seeding kinetics revealed a high level of sequence identity gave rise to 
optimal seeding. However mutant studies have shown that primary sequence 
similarity is not as important as structural similarity between the fibril growth face 
and the seed (O'Nuallain et al., 2004, Krebs et al., 2004). Studies investigating cross-
seeding between A and islet amyloid polypeptide (IAPP) demonstrated that A was 
able to seed IAPP but not vice versa implying that heterologous seeding can be one-
directional (O'Nuallain et al., 2004). It is unknown whether these cross-seeding 
interactions occur in vivo and what the potential implications could be with regards 
to toxicity and therapeutics. 
1.4. Biophysical characteristics of amyloid 
The recent development of structural and biophysical techniques has led to the 
elucidation of structural and biophysical characteristics.  
1.4.1. Cross- pattern 
Amyloid fibrils typically comprise rigid non-branching fibrils with an approximate 
diameter of 6-12 nm and exhibit a typical cross-β pattern when analysed by X-ray 
fibre diffraction (XRFD) (Jahn et al., 2010, Serpell et al., 2000). The cross- pattern 
consists of a diffuse reflection at 4.7 Å along the meridian, suggestive of elongated 
protein chains running approximately perpendicular to the fibril long axis. Also a 
more diffuse reflection at 10 Å along the equator, indicative of sheets spaced 10 Å 
apart (Sunde et al., 1997).  This cross-β structure refers to the spine of the fibril and 
is common to all amyloid proteins, regardless of the primary sequence (Panel A, 
Figure 1.5).  
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1.4.2. Tertiary structure 
Within this cross- structure the β-sheet pairs can be orientated parallel or anti-
parallel to each other (Balbach et al., 2000, Petkova et al., 2004). The structure is 
formed and stabilised by hydrogen bonding through the backbone amide groups 
(Makin, 2005). Furthermore, in the majority of structures obtained, the β-sheets lie 
‘in-register’ with one another, i.e. identical side chains lie directly on top of one 
another. The structure is therefore further strengthened by hydrogen bonding through 
side chains containing amine groups. In such assemblies, the side chains are tightly 
inter-digitated into a ‘steric zipper’ (Sawaya et al., 2007).  Eight classes of steric 
zipper have been described that denote: the face orientation and side chain 
orientations and whether the strands are parallel or anti-parallel (Panel B, Figure 1.5) 
(Sawaya et al., 2007). 
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Figure 1.5 Amyloid cross-β structure and steric zipper orientations. Schematic 
of the amyloid cross-β structure (A). The eight classes of steric zipper taken 
from Sawaya, Sambashivan et al. 2007 (B). 
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The most common of these arrangements is face to face (Panel B, class 1 Figure 1.5) 
(Eisenberg and Jucker, 2012) but other arrangements have been observed, in some 
cases, multiple steric zippers from the same protein (Lewandowski et al., 2011). 
In accordance with the classifications described, 30 amyloid-forming proteins are 
defined as amyloid (Sipe et al., 2012) The field is further complicated by the study of 
peptide fragments, synthetic peptides and recombinant peptides which according to 
the current classifications should be referred to as ‘amyloid-like’ (Sipe et al., 2012). 
Accordingly, for the remainder of this thesis, fibril assemblies observed from 
recombinant or synthetic protein will be referred to as ‘amyloid-like’. 
1.4.3. Quaternary structure of amyloid proteins 
Despite the uniformity of cross- structure in amyloid forming proteins there is 
variation in the quaternary structure. This quaternary structure is generated through 
intra molecular contacts between amino acid side chains that project out from the -
sheet assemblies. It has been shown that single amyloid proteins can have multiple 
quaternary structures, characterised in vitro. A good example of such a protein is 
amyloid- (A), associated with Alzheimer’s disease. A is arguably the best 
characterised amyloid protein studied to date and much of our understanding about 
amyloid structure, aggregation and pathogenicity is derived from studies on A. 
Under different conditions Ais capable of forming at least two very different 
morphologies. When incubated under quiescent conditions, A forms a triangular 
assembly with three-fold symmetry, however, when incubated with agitation it forms 
a structure with two-fold symmetry (Panels, A and B respectively, Figure 1.6) 
(Petkova et al., 2005b, Paravastu et al., 2008). Furthermore, a single point mutation 
in Aresults in a third quaternary assembly unlike those from the wild type 
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structures (Qiang et al., 2012). These structures with be discussed in more detail in 
chapter 5.  
 
Figure 1.6 Examples of quaternary structures of A determined by solid state 
NMR viewed down the fibril long-axis. A formed under quiescent (A) and 
agitated (B) conditions. TEM micrographs of the corresponding morphologies 
shown below. (C and D) 
 
In turn these differences at the molecular level result in different fibril morphologies. 
Panels C and D (Figure 1.6) shown TEM images of two different A morphologies 
formed from under quiescent and agitated conditions respectively.  
1.5. Therapies 
Despite the prevalence and growing awareness of the amyloidoses there is no 
available cure and current treatments are often toxic or invasive and carry a high 
level of risk. Currently, finding new and alternative therapeutics capable of 
effectively targeting these devastating diseases is being prioritised. Figure 1.7 details 
some of the different strategies currently being explored. 
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Figure 1.7 Schematic illustrating various strategies for targeting amyloid 
protein species therapeutically. Several approaches aim to reduce the amount of 
source protein that could go on to aggregate. Alternatively, it may be possible to 
prevent oligomer association in turn preventing fibril formation. Additionally, 
some therapeutics target the mature plaques. There is a further class of 
therapeutics that target the effects of amyloid deposition rather than the protein 
component. 
 
1.5.1. Targeting the source 
The majority of current treatments against the systemic amyloidoses in particular, are 
centred on the removal of the precursor protein. The precursor can be either a wild 
type protein or a protein from which the amyloidogenic peptide is cleaved such as 
immunoglobulins, which are cleaved to generate free light chains. Patients suffering 
from AA amyloidosis are treated with anti-inflammatory drugs to reduce the levels 
of the causative protein serum amyloid A (Gillmore and Hawkins, 2006). Current 
treatments for AL amyloidosis involve administering highly toxic chemotherapeutic 
agents, such as melphalan and dexamethasone, and can cause severe side effects. 
Patients with hereditary amyloidoses often require organ transplantation to remove 
the source of the aberrant transthyretin protein (Dubrey et al., 2011).  
It is clearly desirable to develop new therapeutic strategies that are less toxic or 
invasive.  
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1.5.1.1. Stabilising the native fold 
As described in section 1.3.1, amyloid formation can occur following the 
destabilisation of a protein’s native fold. Therefore a possible strategy for drug 
design is to stabilise of the native fold, preventing monomer dissociation and 
amyloid formation. Bulawa et. al. (2012) have developed a small molecule to 
stabilise the native tetrameric fold of TTR, and reduce the number of available 
monomers for amyloidogenesis. This drug, Tafamadis™, is currently undergoing 
clinical trials and early results are promising (Bulawa et al., 2012). 
1.5.2. Inhibit fibrillogenesis 
A second strategy for reducing amyloid toxicity is to inhibit fibrillogenesis. This can 
take the form of targeting co-localising factors such as GAGs or the peptide 
assemblies themselves. As discussed previously, GAGs are often found to accelerate 
amyloid formation. The GAG mimetic agent eprodisate (Fibrillex™) binds to the 
GAG binding site on the amyloid protein serum amyloid A and prevents GAG 
binding and halts amyloidosis. Eprodisate (trade name Fibrillex™) reached stage 
II/III clinical trials, although without meeting the endpoint criteria, patients did show 
signs of improvement and delay in the onset of disease (Manenti et al., 2008). 
Further studies are being carried out on Fibrillex™ and GAG mimetics remain a 
plausible option for amyloid therapies. 
A rational element can be introduced into the design of amyloid inhibitors, by 
targeting a sequence or region driving aggregation, known as the self recognition 
element (SRE). Following identification, peptide or small molecules can be designed 
to bind to this region and perturb or prevent further association of peptides, thus 
limiting elongation (Amijee et al., 2009). This strategy has been previously shown to 
be effective in inhibiting A fibrillogenesis and disassociating preformed fibrils in 
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vitro. A five residue peptide (LPFFD) was designed based on the amyloidogenic 
region (LVFF) to include a proline residue with the intention of disrupting -sheet 
formation.  Furthermore, it reduced deposition of A in vivo and blocked fibril 
formation in a rat brain model of Alzheimer’s disease (Soto et al., 1998).  Problems 
have occurred when some peptide based inhibitors have been identified as capable of 
forming amyloid.  
An alternative strategy is to disrupt the hydrogen bonding network. Two methods of 
achieving this are outlined in Figure 1.8, N-methylation and peptide backbone 
extension.  N-methylation prevents hydrogen bonding through steric inhibition, and 
blocking fibril extension. A schematic of this process is shown in panel A, Figure 
1.8. N-methylated peptides to date have been successfully designed to inhibit A 
(Hughes et al., 2000, Amijee et al., 2012), IAPP (Kapurniotu et al., 2002) and -
synuclein (Madine et al., 2008b) aggregation. 
 
Figure 1.8 Two amyloid inhibition strategies. Illustration of the N-methylation 
method and demonstration of the altered amide bond (A). Illustration of -sheet 
breakers and example of -sheet breaking amino acids (B). 
A different approach is to limit hydrogen bonding by extension of the peptide 
backbone. One such method described by Madine et. al. (2009), involves substitution 
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of a residue within the SRE with a -sheet breaking alternative such as -alanine or 
-aminobutyric acid (Panel B, Figure 1.8). This methodology has been successfully 
employed to generate inhibitory peptides to -synclein and medin (Madine et al., 
2009b, Madine and Middleton, 2010). Furthermore, one of the -synclein inhibitors 
was also capable of inhibiting A and IAPP (Madine et al., 2009b). 
Caution must be taken when inhibiting aggregation not to stabilise the formation of 
oligomeric species. As discussed earlier, the toxicity of oligomeric species has now 
been established and increasing the oligomer population may result in poorer 
prognosis. Results from Madine et al 2009 however demonstrated that inhibition of 
medin by extension of the backbone reduced the cytotoxicity of medin aggregates 
(Madine and Middleton, 2010). 
1.5.3. Promote clearance of aggregates 
Given the variety of clinical signs and symptoms associated with the amyloidoses, 
diagnosis is frequently delayed and only occurs after large amyloid deposits have 
already formed. Consequently there is a drive to develop methods of clearing 
aggregates within the body. Currently,  a plethora of antibodies  have been developed 
that selectively bind different species along the aggregation pathway (Kayed et al., 
2010, Yanamandra et al., 2011). This can result in the activation of phagocytic 
degradation and clearance of the amyloid deposits (Emadi et al., 2007). 
Significant progress has been made recently targeting co-localising factors such as 
non-fibrillar plasma glycoprotein, serum amyloid P component (SAP) (Pepys et al., 
2002).  
Administering anti-human-SAP antibodies in mice with human SAP in association 
with fibrillar plaques, gave rise to a potent, complement-dependent, macrophage-
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derived giant cell reaction that effectively eliminated amyloid plaques (Bodin et al., 
2010). These therapies are currently undergoing further development.  
1.5.4. The importance of structural information in therapeutic design  
Recent progress in amyloid therapies has been significantly enhanced by the 
advances in structural techniques e.g. the rational design of Tafamadis™ (Bulawa et 
al., 2012). Techniques such as nuclear magnetic resonance (NMR) and X-ray 
crystallography provide atomic resolution detail of amyloid precursors and more 
recently fibrils which are invaluable in helping design effective small molecule 
modulators (Tycko, 2006a, Madine et al., 2008b). 
1.6. Cardiac amyloid 
Virtually all systemic amyloidoses have, to some extent, cardiovascular 
manifestations. Cardiac involvement is most common in immunoglobulin-derived 
and senile systemic amyloidoses (Kholová and Niessen, 2005) and leads to a much 
poorer prognosis when compared with diseases with different organ involvement 
(Dubrey et al., 2011). The symptoms of cardiac amyloidosis include: restrictive 
cardiomyopathy, bilateral dilation of the atria, arrhythmia, and frequently congestive 
heart failure (Falk and Dubrey, 2005).  Due to the non-specific nature of the 
symptoms, cardiac amyloidosis is often mis-diagnosed and, as a result, patients are 
often in the late stages of the disease when a final diagnosis is made (Kholová and 
Niessen, 2005). Diagnosis can be then further complicated by the need to accurately 
determine the amyloidogenic protein precursor responsible in order to establish a 
treatment programme. Once a patient is suspected of cardiac amyloidosis a definitive 
diagnosis is typically obtained by a combination of methods such as 
echocardiography, electrocardiography, cardiac biomarker screening and 
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radionuclide imaging, followed by histological immunoanalysis and increasingly 
mass spectrometry (Hassan et al., 2005, Banypersad et al., 2012).  
There are principally five amyloidoses that affect the heart: a group of hereditary 
amyloidoses that result from mutations in TTR, ATTR, AA amyloidosis, A2M 
amyloidosis and AL amyloidosis (Hassan et al., 2005, Banypersad et al., 2012). 
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1.6.1. ATTR amyloidosis 
ATTR amyloidosis is caused by aggregation of transthyretin (TTR). ATTR 
amyloidosis can be either hereditary or acquired. 
1.6.1.1. Hereditary ATTR amyloidoses 
There are multiple forms of familial amyloidosis, many of which are the result of 
single point mutations in the transthyretin (TTR) gene.  There are over 100 mutations 
of TTR currently understood to form amyloid (Connors et al., 2000). The most 
prevalent variation is a V122I mutation which is present in 3.9 % of the African 
American population (Jacobson et al., 1996). Cardiac amyloidosis is most associated 
with V122I and T60A mutations (Dungu et al., 2012). 
1.6.1.2. Aquired ATTR amyloidosis 
ATTR amyloidosis is caused by the aberrant aggregation of wild-type TTR 
(Westermark et al., 1990). It is almost exclusively affects men over 70 years of age. 
Deposits are almost always limited to the cardiac tissue, only occasionally presenting 
with carpel tunnel syndrome 3-5 years preceding cardiac symptoms (Falk and 
Dubrey, 2005). 
1.6.2. AA amyloidosis 
AA amyloidosis is a relatively rare complication of chronic inflammatory conditions 
such as inflammatory bowel disease and rheumatoid arthritis. It occurs when 
fragments of serum amyloid A protein are deposited in tissues as amyloid plaques. 
Deposits are found in the heart in only 2 % of cases, and the incidence is continually 
reducing, probably reflecting the improved treatments of the inflammatory diseases 
themselves. 
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1.6.3. A2M amyloidosis 
A2M amyloidosis is experienced by few patients receiving long term dialysis 
treatment and results in the accumulation of amyloid plaques composed of 2-
microglobulin in the joints and , very rarely, the cardiac tissue (Gal et al., 1994, 
Gejyo et al., 1985). 
1.6.4. AL amyloidosis 
AL amyloidosis, also known as primary amyloidosis, is the most common form of 
systemic amyloidosis with an incidence of 8.9 cases per million of the population 
(Kyle et al., 1992). This statistic, however, is probably an underestimate given the 
difficulties described earlier in obtaining a correct diagnosis. In the majority of 
patients, more than one organ is affected. Heart involvement portends the worst 
prognosis (Kyle and Gertz, 1995). Death is attributed to heart involvement in 
approximately 50 % of cases, the leading causes of death being congestive heart 
failure and arrhythmia (Kyle and Gertz, 1995). AL amyloidosis  is caused by the 
deposition of the immunoglobulin light chains produced by clonal plasma cells in the 
visceral organs, primarily the kidneys, heart and peripheral nervous system (PNS) 
(Kholová and Niessen, 2005).  
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Figure 1.9 Schematic of immunoglobulin structure (A) and the AL amyloidosis 
pathway (B).  
 
A characteristic of AL amyloidosis is the predominance of the overlight chain 
isoforms in a ratio of 3:1, the opposite of that observed in multiple myeloma (Falk, 
1998). AL amyloidosis is a very heterogeneous disease; both symptoms and organ 
involvement vary greatly between patients. One explanation for this variety can be 
found in the plaque composition; no patient has yet been found to have the same light 
chain component as another (Enqvist et al., 2009). The light chain protein is usually 
cleaved, but each patient typed to date has varying fragment size. The majority of 
light chain proteins consist of the N-terminal variable region and different amounts 
of the constant region. On rare occasions plaques have been observed that consist of 
full length light chains and those containing only constant regions (Olsen et al., 1998, 
Buxbaum, 1992). It has been suggested that the C-terminal region needs to be 
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cleaved to initiate fibrillogenesis, but this does not explain the inclusion of constant 
regions in amyloid plaques in some patients. In a recent study Enqvist et. al. (2009) 
analysed the proteolytic pattern of light chains from six patients in an attempt to 
pinpoint the origin of the fragmented species. They concluded that proteolytic 
cleavage is likely to occur after fibril formation and at the site of deposition. These 
findings were based on further evidence that all light chain components could be 
identified within deposits and fragmentation patterns observed were conserved 
within a patient, but differed between patients (Enqvist et al., 2009).  
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1.6.4.1. Representative immunoglobulin light chain- SMA 
The heterogeneity of AL amyloidosis makes it especially difficult to study and 
characterise. In an attempt to clarify the differences between non-amyloidogenic and 
amyloidogenic light chains, Stevens et al (1995) isolated immunoglobulin light chain 
variable region proteins from three patients (Stevens et al., 1995b). Two of these 
proteins, REC and SMA were extracted from patients with amyloid deposits. The 
third protein, LEN was isolated from the urine of a patient with no apparent amyloid 
deposits.  
 
 
 
 
 
 
 
Figure 1.10 Sequence alignment of the three proteins extracted by Stevens et. al. 
The differences between sequences are highlighted in red. 
 
Synthetic genes were generated for the three variable light chain portions of LEN, 
REC and SMA. Subsequently the genes were incorporated into pASK40 vector for 
recombinant expression in E.coli.  Recombinant production of these proteins has 
provided a means to compare and contrast the amyloidogenic REC and SMA 
proteins against the non-amyloidogenic LEN. SMA differs from LEN by 8 residues. 
Arguably the most significant of these is at position 40, where a proline in LEN and 
REC is replaced by the hydrophobic residue leucine in SMA. It is possible that this 
substitution of a -sheet breaking residue, for a hydrophobic residue, marks the 
difference in amyloid-forming capabilities. The vast majority of light chain 
sequences examined have a proline at position 40. Furthermore, there are currently 
SMA  DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNRNYLAWYQQKLGQPPKLLIYWASTR 60 
LEN  DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNSKNYLAWYQQKPGQPPKLLIYWASTR 60 
REC  DIVMTQSPDSLAVSPGERATINCKSSQNLLDSSFDTNTLAWYQQKPGQPPKLLIYWASSR 60 
     ************** ************.:* ** . * ******* ************:* 
 
SMA  ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSHPQTFGQGTKLELKR 114 
LEN  ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYSFGQGTKLEIKR 114 
REC  ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGGGTKVEIKR 114 
     **********************************:**** * :** ***:*:** 
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no non-amyloidogenic light chains that possess a hydrophobic residue at that 
position. These peptides can be used to identify the differences between 
amyloidogenic and non-amyloidogenic light chains. SMA is used, in this thesis and 
elsewhere, as a model system for AL amyloidosis (Meng et al., 2008). Further 
discussion about the aggregation and structural properties of SMA can be found in 
chapter 7.  
1.7. Amyloid in the vasculature  
In addition to the myocardium, amyloid deposits are frequently reported in the 
surrounding vasculature. Transthyretin and serum amyloid A have been found in the 
aorta and less frequently in small vessels (Mucchiano et al., 2001, Pitkänen, 1984, 
Cornwell and Westermark, 1980). Several groups have identified a distinct form of 
amyloid residing predominately in the medial layer of the aorta (Iwata et al., 1978, 
Cornwell, 1982). Mucchiano et. al. (1992) examined aortic tissue samples obtained 
at autopsy from 84 individuals and noted the level, distribution and type of amyloid 
deposits (Mucchiano et al., 1992). Haggqvist et. al. (1999) then went on to 
characterise the isolated protein using a variety of techniques, resulting in the 
identification of a 5.5 kDa protein derived from and internal cleavage fragment of the 
glycoprotein lactadherin. This protein, which comprises the focus of this thesis, was 
named medin (AMed), based on its location in the arteries (Haggqvist et al., 1999). 
1.7.1. Medin 
1.7.1.1. Lactadherin – the precursor 
A combination of sequence analysis and alignment has revealed that medin is likely 
to be an internal cleavage product of lactadherin (Haggqvist et al., 1999). 
Lactadherin was first described as a breast antigen (BA46) against the human milk 
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fat globule membrane (Ceriani et al., 1977). Antibodies to BA46 were raised and 
developed to target human breast tumours (Ceriani and Blank, 1988, Ceriani et al., 
1977).   
Lactadherin is a 46 kDa protein divided into three domains spanning 364 amino acids 
(Panel B, Figure 1.11). The C-terminal portion of the protein has been shown to have 
strong homology with serum factors VIII and V, C1 and C2 domains (Larocca et al., 
1991). These domains are predominantly responsible for membrane binding and in 
particular binding of phosphatidylserine though the C2 domain (Andersen et al., 
2000). The N-terminal section of lactadherin was later characterised as an epidermal 
growth factor (EGF)-like domain which contained the cell adhesion motif, arginine-
glycine-aspartic acid (RGD) (Couto et al., 1996). 
The medin sequence is located within the C2 domain of lactadherin. The process by 
which medin is excised from lactadherin remains unknown but it seems likely that it 
is a result of enzymatic cleavage rather than alternative splicing. This conclusion 
arises from the isolation of medin of different lengths with a ragged N-terminus  
(Häggqvist et al., 1999). The 50 amino acid peptide represents the core medin 
sequence.  
The structure of the bovine C2 domain has been solved to 1.7 Å and 2.4 Å using X-
Ray crystallography (Shao et al., 2008, Lin et al., 2007). It consists of a distorted -
barrel core made up of 8 major -strands and a further 11 short minor -strand 
regions which pack above and below the barrel. Additionally there are three 
relatively large loops at one end described as spikes 1, 2 and 3. These spikes contain 
hydrophobic amino acids that share similarity with the membrane interacting regions 
(Shao et al., 2008). Medin (highlighted red, Figure 1.11) encompasses 2 major 
strands and part of a third, and 11 minor strands separated by spikes 2 and 3 (Shao et 
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al., 2008). The C2 domains of serum factors VIII and V exhibit conformational 
changes upon membrane binding (Macedo-Ribeiro et al., 1999). The similarity 
between the C2 domain of lactadherin and these serum factor domains may suggest 
that it too undergoes a conformational change upon contact with lipids. This may 
result in partial unfolding of the domain structure, exposing medin to enzymatic 
cleavage.  
The specific function of lactadherin is relatively unknown, it is expressed in many 
cell lines and seems capable of many different functions including: carcinoma 
antigen (see above) (Ceriani et al., 1977), phagocytosis (Hanayama et al., 2002), rota 
virus protection (Newburg et al., 1998), anti-coagulation (Shi and Gilbert, 2003) and 
elastin interactions (Larsson et al., 2006). The most important of these functions for 
the context of this work are arguably its anti-coagulation mechanisms and elastin 
binding properties.  
Lactadherin has been shown to be expressed in smooth muscle cells and co-localise 
to the elastic structures of arteries (Häggqvist et al., 1999). Further studies by 
Larsson et. al. (2006) demonstrated that lactadherin can bind to elastin and that the 
binding is mediated through the medin (C2) domain (Larsson et al., 2006). Binding 
to elastin and a subsequent conformational change may represent a second 
mechanism by which medin is exposed and cleaved from lactadherin.  
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Figure 1.11 Sequence of lactadherin with medin sequence highlighted in red (A) 
Schematic of lactadherin domain structure highlighting the location of medin 
within the C2 domain (B) Crystal structure of lactadherin C2 domain from Bos 
taurus adapted from Shao et. al. (2007) (PDB I.D. 3BN6) Red highlights the 
location of the medin sequence within the domain. The hydrophobic loop 
regions (spikes) hypothesised to interact with membranes are numbered 1-3 (C). 
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1.7.1.2. Prevalence and Distribution 
Medin amyloid is the most common form of human amyloid identified to date. 
Multiple studies have reported on the incidence, type and location of medin (or senile 
aortic amyloid) deposits in the vasculature. Similar to senile systemic amyloidosis it 
is more prevalent with age.  A report by Schwartz in 1970 found medin in all aortas 
from donors over the age of 50 (Schwartz, 1970). Subsequently similar figures have 
been described. Mucchiano et. al. showed that 97% of aortas from persons over 50 
tested positive for medin, opposed to 1 out of 21 aortas from younger donors 
(Mucchiano et al., 1992). Further reports have set the prevalence lower at 79 % and 
68 % by Iwata et. al. and Wright et. al. respectively. Allowing for these differences, 
medin remains the most common form of human amyloid.  
Medin deposits are predominately found in the aorta but it has been shown to localise 
to other large arteries, mainly in the upper half of the body (Peng et al., 2005, Peng et 
al., 2002). Outside the aorta, medin was most commonly found in the temporal, 
carotid and basilar arteries, and less frequently in the superior mesenteric and the left 
coronary artery (Peng et al., 2005). Medin has never been found to be present in 
veins.  
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Figure 1.12 Section of aortic media stained with antibodies specific to residues 
19-26 of medin. Immunoreactive areas stained with diaminobenzidine (A) and 
subsequently stained with Congo Red and visualised under polarised light (B). 
Taken from Häggqvist, Näslund et al. 1999. 
 
When stained with Congo Red, medin displays the typical apple green birefringence 
associated with amyloid formation, although it stains weakly in comparison with 
some other amyloid deposits (Peng et al., 2002). This may account for some of the 
variability in the reported incidences. It commonly appears as nodules and thin 
streaks in all three layers of the artery but predominantly in the inner half of the 
tunica media. Intimal deposits were found in 35 % of persons over the age of 50 
compared with 2 % for advential deposits (Mucchiano et al., 1992). Medin is 
frequently described as being closely associated with the internal elastic laminae 
(Cornwell, 1982). While the majority of medin deposition is extracellular, some 
small deposits have also been identified within smooth muscle cells (Cornwell Iii et 
al., 1983, Cornwell, 1982).  
1.7.1.3. Consequences of medin deposition  
To date no definitive consequences of medin deposition have been confirmed. The 
location of medin deposition has led researchers to investigate possible links with 
other vascular diseases. Sporadic thoracic aneurysm and dissection are life-
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threatening conditions with unknown pathogeneses. They commonly present with 
signs of degeneration of the elastic structures and GAG deposition. This deterioration 
of the tissue structure has been observed in other amyloid pathologies and therefore 
led researchers to investigate a possible role for medin in these conditions. 
Specimens were taken from the thoracic ascending aorta of patients with sporadic 
thoracic aneurysm or dissection and from a control group and analysed for the 
amount of amyloid and medin immunoreactivity. Congophillic material was 
observed in all three groups, demonstrating medin immunoreactivity, with further 
granular deposits that were negative for Congo Red but immunoreactive for medin. 
These granular deposits were more numerous in the disease samples. It was, 
therefore, concluded that these deposits represented oligomeric/protofibrillar medin 
amyloid, consistent with theories suggesting that the oligomeric intermediate species 
are more toxic that the mature fibrils. Furthermore, the study investigated the 
relationship between gelatinase expression and medin, showing that proteases were 
up regulated in presence of medin.  
1.8. Aims 
The overall aim of this thesis is to gain a detailed understanding of the 
amyloidogenic and structural properties of medin, the main component of aortic 
medial amyloid, and SMA, a monoclonal amyloid protein underlying cardiovascular 
amyloid disease. 
This will be achieved by addressing five key objectives: 
 
1. To examine the use of model peptides within amyloid research and establish 
whether the medin peptide comprising residues 42-49 (Med42-49) is a good 
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model system for studying the aggregation properties of full length medin. 
Furthermore, chapter 2 investigates the role of predicted aggregation ‘hot 
spots’ within medin and how they could be targeted for therapeutic design 
 
2. To establish a protocol for the expression and purification of full length 
medin in E.coli. This will provide a replenishable source of peptide for 
biophysical studies. Moreover, it remains necessary to develop reliable 
methods of producing isotopically labelled medin for NMR structural studies. 
 
3. To characterise the aggregation properties of medin using biophysical 
techniques. Very little is known about the aggregation properties of medin 
and the aim of this work is to establish some of the basic characteristics of 
medin aggregation that can be used to enhance further studies of this peptide. 
 
4. To investigate the possibility of a stabilising salt bridge in medin fibrils using 
both direct measurements using SSNMR and characterisation of salt bridge 
mutants. 
 
5. To establish, for the first time, a protocol of the expression of isotopically 
labelled SMA to enable preliminary structural studies of SMA and form the 
basis for more detailed future investigations.  
 36 
 
2. Investigating the packing arrangements of 
medin fibrils  
2.1. Introduction 
Gaining a greater understanding of amyloid molecular structures is vitally important 
for a variety of reasons including identification of self recognition elements which 
could be targeted by therapeutics (as discussed in section 1.5.2), understanding the 
relationship with amyloid toxicity (Van Nostrand et al., 2001) and to elucidate the 
nature of intermediate species along the aggregation pathway (Fändrich, 2012).  
Amyloid fibrils, by their insoluble, non-crystalline nature, are difficult to study by 
conventional methods of structural biology. Advances in high-resolution structural 
techniques such as solid-state nuclear magnetic resonance (SSNMR) and X-ray 
crystallography have greatly enhanced our knowledge of amyloid structures but 
nevertheless there remain only a handful of full length molecular models available, 
these are namely: polymorphs of A1-40 fibrils (Petkova et al., 2002, Paravastu et al., 
2008) and fibrils from a mutated variant (D25N) (Qiang et al., 2012), IAPP fibrils 
(Luca et al., 2007) and the native tetramer of transthyretin (TTR).  
Structural information has been integral to the design and refinement of a therapeutic 
agent against the acquired amyloidosis ATTR (Klabunde et al., 2000). Elucidation of 
the native tetramer structure of TTR led to the rational design of a stabilising small 
molecule that prevents the dissociation of monomers and thus amyloid formation 
(Figure 2.1) (Bulawa et al., 2012). TTR is a major carrier of thyroxine T4 in rodents 
however the binding sites in human TTR are rarely occupied and therefore available 
for small ligand binding. The TTR tetramer has two dimer-dimer interfaces; the 
thyroxine binding site is located on at the z-axis interface. The binding pocket 
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consists of two subsites. Many rounds of optimisation resulted in a compound 
comprising two differentially substituted aryl rings. Each of the rings occupies one of 
the subsites. Tafamidis™ or 2(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid is 
capable of stabilizing the dimer-dimer interface through a combination of specific 
hydrophobic residues and electrostatic interactions. Tafamidis™ is now in clinical 
trials and early results are promising (Bulawa et al., 2012). This therapeutic strategy 
would not have been possible without high resolution molecular detail.  
  
Figure 2.1 Crystal structure of Tafamidis bound to TTR (PDB ID: 3TCT). 3D 
ribbon diagram depiction of the TTR tetramer with tafamidis bound (A). The 
four TTR monomers are individually coloured. Magnified image of tafamidis 
bound in one of the T4-binding sites (B). Taken from (Bulawa et al., 2012). 
 
This therapeutic strategy targeted the source of amyloidogenic protein (the wild type 
tetramer). There is however a great interest in targeting fibrils themselves, in order to 
break up existing aggregates as well as preventing formation.  
In order to overcome some of the challenges surrounding structural studies of these 
large insoluble protein aggregates, many studies use small peptides or fragments as 
model systems (Balbach et al., 2000, Madine et al., 2008c). Previous studies of such 
model systems have shown that aggregate structure is highly sensitive to alterations 
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in sequence, particularly via truncation or mutation, and may be completely different 
from the parent molecule from which they are derived. For example, fibrils formed 
by the 40-residue A (Aβ1-40) comprise parallel and in-register hydrogen bonded β-
strands (Balbach, 2002, Petkova et al., 2002). This organisation is reproduced in 
fibrils of the 26-residue peptide fragment Aβ10–35 (Burkoth et al., 2000), whereas the 
shorter peptides Aβ16-22 and Aβ11–25 adopt an anti-parallel β-strand arrangement 
within fibrils, with a pH-dependent registry in the case of Aβ11–25 (Balbach et al., 
2000, Petkova et al., 2004). Hence, it cannot be assumed that a smaller fragment is a 
suitable model of the parent peptide. 
The first study on medin protein was performed on protein extracted from aortic 
tissue (Häggqvist et al., 1999). During analysis it was noted that an octapeptide, 
generated as a result of tryptic digest, with the sequence NH2-NFGSVQFV-COOH 
was capable of forming amyloid-like aggregates in isolation. It was later noted that 
this octapeptide shares sequence similarity with fragments of the islet amyloid 
polypeptide (IAPP) also known as amylin, NH2-NFGAIL-COOH and NH2-NFLVH-
COOH. Further work was then carried out to identify the minimum motif required 
form fibril formation, which was NH2-NFGSV-COOH (Reches and Gazit, 2004).  
A more comprehensive study on medin aggregation was later carried out by Larsson 
et al. (2007). Using a variety of synthetic and recombinant fragments and full length 
medin, they tested them for their ability to bind Congo Red, Thioflavin T and to form 
fibrillar structures visible by electron microscopy. They indicated that the C-terminal 
18-19 residues comprised the amyloid promoting region (Larsson et al., 2007).  
Recent work by Madine et al (2009) investigated the structural properties of a 
peptide representing the C-terminus of medin, comprising residues 42-49 (Med42-49). 
This peptide has previously been shown to be highly amyloidogenic in isolation 
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(Larsson et al., 2007). Madine et al (2009) showed that this peptide aggregates 
within two days to form bundles of microcrystalline-like needles displaying a high 
degree of order. Using 
13
C selectively labelled peptides coupled with solid-state 
nuclear magnetic resonance (SSNMR) methods they investigated the molecular 
architecture of the resultant amyloid-like aggregates (Madine et al., 2009a). They 
used rotational resonance (RR) experiments to determine constraints on distances 
between selective atomic sites within the fibrils. The data was consistent with 
aggregates formed from unbroken β-strands hydrogen bonded in a parallel in-register 
arrangement within β-sheets. Moreover, additional RR experiments identified close 
(> 6.5 Å) contacts between residues F43 and V46 and between S45 and V46. The 
constraints determined from SSNMR experiments were combined with X-ray fibre 
diffraction data to generate a structural model for the cross--spine of Med42-49 
(Madine et al., 2009a). 
These data have led to a much greater understanding of the structure of Med42-49 
aggregates but it is not known how relevant the structure of the model peptide fibrils 
is to the structure of full length medin.  
The aim of this work is to investigate how the length of the medin affects the rate of 
aggregation, morphology and structure, and thus whether Med42-49 is a good model 
for studying the structure of full length fibrils.  
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2.2. Materials and methods 
2.2.1. Overall strategy 
The characteristics and fibril structure of Med43-49 investigated by Madine et al 
(2009) was compared with a longer medin sequence and full length medin with the 
aim of identifying any differences in their aggregation kinetics, morphology and 
structure. 
2.2.2. Amyloid prediction servers 
Amyloid prediction servers predict aggregation prone regions based on the 
physiochemical properties of a peptide’s constituent amino acids. They were used 
here to identify amyloidogenic regions in the medin sequence which, in turn guided 
the design of the intermediate length medin peptide. Three different servers were 
used to obtain a consensus prediction and provide more reliable results. If two or 
more servers predicted a particular area sequence it was considered to be 
amyloidogenic. 
2.2.2.1. Zyggregator 
The Zyggregator server was developed following the work of Chiti et al (2003) 
which demonstrated that the effect of mutations on aggregation propensity was 
largely down to the physicochemical properties of the substituted residues 
themselves. Properties such as hydrophobicity, secondary structure propensity and 
charge all help to determine the aggregation potential of a sequence (Chiti et al., 
2003). This work led to the development of the Zyggregator server which calculates 
an aggregation profile of a sequence based on the properties of its constituent amino 
acids (Tartaglia and Vendruscolo, 2008). An input sequence is entered into the server 
in FASTA format and the results are displayed in a variety of formats. Any residues 
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with a score above 1 are thought to promote aggregation of the sequence. This 
method allows the user to calculate aggregation profiles of an input sequence at 
different pH values. The aggregation profile of medin was calculated at pH 7.4. 
2.2.2.2. AGGRESCAN 
 The AGGRESCAN server also calculates an aggregation propensity value for each 
residue within the input sequence and provides a graphical output of the results. 
Areas of the profile above a pre-calculated threshold are termed aggregation ‘hot 
spots’(Conchillo-Solé et al., 2007).  
2.2.2.3. Prediction of Amyloid STructure Aggregation (PASTA) 
Unlike Zyggregator and AGGRESCAN, the PASTA algorithm predicts which 
portions of a given input sequence  stabilises the corresponding cross- structure and 
hydrogen bond networks (Trovato et al., 2007). The server is based on the 
assumption that the same stabilising hydrogen bonds found in globular proteins, 
stabilise amyloid structures (Trovato et al., 2006). 
2.2.3. Preparation of medin peptide samples for NMR studies 
Synthetically produced medin peptides were purchased from Protein Peptide 
Research (Cambridge, U.K.) with selective uniform 
13
C and 
15
N isotope labels 
(indicated with asterisk in Figure 2.4).  
Lyophilised medin peptides were initially dissolved in hexafluoroisopropanol 
(HFiP), bath sonicated for 10 minutes and then the HFiP removed under a stream of 
nitrogen. The samples were then placed on a high vacuum overnight to remove the 
last remaining traces of HFiP. This process was repeated three times prior to 
resuspension in 10 % dimethylsulphoxide (DMSO) 90 % H2O to induce aggregation. 
Medin was incubated at a concentration of 200 M with agitation at room 
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temperature for up to 21 days. These conditions were selected to mirror the 
conditions used by Madine et al (2009) thus enabling direct comparison of the three 
peptides. Furthermore, at lower DMSO concentrations both peptides became 
insoluble and precipitated.  Moreover, the in vivo concentration of medin is unknown 
and therefore a high concentration was utilised to ensure optimal conditions for 
NMR experiments. The peptide suspension was then centrifuged at 21,000 g for 1 
hour to generate a tightly packed pellet before being transferred to a zirconium  4 
mm rotor with a Kel-F cap (Bruker, U.K.) in preparation for NMR studies. 
2.2.4. Characterisation of medin peptide aggregation 
2.2.4.1. Aggregation studies of medin peptides by thioflavin T 
Both peptides
 
were incubated at a concentration of 200 M with agitation at room 
temperature for up to 21 days. Aliquots (25 L) of the suspensions were removed at 
0, 2, 4, 7 and 14 days and frozen. Following completion of the time course aliquots 
were defrosted and added to 180 L of 10 M ThT solution. Emission spectra were 
recorded on a Cary Eclipse Varian fluorescence spectrometer operating at room 
temperature.  Spectra were recorded from 450-600 nm with an excitation wavelength 
of 450 nm and a 5 nm band pass. Values at 482 nm were recorded and each time 
point represented as a percentage of the end point fluorescence. 
2.2.4.2. Morphology of medin peptides by transmission electron microscopy. 
The resultant peptide aggregates were visualised using TEM. Peptide suspensions 
(10 L) were loaded onto carbon coated copper grids held between tweezers. Excess 
solution was removed by placing the grid perpendicular to blotting paper. The grid 
was then inverted onto a droplet of dH20 to wash of excess peptide aggregates. The 
grid was blotted again before being inverted onto a droplet of 4 % uranyl acetate to 
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negatively stain the aggregates. Excess stain was removed by blotting before allow 
the grid to air dry prior to visualisation. The grids were observed using a Technai 10 
electron microscope operating at 100 kV located in the EM Unit in the physiology 
building at the University of Liverpool. 
2.2.5. Solid state nuclear magnetic resonance (SSNMR) studies on synthetic 
medin peptides. 
All cross-polarization magic-angle spinning (CP-MAS) 
13
C SSNMR experiments  on 
the synthetic medin peptides were carried out on a Bruker Avance 400 spectrometer 
operating at a magnetic field of 9.3 Tesla located in the NMR Centre for Structural 
Biology at the University of Liverpool. The peptide samples were rotated at the 
magic angle at rates between 6 kHz and 13 kHz (±1 Hz). All experiments utilized an 
initial 4.0-s 1H 90° excitation pulse length, 1-ms Hartmann-Hahn contact time at a 
1
H nutation frequency of 65 kHz, two pulse phase modulated (TPPM) proton 
decoupling  (Bennett et al., 1995) at a field of 85 kHz during signal acquisition and a 
2-s recycle delay.  
2.2.5.1. Dipolar assisted rotational resonance (DARR) experiments 
Two-dimensional 
13
C-
13
C broadband dipolar re-coupled spectra were obtained using 
the dipolar-assisted rotational resonance (DARR) experiment (Takegoshi et al., 
2001). Spectra were recorded with 128 hypercomplex points in the indirect 
dimension (t1), with a mixing time of 20 ms during which the proton nutation 
frequency was adjusted to the spinning frequency of 8 kHz. Chemical shift values 
were referenced to external adamantane at 37.8 ppm. 
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2.2.5.2. Rotational resonance experiments. 
A two-dimensional version of the rotational resonance (RR) exchange experiment 
(Madine et al., 2009a) was used to selectively observe the dipolar interactions 
between the aromatic ring (F) and valine methyl (VV') 13C spins.  Spectra were 
recorded with 64 hypercomplex points in the indirect dimension (t1) and the spinning 
frequency (R) was adjusted to the difference in the resonance frequencies (CC) 
for the Fand V spins (i.e., the n = 1 RR condition). Protons were decoupled at 
100 kHz during a mixing time of 30 ms.  
2.2.5.3. Site-specific 13C-1H dipolar couplings 
Site-specific 
13
C-
1
H dipolar couplings, which are sensitive to local dynamics on the 
s-ms time scale, were measured using the constant time dipolar and chemical shift 
(CT-DIPSHIFT) correlation experiment (Hong et al., 1997).  In a series of 8 
experiments, peak intensities were measured for 8 t1 intervals, where t was 
incremented from zero to one rotor period (2/R) at a spinning frequency of 6 kHz.  
The 8 spectra (Sn), each defined by 1024 points, were then replicated 16 times and 
concatenated (S1, S2 … S8, S1, S2 … S8, etc), to give a 1024 x 128 matrix, which was 
Fourier transformed in the indirect dimension to produce the pseudo-two 
dimensional spectra, with the 
13
C chemical shift information in the direct dimension 
and C-H dipolar coupling information in the indirect dimension. 
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Figure 2.2 Schematic to illustrate how the dipolar spectrum of a spin system can 
be Fourier transformed to give a pure dipolar spectrum. Peak intensities of at 8 
different rotor period fractions were recorded and fitted to curves of simulated 
coupling strengths. These data were then replicated 16 times and concatenated. 
This is then FT in the indirect dimension to give C-H dipolar coupling 
information. 
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2.2.6. Solution state NMR studies of Med1-50 
1D proton NMR spectra were recorded at 298 K on Bruker Avance 600 MHz 
spectrometer equipped with 
1
H,
13
C,
15
N triple resonance gradient cryoprobe. Spectra 
(64 scans) were recorded on freshly prepared synthetic medin samples (see section 
2.2.3) and after 6 days incubation at 25 °C with no agitation. The large 
resonance due to the water protons was suppressed by the WATERGATE 
pulse sequence (Sklenar et al., 1993). The spectra were processed using TopSpin 
(Bruker) and plotted in Origin Pro 8.5. 
2.3. Results 
2.3.1. Aggregation prediction servers 
Aggregation prediction servers identify aggregation prone regions based on the 
physicochemical properties of the constituent amino acids, and pinpoint areas that 
can be tested experimentally. Prediction servers were used here to direct the design 
of the intermediate medin sequence and in turn investigate the role of different 
aggregation ‘hot spots’ on the structure and aggregation properties of medin. The 
sequence of medin was analysed using three different predictive methods, 
Zyggregator (Tartaglia and Vendruscolo, 2008), AGGRESCAN (Conchillo-Solé et 
al., 2007) and PASTA (Trovato et al., 2007) to obtain more reliable prediction 
results. All three servers identified the region encompassing residues NH2- F
46
GSV-
COOH, as a region that promotes aggregation (Figure 2.3). The known 
amyloidogenicity of the peptide Med42-49 (Larsson et al., 2007, Madine et al., 2009a, 
Reches and Gazit, 2004) indicates the reliability of the predictions in this case.  
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Figure 2.3 The aggregation prone regions of Med1-50 (shown in red) predicted by 
three independent servers: Zyggregator, Aggrescan, and PASTA.  
 
Zyggregator and AGGRESCAN also predicted that residues NH2-N
9
AWVA-COOH 
are prone to aggregation (Figure 2.3).  A third region with the sequence NH2-
V
32
TGII-COOH was predicted by AGGRESCAN and PASTA (Figure 2.3).  
From the results of the predictions, two peptides were produced synthetically, a 
peptide encompassing residues 30-50 (Med30-50) and full length medin (Med1-50) 
(Figure 2.4). Med30-50 encompasses two of the aggregation prone regions and was 
investigated alongside selectively labelled full length medin (Med1-50).  In order to 
compare results for both of these peptides to data previously collected for Med42-49, 
both peptides were synthetically produced, incorporating the same isotope labelling 
scheme.  
 
 48 
 
 
Figure 2.4 Medin peptide sequences. Med42-49 is shown in red, Med30-50 in blue 
and full length wild type medin is shown in black. Asterisks indicate the 
presence of uniform 
13
C and 
15
N isotope labels. Residues underlined are 
predicted to form amyloid.  
 
2.3.2. Kinetic and morphological characterisation of Med 30-50 and Med 1-50 
2.3.2.1.Aggregation kinetics of Med 30-50 and Med 1-50   studied
 
by
 
Thioflavin T 
The aggregation kinetics of both Med 30-50 and Med 1-50 were investigated using ThT 
fluorescence assay. Both Med30-50 and Med1-50 give rise to the characteristic rise in 
ThT fluorescence associated with amyloid formation (Figure 2.5). 
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Figure 2.5 ThT fluorescence measurements of Med30-50 (A and B) and Med1-50 (C 
and D) incubated at a concentration of 200 M in 10 % DMSO and 90 % H2O. 
Samples were taken discreet time points over a three week period. Data were 
recorded on a Cary Eclipse Varian fluorescence spectrometer at 25 °C. Data 
represent mean data for 2 replicates. Panels A and C represent raw excitation 
spectra for one of the replicates. Panels B and D show the averaged data for the 
two replicates converted to percentage aggregation; fluorescence intensity at 
T21 represents 100 % and T0 represent 0%. 
 
Aggregation of the peptides was carried out over a period of 21 days and samples 
were removed from the solution at discreet time points during the incubation. The 
length of the time intervals between samples make it difficult to draw conclusions 
about the exact length of the lag phase and the maximum fluorescence. Med30-50 
aggregation may exhibit a small lag phase before a period of growth and elongation 
(Panel A, Figure 2.5). There is also a dip at time 14 days, however this decrease is 
within the margin of error and therefore the relevance cannot be determined. In 
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contrast Med1-50 exhibited a longer lag phase and did not reach equilibrium within 21 
days (Panel B, Figure 2.5). Data for Med1-50 in particular, was consistent with 
nucleation dependent growth with a lag phase followed by a period of growth and 
elongation (Cabriolu et al., 2010). 
Previous in situ SSNMR analysis of Med42-49 aggregation indicated that large or 
insoluble species occurred after monitoring for 6 hours, with aggregation reaching 
completion by 24 hours (Madine et al., 2009a). Med42-49 aggregation is not 
accompanied by an increase in ThT fluorescence and so could not be studied by this 
method. ThT insensitivity for short amyloidogenic peptides is often observed 
(Groenning, 2010, Goldsbury et al., 2000) although the reasons are not well 
understood. It is possible that the length of Med42-49 strand and/or the properties of 
the exposed residues do not favour ThT binding or fluorescence enhancement.  
Together these data indicate that although truncation of the medin sequence alters the 
aggregation kinetics, both peptides demonstrate the rise in thioflavin T fluorescence 
associated with amyloid formation. In order to directly compare the different kinetic 
parameters such as lag time and growth and elongation rate, the aggregation of Med 
30-50 and Med 1-50 would need to be followed in real time.  
2.3.3. Morphology of Med 42-49, Med 30-50 and Med 1-50 aggregates studied by 
TEM. 
The morphology of Med 30-50 and Med 1-50 was studied by TEM after 21 days and 
compared to previous images of Med 42-49. Each of the three peptides gave a distinct 
morphology. Med42-49 forms large numbers of rod-like fibres or needles (Panel A, 
Figure 2.6), Med1-50 shows a dense network of slender, amyloid-like fibrils (Panel C, 
Figure 2.6) and Med30-50 aggregates appear to be granular in character (Panel B, 
Figure 2.6). Hence, the resulting morphology of the medin-derived peptides appears 
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to be highly sensitive to their length and/or sequence. These results also indicate that 
not all predicted regions are required for aggregate formation to occur. 
 
 
Figure 2.6 Electron micrographs of Med42-49 (A)  reproduced from (Madine et 
al., 2009a) depicting rod-like fibrils or needles. Electron micrographs of Med30-50 
(B) indicate the presence of amorphous aggregation whereas and Med1-50 (C) 
demonstrates the presence of slender amyloid-like fibrils. Scale bars represent 
1000 nm.  
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2.3.4. Peptide NMR 
Solid state NMR experiments on Med42-49 aggregates provided information about 
their structure and packing arrangement (Madine et al., 2009a). Here the same 
SSNMR experiments are applied to  Med 30-50 and Med 1-50  to investigate the 
structure and molecular architecture of these longer peptides and compared to Med42-
49 . 
2.3.4.1. DARR spectra of Med 30-50 and Med 1-50 aggregates 
As shown in Figure 2.4, both Med 30-50 and Med 1-50 are 
13
C/
15
N labelled at 5 
positions: NH2-FGSVQ-COOH. Residue selective labelling is achieved by solid-
phase synthesis and simplifies otherwise complex spectra and increases sensitivity 
and resolution. The DARR experiment is a broadband recoupling experiment which 
allows the detection of inter-residue contacts that can then be assigned. DARR 
spectra of Med 30-50 and Med 1-50 were collected and used to assign the selectively 
labelled residues in preparation for further structural analyses. It was however not 
possible to assign Q
47
 in either Med30-50 or Med1-50. The chemical shift values for Q 
C reportedly range from 54.1 - 57 ppm for a -sheet conformation and between 
54.55 and 58.23 for a random coil arrangement (Wang and Jardetzky, 2002). This 
region of the DARR spectrum also corresponds to typical C-C valine shifts. It is 
therefore not possible to distinguish between C, C of V46 and Q47 in this data set. 
However, the C resonance of V46 can clearly be identified from its distinct 
chemical shifts at around 19 ppm, hence allowing the resonance assignment of this 
residue (Figure 2.7). Furthermore, the chemical shift values obtained can provide 
information about the secondary structure of the C-terminus of these peptides 
(Wishart and Sykes, 1994).  It has been shown previously that C carbons 
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experience a downfield shift when located within an -helix and an upfield shift 
when found in a -stand. Change in chemical shift values for the labelled residues of 
each of the peptides were calculated using the following equation: 
                             Equation 2.1 
 
where C and δCβ are the chemical shift values for C and Cβ, and subscripts RC 
and obs denote the mean random coil (Wang and Jardetzky, 2002) and observed 
values, respectively (Wishart and Sykes, 1994) and Δis the chemical shift index. 
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Figure 2.7 Regions of a representative 
13
C DARR spectrum for Med30-50 with 
dashed lines showing peak assignments to the F43, G44, S45 and V46 spin 
systems (A). C chemical shifts for Med42-49, Med30-50 and Med1-50 are 
summarised in Table 2.1.Chemical shift index (Δδ) for residues F43, G44, S45 
and V46 of Med42-49, Med30-50 and Med1-50 (Wishart and Sykes, 1994). Positive 
values of Δδ are consistent with a helical structure, and negative values are 
consistent with a β-strand structure. 
 
A representative 
13
C DARR spectrum of Med30-50 is shown in panel A, Figure 2.7, 
and the measured chemical shift values for the NH2-FGSV-COOH sequence of all 
three peptide aggregates are given in Table 2.1. Although the accuracy of the 
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measurements is compromised to some extent by the NMR line widths (typically 
1.0–2.0 ppm), the chemical shift values nevertheless show some interesting site-
specific and peptide-specific differences. The values for C of F43 range from 55.8 
to 52.6, a difference of >2.5 ppm (Table 2.1). Values for C and C of G44 and V46 
also differ by 1.0–1.5 ppm (Table 2.1). This distribution of values amongst the three 
peptides may reflect differences in local conformation within the NH2-FGSV-COOH 
sequence.  
Despite these differences, secondary structure chemical shift, relating to random coil 
values (Δ), are largely negative (Panel B, Figure 2.7) and thus broadly consistent 
with a -sheet structure across the C-terminal region. Conversely, F43 of Med42-49 
gives a positive Δ value, which is consistent with a more -helical geometry (Wang 
and Jardetzky, 2002). In contrast to the longer peptides, F43 within Med42-49 is close 
to the N-terminus, and its geometry may therefore be more weakly constrained by 
neighbouring residues.  
Interestingly, chemical shift values for the F43 ring (Table 2.1) are quite similar for 
Med30-50 and Med1-50 but somewhat different for Med42-49 implying that the shorter 
peptide may have a different side chain packing arrangement to the longer peptides.
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Table 2.1 
13
C chemical shift values for the amide carbon (C), C , side chain (') and all aromatic) positions of medin peptide aggregates. 
Values for each site corresponding (top to bottom) to Med42-49, Med30-50 and Med1-50.  Line width values shown in parentheses.  is defined as  
                           
Residue  Chemical shift (ppm) 
 C C C  C(’)a Cb 
F43 170.4 55.8 (1.5) 35.1 (1.8) 3.19 136.9 (2.1) 128.5  
 170.3 52.6 (1.6) 39.5 (2.0) -4.41 136.0 (2.2) 129.1 
 170.6 53.1 (1.6) 38.9 (1.7) -3.31 136.0 (2.2) 129.3 
G44 169.5 42.7 (1.3) - -2.64 - - 
 167.9 41.7 (1.4) - -3.64 - - 
 168.2 41.5 (1.5) - -3.84 - - 
S45 171.0 53.6 (2.0) 62.7 (1.0) -3.57 - - 
 169.7 52.9 (1.6) 62.9 (1.3) -4.47 - - 
 170.2 53.1 (1.6) 62.1 (1.5) -4.94 - - 
V46 173.4 58.8 (1.5) 33.6 (1.4) -3.92 18.3 (1.2) - 
 172.5 57.7 (1.5) 32.0 (1.4) -3.42 18.6 (1.1) - 
 172.9 58.7 (1.6) 32.1 (1.5) -2.52 18.5 (1.2) - 
 57 
 
2.3.4.2. Investigating side chain packing arrangements examined by NMR 
rotational resonance experiments. 
The side chain packing of F43 in the three peptide aggregates was examined further 
using selective dipolar recoupling NMR measurements. Two-dimensional exchange 
spectra of Med42-49, Med30-50 and Med 1-50 were collected using MAS rates of 11,126, 
11,116 and11,146 Hz respectively. The rate corresponds to the frequency difference 
between the F and V/V’ (i.e. n = 1 rotational resonance). At rotational resonance, 
pairs of nuclear spins are recoupled under MAS, provided the distance between them 
is < 6.5 Å. If this condition is met, cross-peaks corresponding to the resonances of 
the two nuclei may be observed in the 2D spectrum. Figure 2.8 shows cross-peaks 
correlating the 
13
C-
13
C dipolar coupling between F and V/V’ of Med42-49 (Panel 
A, Figure 2.8). For F and V/V’ to be < 6.5 Å apart pairs of -sheets must be 
packed together in a face-to-back arrangement (Nelson et al., 2005, Nelson and 
Eisenberg, 2006) (taking into account the additional SSNMR structural restraints 
from (Madine et al., 2009a)). Coincidentally, the MAS rate also coincides with the n 
= 1 rotational resonance condition for the directly bonded amide C O and C spins 
(dashed lines) giving strong cross-peaks which can be used as an internal reference. 
It is not possible to identify which CO-C spins are recoupled due to overlap in that 
region of the spectra. Equivalent spectra of Med1-50 and Med30-50 show cross-peaks 
correlating the strongly coupled amide CO and C spins, but cross-peaks between 
F and V/V’ are absent (panels B and C, Figure 2.8).  Hence for the longer 
peptides, the F–V/V’ distance is greater than 6.5 Å, and the molecular packing is 
thus different in some respect from that of Med42-49.  
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Figure 2.8 Rotational resonance spectra for Med 
42-49
 (A) Med 
30-50
 (B) and Med 
1-50
 (C).  MAS rates correspond to n = 1 rotational resonance with respect to the 
frequencies of F and V/’ in each case (11126 Hz, 11116 Hz and 11146 Hz 
respectively). The F-V/’ cross peak is highlighted by the dotted line in (A) but 
is absent from (B) and (C). The dashed lines highlight cross-peaks arising from 
strongly coupled CO-C spins. In each spectrum the intensities were 
normalised between 0 and 1 and peaks are represented by the same 24 contour 
levels. 
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2.3.4.3. Aromatic ring flexibility- CT-DIPSHIFT solid-state NMR experiments 
Local dynamics within amyloid fibrils have until recently been neglected in 
structural studies yet potentially carry useful information about the fibril architecture 
(Helmus et al., 2011, Scheidt et al., 2011, Sackewitz et al., 2008). Here local 
dynamics of NH2-FGSV-COOH region were investigated to determine whether 
measurements within this area could provide clues about differences in the side chain 
packing in the three peptide aggregates. The 
13
C-detected DIPSHIFT SSNMR 
experiment was used to measure 
13
C-
1
H dipolar couplings within the peptide 
backbone and side chains.  
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Figure 2.9 (Top) Stack plot showing the 2D CT-DIPSHIFT spectra for Med42-49. 
(Middle) A corresponding pseudo-2D spectrum. A slice through the spectrum 
representing the C―H dipolar anisotropy spectrum at the frequency of Cϕ 
(dotted vertical line) for F43 shown on the right vertical axis. This dipolar 
anisotropy spectrum consists of a centre band flanked by a series of side bands 
separated by the sample spinning frequency. (Bottom) C-H dipolar anisotropy 
spectrum of F43 C, experimental data is shown in black and simulated rigid-
limit dipolar spectra are shown in red (the data are offset for clarity). 
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Figure 2.9 is an example of a two dimensional CT-DIPSHIFT spectrum for Med42-49 
and illustrates how the spectra shown in Figure 2.10 are taken from a slice at the 
frequency indicated by the dashed line.  
Spinning side band patterns extracted from the indirect dimension of the two-
dimensional spectrum carry site-specific information about the 
13
C-
1
H dipolar 
anisotropy, which is sensitive to motions on the s-ms timescale (Figure 2.9).  
Different relative side band intensities correspond to different motional averaging. 
The larger the central band intensities with respect to the side bands, the greater the 
motional averaging. For each of the three peptide aggregates, side band patterns were 
extracted at the 
13
C frequencies of the protonated carbon sites.  
As an example, panels A-C Figure 2.10, show the side band patterns for C of F43 
for Med42-49, Med30-50 and Med1-50 alongside simulated side band patterns calculated 
for dipolar couplings assuming complete rigidity of the C of F43. 
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Figure 2.10 Dipolar anisotropy spectra for the F43 aromatic carbons (F) of 
Med42-49, Med30-50 and Med1-50 aggregates (B-D). Experimental spectra are 
shown in black, and simulated rigid-limit dipolar spectra are shown in red. The 
spectra are offset to improve clarity. 
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The amplitudes of motion at each site can be expressed as an order parameter S 
(Huster et al., 2001), which is calculated from the observed dipolar anisotropy       
divided by the maximum anisotropy (i.e. rigid limit) ( ) (Equation 2.2). 
  
  
 
          2.2 
  
Complete isotropic motional averaging gives an order parameter of zero, and a 
completely rigid site gives an order parameter of 1. The dipolar coupling rigid limit 
is calculated using equation 2.3 and setting the inter-nuclear distance to correspond 
to the C-H bond limit: 
        
  
  
         
              2.3 
 
The dipolar coupling constant         for a hetero-nuclear dipolar coupling between 
two spins (Ij and Sk) is related to the inter-nuclear distance         by the 
gyromagnetic ratio of the two nuclei I and S, reduced Planks constant (  and the 
molecular moment 0.  
For Med42-49, all of the sites have high-order parameters (>0.9), consistent with no 
motional averaging on the s–ms timescale of the peptide backbone and side groups, 
including F43 (Figure 2.11).  
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Figure 2.11 Site-specific order parameters for the medin peptide aggregates. 
Lower values are consistent with increased amplitudes of motion on the µs–ms 
timescale. Asterisks indicate that the peaks for C of F43 and S45 overlap in the 
DIPSHIFT spectra, and the values thus represent averages for the two sites. 
 
Residues within amyloid cores tend to be rigid in both the backbone and side chain 
sites, as observed for prion fibrils (Helmus et al., 2011) and also for stabilised A 
protofibrils (Scheidt et al., 2011), whereas N-terminal and C-terminal flanking 
residues are more dynamically disordered.  
It appears that the N-terminal segment of Med42-49 is highly ordered and may 
therefore be stabilised by a full complement of inter-strand hydrogen bonds and 
inter-sheet side chain interactions. For Med30-50 and Med1-50, the backbone order 
parameters are also consistent with a rigid amyloid core (Figure 2.11). Order 
parameters for F43 however, are substantially lower (~0.6) indicating higher 
amplitudes of motion of the aromatic ring compared with Med42-49 (Figure 2.11). 
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Thus, the dynamics again suggest that the chain packing of Med42-49 is different from 
the two longer peptides. 
2.3.4.4. Solution state NMR studies of Med1-50 
A key area of current amyloid research is the study of intermediate species along the 
amyloid pathway such as oligomers. These oligomers, unlike the mature fibrils, are 
often soluble and may therefore be amenable to study by solution NMR. In order to 
investigate whether this would be a viable avenue of investigation, preliminary 
solution state experiments were carried out. As the solid state NMR data of the three 
peptides indicate that they each have distinct morphologies and aggregate structures, 
thus only freshly dissolved Med1-50 was prepared for solution state NMR 
investigation.  
Furthermore, the selective labelling scheme would reduce the complexity of the 
spectra and would be a good sample to test the possibility of characterisation of the 
early oligomerisation of medin using solution state NMR.  
1
H-NMR spectra of synthetic medin (20 M) were collected on freshly prepared 
medin (see section 2.2.3 for details) and following 6 days incubation in the NMR 
tube. Interestingly, even freshly prepared medin showed evidence of oligomerisation 
giving broad peaks and uncharacteristic of a monomeric 50 amino acid peptide 
(black spectrum, Panel A, Figure 2.12).  After 6 days incubation, precipitate was 
visible at the bottom of the NMR tube, the signals are considerably broader and there 
is a loss in intensity (red spectrum Figure 2.12). This suggests that medin has formed 
large aggregates that have precipitated and are therefore no longer visible by solution 
state NMR. 
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Figure 2.12 
1
H-NMR spectra of synthetic medin (200 M) dissolved in 90% 
1
H2O + 10% deuterated DMSO. Data were collected on a Bruker Avance 600 
spectrometer operating at a static magnetic field of 14 T. Black spectra 
represents freshly prepared medin sample and red spectra were recorded after 
6 days incubation in the NMR tube at 25 °C. Full 
1
H-NMR spectra are shown in 
A, expanded amide and carbon regions are shown in B and C respectively. 
 
Two-dimensional HSQC experiments were carried out on the same sample. These 
data show attenuation of the peaks over the time course, with the exception of the 
glutamine side chain (Figure 2.13). This suggests that the side chain group retain 
flexibility whereas the backbone amides are restrained. There is no chemical shift 
change suggesting that these peaks represent multiple steady-state oligomer 
populations.  
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The broad linewidths observed in the 1H-NMR spectra of the freshly dissolved 
peptide and the lack of shift changes in the 2D indicate that it would be very difficult 
to study medin aggregation in this way. As such, this approach was abandoned in 
favour of further biophysical characterisation and additional solid-state NMR 
experiments. 
 
Figure 2.13 Heteronuclear single quantum coherence (HSQC) spectra overlay of 
full length synthetic medin isotopically labelled in the region NH2-FGSVQ-
COOH in 90 % H20, 10 % DMSO. Spectrum of freshly prepared sample (black) 
overlaid with a spectrum recorded following 6 days incubation (red). Data were 
collected on a Bruker Avance 600 spectrometer operating at a static magnetic 
field of 14 T.  Asterisks represent ambiguous assignment. 
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2.4. Discussion 
2.4.1. Investigating the role of predicted amyloidogenic regions on the kinetics, 
morphology and structure of medin 
Kinetic analysis of the three peptides suggests that they have distinct aggregation 
kinetics. Previous data indicate the Med42-49 aggregates rapidly within 48 hours 
(Madine et al., 2009a), and data shown here (Figure 2.5) imply that Med30-50 and 1-50 
have not reached completion after 21 days of incubation. There are also differences 
in the lag times between Med30-50 and 1-50 further demonstrating the variation in the 
aggregation kinetics of the three peptides. TEM analysis revealed striking 
morphological differences between the three peptides (Figure 2.6). Together these 
data indicate that truncation of the medin sequence results in distinct aggregation 
kinetics and morphologies. 
There is an increasing body of detailed structural information on the fibrillar 
aggregates of , IAPP and several other amyloidogenic polypeptides associated 
with disease, as well as for numerous shorter peptides derived from these molecules. 
Solid-state NMR has played a key role in providing experimental constraints from 
which models of fibril architecture have been constructed (Paravastu et al., 2008, 
Luca et al., 2007, Van Melckebeke et al., 2010). Although medin is the most 
common form of localised amyloid, virtually nothing is known about its fibrillar 
assembly at the molecular level.  
Investigation of two peptides Med30-50 and Med1-50 together with previous data on 
Med42-49 by Madine et al (2009) provided a means to examine the effect of three 
predicted amyloidogenic regions on the aggregation properties of medin. 
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Several methods shown here suggest that Med42-49 has a different fibril packing 
arrangement to Med30-50 and Med1-50. The properties of F43 appear to be particularly 
diagnostic of differences in the molecular organisation of the Med42-49-spine 
compared with Med30-50 and Med1-50. In the structural model of the Med42-49 -spine 
described by Madine et al (2009) (Panel A, Figure 2.14), F43 and F48 of adjacent -
sheet layers are positioned close enough together to allow a stabilising  
interaction between them. The fibril architectures of Med30-50 and Med1-50 may 
preclude such a  interaction because cross-peaks between F43-V46 are not 
visible in the RR experiments suggesting that the inter-nuclear distance between F43-
V46 is longer in Med30-50 and Med1-50 than in Med42-49 (Panel B, Figure 2.14). This 
might also explain the higher mobility of F43 ring seen for the two longer peptides. It 
is possible that the anomalous chemical shifts seen for F43 of Med42-49 (Panel B, 
Figure 2.7) reflect local distortions in the backbone geometry that are needed to 
accommodate the  interaction. 
 
Figure 2.14 A model of the Med42-49 cross--spine comprising two-sheet layers 
in a face-to-back arrangement (Nelson et al., 2005). The model satisfies the close 
through-space distance between F43 and V46 and allows a  interaction 
between F43 and F48 of adjacent -sheet layers as seen in Med42-49.  
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Until further structural constraints are obtained, it is only possible to speculate on the 
origins of the different F43 ring position and dynamics for Med30-50 and Med1-50 
compared with Med42-49. Structural models of longer amyloidogenic polypeptides 
often indicate the presence of one or more turn regions within the fibril structure 
(Paravastu et al., 2008, Petkova et al., 2002, Luca et al., 2007) whereas fibrils of 
shorter peptides, including Med42-49, tend to be assembled from linear strands 
(Madine et al., 2008c, Madine et al., 2009a). 
 The different aggregate morphologies for Med1-50 and Med30-50 observed using TEM 
suggest that truncation of the 19 residues at the N-terminus significantly alters the 
structure of the fibrils. The similar SSNMR results for Med30-50 and Med1-50 may 
therefore not necessarily translate into similar fibril architectures for the two peptides 
at the molecular level, but further SSNMR measurements may confirm this.  
Previous studies on amyloid fragments have shown that they rarely have the same 
fibril structure as their full length counterparts (Paravastu et al., 2006, Bu et al., 
2007, Paravastu et al., 2008). This research emphasises the need to investigate the 
full length peptide alongside fragments, to correctly identify key structural and 
amyloidogenic features for future investigation. 
Preliminary solution state NMR investigations of the early stages aggregation 
indicate that even freshly dissolved Med1-50 shows signs of aggregation. Although the 
study of early amyloid species is important, given the known toxicity of oligomeric 
species, the structural characterisation of these species by solution state NMR was 
not pursued within this thesis.  
Taken together, these results indicate that at least two of the three predicted 
amyloidogenic regions are required for the formation and elongation of medin fibres 
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observed in the disease state. These results provide the motivation for further, more 
detailed structural studies of this poorly characterised amyloidogenic polypeptide. 
This data also demonstrates that Med42-49 is not a good structural model for full 
length medin. Consequently, full length medin will be studied for the remainder of 
this thesis.  
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3. Recombinant expression and purification of 
medin 
3.1. Introduction 
As the previous chapter has demonstrated, it is important to study full length medin. 
To date there are no detailed published protocols for the production of recombinant 
medin. The primary objective of this work was to establish a method for the 
production of soluble medin, in sufficient quantities for aggregation studies and 
structural analysis by solid state NMR. NMR experiments, in particular solid state 
NMR experiments, require large quantities of isotopically labelled protein. This 
chapter will discuss the methods used to produce, purify and prepare medin for 
aggregation and structural studies.  
Isotope labelling is an important part of sample preparation for NMR spectroscopy. 
The use of stable isotope labels (
13
C and 
15
N) improves resolution and sensitivity, 
and can reduce the complexity of spectra allowing for better interpretation of the data 
(Lian and Middleton, 2001). The majority of macromolecular NMR studies employ 
13
C, 
15
N and 
2
H either in isolation or combination. There are multiple methods and 
strategies used to label proteins of interest. These include: selective labelling of 
single residues using cell free or synthetic peptide production (Torizawa et al., 2004), 
selective or inverse labelling where metabolic precursors or unlabelled amino acids 
are incorporated into the media (Hiroaki et al., 2011) or uniform labelling (McIntosh 
and Dahlquist, 1990) in which all residues are labelled.  
For the purposes of this thesis the most cost effective and straightforward way to 
produce uniformly labelled proteins is to use a bacterial expression host, most 
commonly Escherichia coli (E.coli).  These cells are ideal for this purpose as they 
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grow rapidly, have a high plasmid copy number and are easy to maintain. 
Furthermore, there are many strains and vectors available, which provide a high level 
of control over the expression process. Generally E.coli will grow in a variety of 
growth media and rarely require the addition of expensive growth supplements. It is 
this property that allows the expression of isotopically labelled protein in milligram 
quantities suitable for NMR and unlabelled protein for other studies. 
This chapter details the techniques and work-flow involved in producing both 
unlabelled and isotopically labelled wild-type medin. The protein prepared using the 
methods described here was later used to characterise the aggregation properties of 
medin in subsequent chapters. 
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3.2.   Materials and methods 
3.2.1. Recombinant expression of medin in E.coli 
3.2.1.1. Construct design 
The medin gene was purchased from GenScript (U.S.A.) and inserted into a 
pMALC2X (Invitrogen) vector. The pMALC2X vector enables the expression and 
purification of the protein of interest fused to maltose binding protein (MBP). The 
cloned gene is inserted downstream of the MalE gene which gives rise to the 
expression of an MBP-fusion protein. It also encodes for a factor Xa cleavage site 
that allows for the separation of the target protein from MBP. In addition the 
pMALC2X vector contains ampicillin resistance gene for selection. This vector was 
chosen for the high solubility of MBP which would increase the yield of soluble 
protein and minimise the incorporation of medin into inclusion bodies (Waugh, 
2005) A tobacco etch virus (TEV) protease cleavage site was also cloned into the 
vector as TEV protease was available in-house thus making it more cost effective 
than purchasing factor Xa (Figure 3.1).  
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Figure 3.1 (A) Deoxyribose nucleic acid (DNA) sequence of the inserted gene 
containing the TEV protease recognition sequence (red) followed by medin 
sequence (black) and the stop codon in brackets. (B) Schematic of the resultant 
fusion protein. Red arrows indicate the protease cleavage site, black arrows 
indicate restriction sites. 
 
3.2.1.2. Preparation of chemically-competent cells 
Competence is the term given to cells that are capable of incorporating extracellular 
deoxyribose nucleic acid (DNA) from the environment into their own genome. Some 
cells are naturally competent, but most cells need to be treated to make them 
transiently permeable to exogenous DNA. There are two principal methods for this 
process, electroshock and chemical competency; this work employed the use of 
chemically competent cells.  
The protocol used is a variant of the Hanahan method (Hanahan et al., 1991) and is 
based on the use of calcium chloride. Prior to starting the protocol all glass and 
plastic ware was free of detergent and chilled. A single colony was selected from a 
streaked agar plate containing the plasmid and used to inoculate 2 ml of super 
optimal broth (SOB) media (Appendix 1) and grown overnight at 25 °C. Sterile 
glycerol was added to 1 ml of this starter culture at a final concentration of 15 % 
(v/v) and transferred to a cryovial for long term storage at -80 °C. The remaining 1 
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ml of culture was used to inoculate 250 ml of SOB media and grown at 20 °C until 
an optical density (O D) of 0.3 at 600 nm (OD 600 = 0.3) was obtained. Cells were the 
harvested by centrifugation at 3000 g for 10 minutes and gently resuspended in 80 ml 
of ice cold CMB80 buffer (Appendix 1). The resuspended cells were then incubated 
on ice for 20 minutes and the centrifuged a second time at 4 °C prior to resuspension 
in 10 ml of ice cold CMB80 buffer. The OD at 600 nm of the suspension was tested 
by adding 20 L of the cell suspension to 200 L of super optimal media with 
catabolite repression (SOC) media. The OD was adjusted to between 1 and 1.5 by the 
addition of CMB80 buffer. Aliquots of 50 L were generated and stored at -80 °C 
indefinitely.  
3.2.1.3. Transformation of vector into chemically competent cell lines. 
Transformation is the process whereby an engineered vector is incorporated into the 
genome of competent cells. A standard method was followed for all vectors and cell 
lines (Sambrook, 1989). In brief 50 L aliquots of competent cells were thawed on 
ice prior to the addition of 2 L of target vector. Following incubation on ice for 30 
minutes the cells were heat-shocked at 42 °C for 45 seconds and then returned to ice. 
950 L of SOB media was then added and the cells incubated at 37 °C for 30 
minutes prior to plating out on agar plates containing antibiotic. The agar plates were 
incubated at 37 °C overnight and then stored at 4 °C.  
Two E.coli strains were used in the process of this work, BL21 (DE3) cells for 
expression and XL1 blue cells for cloning, both supplied by NEB.  
3.2.1.4. Expression tests 
In order to identify the optimal conditions for growth and expression of the target 
protein, trials of temperature and expression time were carried out. The vector was 
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transformed into E.coli BL21 (DE3) competent cells. A colony was then selected and 
grown in 50 ml of Luria broth (LB) (Appendix 1) containing antibiotic overnight at 
37 °C. This culture was then spun down at 3000 x g and used to inoculate 2 L of LB. 
The culture was incubated at 37 °C until an OD 600 = 0.8 was reached. The culture 
was then divided equally into 3 flasks. Then they were equilibrated at three different 
temperatures 20 °C, 30 °C and 37 °C. Expression of the fusion protein was induced 
by the addition of isopropyl -D-thiogalactoside (IPTG) to a final concentration of 1 
mM. Cell growth was then allowed to continue and samples were taken from all 
three flasks after 3 and 5 hours incubation. The remaining cultures at 20 °C and 30 
°C were allowed to continue growing overnight and harvested the following 
morning. All the samples were then lysed by sonication and then centrifuged at 
19000 x g, the supernatant and pellet were collected for analysis by sodium-dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
The resuspended cells were subjected to a single freeze-thaw cycle prior to 2 French 
press cycles in the presence of DNase at a final concentration of 20 ng/ml and a 
cOmplete™ EDTA-free protease inhibitor cocktail tablet (Roche applied sciences). 
The lysed cells were then centrifuged at 19000 x g to remove the cell debris and the 
supernatant filtered through a 0.22 µm Acrodisc
TM
. 
3.2.1.5. Expression of medin in the pMALC2X vector 
The transformation, overnight culture, inoculation of the media and initial growth 
were carried out as described in section 3.2.1.4, using terrific broth (TB) (Appendix 
1) instead of LB as it resulted in a higher cell density and thus a higher yield of 
expressed protein. As detailed above, the fusion protein expression was induced by 
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the addition of IPTG to a final concentration of 1 mM. Cell growth was then allowed 
to continue for a further 3 hours at 30 °C prior to cell lysis as described above.  
3.2.1.6. Sub-cloning of medin into pOPINS vector 
The pOPIN suite of vectors developed at the Oxford Protein Production Facility 
(OPPF) can be used in conjunction with the In-Fusion™ PCR cloning system 
(Clontech) (Berrow et al., 2007). This method is a ligase independent method that is 
quicker and more efficient than many sub-cloning techniques and the pOPIN suite 
provides several options for fusion partners and cleavage sites. A second vector was 
designed to improve the expression and purification of medin (Figure 3.2, Figure 
3.3.)  
 
 
 
Figure 3.2 Schematic representation of the pOPINS-medin construct 
highlighting the key features of the plasmid. Generated using SnapGene® 
Viewer 1.5.2 (from GSL Biotech, available at snapgene.com). 
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Cloning was carried out as described in Berrow et. al.(Berrow et al., 2009). In brief 
the medin sequence was amplified using the polymerase chain reaction (PCR) with 
specific primers (Sigma Aldrich) designed for insertion into pOPINS, red areas 
indicate the vector specific sequence and black is template specific:   
 
Forward primer  
GC GAA CAG ATC GGT GGT CGT CTG GAC AAA CAG GGT AAC 
Reverse Primer  
ATG GTC TAG AAA GCT TTA AGC AAC GAA CTG AAC GGA AC 
 
 pOPINS was grown up in XL1 blue cells in LB at 37 °C overnight and then isolated 
from the cells using a midi-plasmid prep kit (Sigma Aldrich). The purified plasmid 
was then digested for 2 hrs at 37 °C with HindIII and Kpn1 (NEB). The amplified 
medin sequence and the digested vector were then added to the dried down In-
Fusion™ mixture (Clontech) and incubated at 42 °C for 30 minutes. 2 L of the 
mixture was then used to transform an aliquot of XL1 blue cells and plated out onto 
an agar plate containing 0.1 mM IPTG, 40 g/mL XGal and 35 g/mL of 
kanamycin. Several white colonies were selected, grown in 5 mL of TB and the 
plasmid isolated using a midi-plasmid prep kit (Sigma Aldrich). The purified plasmid 
was then sequenced (GATC, London U.K.).   
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Figure 3.3 (A.) Schematic of the sub-cloning work-flow. (B.) Schematic of the 
fusion protein generated from the pOPINS-medin construct, arrow indicates 
cleavage site.  
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3.2.1.7. Agarose gel electrophoresis 
A 1 % agarose gel was run to confirm that the PCR reaction and digestion were 
successful. To construct the gel, 1 g of agarose was dissolved in 100 ml of tris-
acetate-EDTA (TAE) buffer (Appendix 1) by heating, poured into the gel cast and 
0.5 g/ml ethidium bromide added and mixed. Once set the gel was transferred to a 
gel tank and covered in TAE buffer. 5 l of the PCR reaction or digested vector was 
mixed with 1 l 5 x gel loading buffer (NEB) and loaded. The gel was run at 100 V 
for 60 minutes prior to visualisation under UV light.  
3.2.1.8. Expression of pOPINS construct 
Initially expression tests of the new construct were carried out as described in section 
3.2.1.4 and the optimal conditions were shown to be overnight incubation at 20 °C. 
The overall expression and lysis protocol was carried out as described above. The 
only exception being that kanamycin was used as opposed to ampicillin for selection, 
at a final concentration of 35 g/ml.  
For the preparation of 
13
C and 
15
N labelled medin, BL21 (DE3) cells were initially 
grown overnight in LB and then transferred to minimal media for expression with 
13
C6 glucose as the only carbon source and 
15
NH4Cl  as the only nitrogen source (See 
Appendix 1 for full details). All other variables remained the same as for those 
described for rich media. 
3.2.2. Purification of MBP- medin fusion protein 
3.2.2.1. Amylose affinity purification 
The fusion protein can be isolated from crude extract by the use of affinity 
chromatography. The MBP-tagged protein will bind to amylose resin, whereas other 
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protein will flow through the column. The bound target protein can be eluted by the 
addition of maltose to the buffer which out competes MBP for amylose binding. 
A 10 ml self-packed amylose column (GE Healthcare, NEB) was equilibrated with 5 
column volumes (CV) of amylose binding buffer (Appendix 1), 5 CV of maltose 
buffer (Appendix 1) and a further 5 CV of amylose binding buffer. The filtered 
supernatant was then loaded onto the column at a flow rate of 2 ml/minute using a 
peristaltic pump. The column was washed with 10 CV of amylose binding buffer to 
remove any non-specific binding. The fusion protein was eluted with 3 CV of 
maltose buffer in 3 ml fractions. Fractions were tested for the presence and quantity 
of fusion protein using Bradford reagent (Sigma Aldrich). 10 L of the fraction was 
added to 990 L of Bradford reagent and the absorbance at 590 nm recorded and 
compared to a standard curve (Marion M, 1976). The fractions containing the fusion 
protein were then pooled prior to cleavage. 
3.2.2.2. Cleavage 
TEV protease was expressed and purified in-house as described in Appendix 2. TEV 
protease was added in a ratio of 1:20 with the fusion protein and incubated for 4 
hours at 37 °C.  
3.2.2.3. Isolating medin 
Due to the large difference in molecular weight between medin and MBP gel 
filtration was used to isolate medin. Prior to gel filtration the sample was 
concentrated to a volume of  2 ml using an Amicon® Ultra-15 centrifugal filter with 
a 30 kDa cut off (Millipore) to optimise separation. A Superdex 75 26/60 gel 
filtration column (GE Healthcare) was equilibrated overnight (10 CV) in amylose 
binding buffer at a flow rate of 2 ml/min. The concentrated sample was then loaded 
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and run at 2 ml/min on an ӒKTA protein purifier (GE Healthcare). Elution was 
monitored by absorbance at 280 nm and 2 ml fractions were collected.  
3.2.2.4. Purification of SUMO-Medin fusion protein 
The SUMO-medin fusion protein can also be isolated from crude extract with the use 
of affinity chromatography. The presence of the His6-tag enables the use of 
immobilised metal affinity chromatography (IMAC), using resin functionalised with 
Ni
2+
 ions. The histidines bind to the nickel ions whilst other proteins wash through 
the column. The bound protein is then eluted with imidazole, which competes with 
the Ni
2+
 to chelate the histidines.  
As far as possible the purification was carried out on ice. A 5 ml His-Trap FF ™ 
column (GE Healthcare) was equilibrated with 5 CV of His-trap buffer A and 5 CV 
of his-trap buffer B followed by a further 5 CV of His-trap buffer A at 4 ml/min. 
Following equilibration, the filtered supernatant was loaded onto the column using 
an ӒKTA purification system at 1 ml/min (GE Healthcare).  
A step-wise gradient was employed to remove non-specific contaminant proteins. 
This was followed by a linear gradient (Figure 3.9), to elute the target protein. 
Fractions of 3 ml were collected and those containing the fusion protein were pooled 
and desalted to remove the imidazole in preparation for the reverse His-trap 
purification step after cleavage. A Hi-Prep desalting column 26/10 (GE Healthcare) 
was equilibrated with 2 CV of His-trap buffer A prior to sample loading via the 
peristaltic pump. 2 ml fractions of the desalted protein were pooled in preparation for 
cleavage. 
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3.2.2.5. Cleavage and removal of the His6-SUMO tag. 
The His6-SUMO tag was removed by incubation with SUMO-protease (produced in-
house), at a final concentration of 2.5 M, at 25 °C for 3 hours. In order to remove 
the tag, the mixture was passed back down an equilibrated 5 ml His-Trap FF ™ 
column (GE Healthcare) and the flow through containing the medin peptide was 
collected and snap frozen in liquid nitrogen for later use.  
3.2.3. Characterisation 
3.2.3.1. SDS PAGE gel analysis and staining methods 
The expression and purification of medin was analysed by SDS-PAGE using the 
Laemmli method (Laemmli, 1970). Analysis was carried out using 15% 
polyacrylamide gels in a Bio-Rad gel electrophoresis system. 5 l protein samples 
were added to 5 l of 2 x sample buffer, boiled and loaded onto the gel. All gels were 
run at 200 V for 60 minutes and then stained with Coomassie Brilliant Blue G-250 
stain and de-stained with destain solution (Appendix 1). 
Medin was difficult to visualise with the Coomassie Brilliant Blue G-250 with 
normal SDS-PAGE gels so other gel compositions and visualisation techniques were 
considered.  
Tris-Trycine gels were constructed and run as described by Schagger and von Jagow 
omitting the spacer gel as it is usually only necessary for separating peptides with a 
molecular weight below 3 kDa (Schägger and von Jagow, 1987). See  
Appendix 1 for further details of buffers and gel construction. 
Silver staining was carried out as published in Cell Biology: a laboratory handbook 
(Celis, 2006). In brief, the gel was fixed for a minimum of 2 hours and then washed 
in 20 % EtOH, The gel was rinsed in sensitising solution, and then washed twice 
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with dH2O. Chilled silver stain was added to the washed gel and incubated for 20 
minutes. The stain was removed and the gel washed a further two times with dH2O 
prior to the addition of developing solution. 
Gluteraldehyde cross-linking was carried out in an attempt to reduce protein leaching 
from the gel (Hopwood, 1972). Cross linking was performed with consecutive 
washes of methanol, acetic acid and water in different ratios (Appendix 1). The gel 
was then incubation with 1 % gluteraldehyde in H20 for 30 minutes, followed by 
further washes and then stained as normal with Coomassie Brilliant Blue G-250. 
Trichloroacetic acid (TCA) can be used to precipitate proteins within a 
polyacrylamide gel (Link and LaBaer, 2011). The gel was first incubated with 10 % 
TCA for 30 minutes and then washed with 50 % methanol and 10 % acetic acid 
mixture in H2O prior to staining with Coomassie Brilliant Blue G-250. 
3.2.3.2. Western blot analysis 
Polyclonal anti-bodies against two epitopes of medin, corresponding to residues 1-10 
and 19-31, were raised in rabbit and purified by GenicBio (Hong Kong). Anti-rabbit 
IgG peroxidase conjugate (A6154) was purchased from Sigma Aldrich. 
SDS-PAGE 15% gels were run as described above and then transferred to 
polyvinylidene fluoride (PVDF) membrane in ice-cold transfer buffer (Appendix 1) 
for 1 hr at 100 V. The membrane was blocked overnight at room temperature with 
PBS with 5 mg/ml BSA to prevent non-specific binding. The primary antibody was 
added at a concentration of 1:10000 in PBS containing 5 % Tween. Following a 1 hr 
incubation at room temperature, the membrane was washed and then incubated with 
anti-rabbit IgG peroxidase conjugate (A6154) as per the manufacturers’ instructions. 
The immunoreactive bands were visualised by the addition of 0.5 mg/ml 
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3,3’diaminobenzidine tetrahydorchloride (DAB) (Sigma Aldrich) with 10 L 
hydrogen peroxidase in  50 ml of phosphate buffered saline (PBS) (Appendix 1).  
3.2.3.3. Tryptic digest MS-MS. 
Purified peptide (2 g) was resuspended in 50 mM ammonium bicarbonate pH 7.8 
containing 2 M urea and digested overnight with 0.1 g trypsin. The resulting 
peptides were cleaned up using C18 Zip Tips (Millipore) in readiness for analysis by 
either MALDI-MS or ES-MS. MALDI-MS analysis was performed using a MALDI-
TOF instrument (Waters-Micromass) on samples dried on to the target plate using a 
saturated solution of alpha-cyano-4 hydroxycinnaminic acid in 50 % acetonitrile/0.1 
% trifluoroacetic acid. For ES-MS analysis, the sample was infused into the nano 
electrospray source of the mass spectrometer (Waters Q-ToF micro), at a flow rate of 
150l/hour, via a gas tight syringe. The positive ion mass spectrum of the sample 
was recorded. 
3.3. Results and Discussion 
3.3.1. Cloning, expression and purification of medin  
3.3.1.1. pMALC2X construct 
The pMALC2X construct was transformed into BL21 (DE3) competent cells for 
expression of the fusion protein. BL21 (DE3) cells are a widely used expressing 
strain of E.coli. as they have reduced protease activity which often results in high 
protein yields. Expression tests are a quick and efficient way of identifying the 
optimal expression conditions for a construct and for pMALC2X these conditions 
were shown to be 3 hours incubation at 30 °C. The yield of fusion protein was 
further improved by the use of TB media instead of LB. Despite the use of the MBP-
tag to improve solubility, approximately half of the expression fusion protein was 
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found in the pellet; nevertheless, the yield of fusion-protein was sufficient to 
continue with only the soluble portion (Figure 3.4, lanes 2 and 3).  
 
Figure 3.4 15 % SDS-PAGE of the expression and purification of medin in the 
pMALC2X vector. Gel on the right demonstrates the improved performance of 
the increased amylose column. Lane 1. Low-molecular weight markers, lane 2. 
flow-through from the 10 ml amylose column showing full fusion protein 
capture. Both gels were stained with Coomassie Brillian blue stain. 
 
The affinity purification using amylose resin to bind the MBP tag was successful 
(Figure 3.4, lane 5) with few contaminants remaining after this initial stage of 
purification.  However the yield was so high that it exceeded the binding capacity of 
the amylose column and appeared in the flow through (Figure 3.4, lane 4). This 
problem was overcome by increasing the bed volume of the column from 5 ml to 10 
ml of amylose resin, thus increasing the binding capacity, which then resulted in 100 
% capture (right-hand gel, lane 2, Figure 3.4). There was no fusion protein observed 
in the flow through. 
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Cleavage of the fusion protein by TEV protease was inefficient under normal 
conditions (overnight incubation at 4°C) and resulted in only approximately 50 % 
(Figure 3.4, lane 6).  As such a cleavage trial of different temperatures and 
incubation times was carried out in an attempt to improve the yield (Figure 3.5).  
 
 
Figure 3.5 15 % SDS-PAGE of the MBP-fusion protein cleavage trial results, 
each lane represents a different condition. Gel is visualised using Coomassie 
Brilliant blue stain. 
 
 
The best cleavage was observed at 37 °C after 16 hrs of incubation (Figure 3.5, lane 
10.) There was also a large amount of precipitate under these conditions therefore it 
was decided that cleavage at 37 °C for 4 hrs was the best compromise between 
cleavage and the amount of precipitate. Normally TEV protease demonstrates very 
efficient cleavage and it is unknown why it is poor in this case (Kapust and Waugh, 
2000). There are a few possible explanations for this poor cleavage. Medin, like 
many amyloid proteins, is highly hydrophobic and it may be wrapping around and 
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‘sticking’ to the MBP and therefore occluding the cleavage site. A second possibility 
is that fusion protein is aggregating, again blocking the cleavage site. There have 
been reports of MBP aggregation (Zanier et al., 2007) and as expected, medin is 
prone to self-assembly.  
Size exclusion chromatography was used to isolate medin from the cleavage mixture. 
This was considered to be a suitable purification method as there is a large difference 
in molecular weight between the proteins, 45 kDa and 5.5 kDa for MBP and medin 
respectively. Initially the protein mixture was concentrated down to 2 ml in an 
Amicon® Ultra-15 centrifugal filter with a 30 kDa cut off (Millipore) to ensure good 
resolution the column. It was loaded onto a Superdex 75 26/60 gel filtration column 
(GE Healthcare) and all the peak fractions were kept for SDS-PAGE analysis. As can 
be seen in Figure 3.6 (peak 1), a large amount of protein elutes in the void volume 
suggesting that the species present is larger than 75 kDa. Theoretically the largest 
species present would be any intact fusion protein with a molecular weight of 48 kDa 
which should not elute in the void volume. Furthermore the size of the peak suggests 
that it is unlikely to be a contaminant. SDS-PAGE analysis confirms that this peak 
contains un-cleaved fusion protein. It is likely that the fusion protein has aggregated 
and is therefore unable to enter the column matrix but dissociates under the 
denaturing conditions of SDS-PAGE. This would also be consistent with occlusion 
of the cleavage site.  
 90 
 
 
Figure 3.6 Gel filtration chromatogram of cleavage mixture. Concentrated 
cleavage mixture was run on a Superdex 75 26/60 gel filtration column (GE 
Healthcare) in 20 mM Tris, 0.2 M NaCl, pH 7.4 at 2 ml/min. 15 % SDS-PAGE 
analysis of peaks 
 
Peak 4 contains MBP alone (peak 4, inset, Figure 3.6). The two smaller peaks (2 and 
3) at ~120 and ~140 ml are shown to include both un-cleaved and isolated MBP 
(Figure 3.6). It is probable that they represent different sized aggregates or 
conformers. Medin should elute at approximately 250 ml, a small peak can be seen at 
the correct elution volume, yet the intensity is not what would be expected and there 
was no protein band visible following SDS-PAGE analysis of the peak. This may 
again be a result of aggregation; however it is more likely that hydrophobic nature of 
medin has caused it to adhere to the filter in the concentration step or prior to 
loading. Due to the numerous problems with the purification, it was decided to sub-
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clone medin into an alternative vector that may improve or eliminate the problems 
encountered with the pMALC2X vector.  
3.3.1.2. pOPINS construct 
The pOPINS vector was chosen because the fusion partner His6-SUMO is highly 
soluble and a more comparable size to medin. Furthermore the SUMO protease 
recognises tertiary structure rather than sequence and therefore may overcome some 
of the cleavage problems that occurred with the pMALC2X construct. Moreover the 
His6 element provides a simple method of fusion protein purification and subsequent 
removal of the tag (Figure 3.2). 
The medin sequence was amplified using the vector specific primers successfully as 
confirmed by agarose gel electrophoresis, (Figure 3.7, panel A). The pOPINS vector 
was grown, purified and linearised as described in (Berrow et al., 2007). This was 
confirmed by visualisation on an agarose gel with a strong band at ~ 5.5 Kbp (Figure 
3.7). The In-Fusion™ reaction was successfully carried out and the resultant mixture 
transformed into XL1 Blue cells and plated onto an LB-Agar plate containing 
kanamycin, XGal and IPTG. Following an overnight incubation, a mixture of blue 
and white colonies was observed. Several white colonies were selected, grown and 
the plasmids purified and sent for sequencing. The sequencing data confirmed the 
insertion of the medin gene into the pOPINS vector (Appendix 2).  
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Figure 3.7 Agarose gel of sub-cloning elements. Amplified medin gene generated 
using the vector specific primers (A). Purified linearised pOPINS vector (B). 
 
The pOPINS vector containing the medin gene was transformed into BL21 (DE3) 
cells for expression. Initially expression tests were carried out to identify the optimal 
conditions of growth and expression.  
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Figure 3.8 Expression trials of medin-pOPINS vector in BL21 (DE3) cells. Lanes 
1 and 11. Low molecular weight markers (Sigma Aldrich). All other lanes 
represent different growth conditions (SN = supernatant, P = pellet).   
 
These tests indicated that the optimal conditions for yield and solubility were 
overnight incubation at 18 °C (Figure 3.8, panel B, ON 18°C SN). These conditions 
were also optimal for expression in isotopically labelled media. The cells were 
harvested and lysed as described for the pMALC2X vector. The initial his-trap™ 
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purification was very effective at isolating the fusion protein. The small step 
gradients eliminate any non-specific binding and then a large amount of protein 
elutes at the upper end of the imidazole gradient consistent with the fusion protein 
(Figure 3.9).  
 
 
Figure 3.9 Affinity purification chromatogram of the fusion protein isolation. 
Sample was run on a 5 ml histrap FF column (GE Healthcare) in his trap buffer 
A with a gradient of his-trap buffer B (Appendix 1).   
 
SDS-PAGE analysis of the large peak indicated the presence of three large protein 
bands approximately 20 kDa in size that bound to the his-trap™ column (Figure 
3.10, lane 2). It may be that these represent three different conformations of fusion 
protein. The pooled fractions containing the fusion protein were desalted back into 
his-trap buffer A prior to cleavage. Cleavage was carried out at 25 °C for 2 hours, 
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approximately 60 % of the fusion protein was cleaved within this time (Figure 3.10, 
lanes 2 and 3). It appears that the upper two proteins are cleaved successfully, 
however the lower protein band remains un-cleaved. As it is has run the furthest 
through the gel matrix, it is possible that in this third conformation the medin peptide 
is wrapped tightly around the SUMO fusion partner making it more compact and 
thus enabling it to travel further than its counterparts. As a consequence the cleavage 
site may be inaccessible to the SUMO-protease.  
 
Figure 3.10 Tris-Trycine SDS-PAGE analysis of the purification and cleavage of 
medin within the pOPINS construct  
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3.3.2. Characterisation of medin 
3.3.2.1. Visualisation 
Throughout the purification, it has been difficult to observe medin upon SDS-PAGE 
analysis with normal Coomassie staining. Initially it was thought that the 
concentration might be too low. Therefore, for the cleavage trail, the lanes were 
overloaded to identify if this was the problem (Figure 3.5). Faint bands can be seen 
in Figure 3.5 at the appropriate molecular weight (5.5 kDa), however, they are at a 
much lower intensity than expected for the amount of protein loaded. The next line 
of investigation was to explore alternative stains to eliminate the unlikely possibility 
that medin does not bind Coomassie stain. This is often seen for small amyloid 
peptides including A (M. Pandya, personal communication). Ponceau red and silver 
staining was tried with limited success. The third possibility was that medin, as a 
small protein, was washing out of the gel during staining and destaining. Several 
methods were attempted to investigate this possibility; TCA precipitation, 
gluteraldehyde cross-linking and membrane transfer. The aim of all of these methods 
was to immobilise the protein in some way to prevent leaching during wash steps. 
Unfortunately, all of these methods proved to be unsuccessful, in that they were no 
more effective than the initial overloading. 
The best method for visualising medin is to overload lanes of a tris-trycine gel as can 
be seen in Figure 3.10. The denser gel helps to prevent lateral diffusion within the gel 
and concentrates the sample. This can then be stained with Coomassie stain and 
destained as described previously. Although this method did provide positive results 
it was highly dependent on concentration and only very concentrated samples were 
visible. It was not possible to concentrate medin to high levels as the process 
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accelerated aggregation and resulted in high order aggregates that did not enter the 
stacking gel. 
3.3.2.2. Western blot analysis 
Further verification can be obtained by Western blotting with specific medin 
antibodies, thus providing confirmation that the purified product is indeed medin. 
Figure 3.11 shows the presence of two immunoreactive bands present in the flow 
through following reverse purification.  
 
 
Figure 3.11 Western blot analysis of medin. Lane 1. SeeBlue prestained markers 
(Invitrogen). Lane 2. Flow through from reverse-his purification indicating two 
immunoreactive bands at approximately 5 kDa and 20 kDa.  
 
The band at approximately 5 kDa corresponds to monomeric medin. The second 
fainter band at approximately 20 kDa could be tetrameric medin or a small amount of 
uncut fusion protein. 
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3.3.2.3. Tryptic digest and mass spectrometry 
Additional conformation of the sequence was confirmed by tryptic digest and 
subsequent mass spectrometry. Results from the digest show the presence of peptides 
with masses that match those predicted for the medin sequence (Table 3.1).  This 
data suggest that the purified peptide is indeed medin. The only expected peptide 
missing was the C-terminal fragment with the sequence NH2-NFGSVQFVA-COOH. 
This peptide has previously been identified as the most amyloidogenic fragment of 
medin (Larsson et al., 2007), and it is possible that upon cleavage it aggregates very 
rapidly and therefore is no longer amenable to mass spectrometry. 
 
Table 3.1 Tryptic digest fragments, depicting the sequence, expected mass from 
digest (calculated using MASCOT server) and actual masses obtained from 
MALDI and ES-MS. Fragments, R and LDK are too small to reliably obtain 
masses using MALDI and ES-MS. 
 
Fragment sequence 
Expected 
mass 
MALDI ES-MS 
R - - - 
LDK - - - 
QGNFNAWVAGSYGNDQWLQVDLGSSK 2841.3 2841.2  
EVTGIITQGAR 1144.6 1144.5 1144.5 
NFGSVQFVA 968.4   
 
 
3.4. Discussion 
Aortic medial amyloid is the most common form of localised amyloid yet there 
remains no published method for the large scale expression and purification of 
medin. Chemically synthesised proteins are expensive to purchase and often difficult 
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to obtain therefore it is preferable to use an expression host which is more cost 
effective and provides a replenishable source of peptide. Furthermore, there is 
evidence that synthetically produced and recombinant proteins behave differently in 
vitro (Finder et al., 2010). The lack of a reliable expression protocol has no doubt 
limited research on medin and AMA. The objective of this chapter was to establish 
expression and purification protocols for the production of recombinant medin for 
future characterisation studies. Moreover, the use of an E.coli expression host 
enables the relatively facile incorporation of isotope labels required for NMR 
structural analysis.  
Medin was ultimately cloned into the pOPINS vector and expressed in BL21 (DE3) 
E.coli cells. Small proteins are often susceptible to proteolytic degradation; the use of 
a fusion protein can help protect the peptide from degradation. The use of affinity or 
solubility tags can also assist in the purification. The pOPINS vector contains both a 
His6 affinity tag and a SUMO solubility tag and these tags improved the expression 
and purification of medin. Overall, this system produced approximately 4 mg of 
purified medin per litre of culture. 
One of the biggest challenges of this work was confirmation and visualisation of the 
purified product. It seems likely that the difficulties in visualising medin by SDS-
PAGE are likely a result of two effects, low concentration and a degree of washing 
out during staining. Similar difficulties have been observed for other amyloid 
peptides (personal communication, M.,Pandya,). This is also reflected in the 
numerous alternative staining techniques described in the literature (Walsh et al., 
2009). Attempts to overcome this by concentrating medin to high levels were 
hampered by aggregation. Despite these issues, it was possible to visualise a protein 
band that correlated with the correct molecular weight for medin in some tris-trycine 
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gels (Figure 3.10). It was also possible to confirm the sequence by a combination of 
Western blot analysis (Figure 3.11) and tryptic digests coupled with mass 
spectrometry (Table 3.1).  
This work also demonstrates for the first time the expression of uniform 
13
C/
15
N 
isotopically labelled medin suitable for NMR structural studies. Expression in 
minimal media produced 3 mg of uniform 
13
C/
15
N isotopically labelled medin per 
litre of culture.  
Many amyloid related diseases are caused by mutated variants of amyloid proteins 
(Connors et al., 2000). These variants can have different aggregation kinetics and 
structures (Tycko et al., 2009). This recombinant expression system has now been 
adapted to express mutants of medin (see Chapter 5). This could help identify key 
residues within the medin sequence that are important for aggregation and could 
ultimately become therapeutic targets. 
These protocols will now enable in depth studies into the biophysical and structural 
properties of medin and could lead to a greater understanding of how it affects the 
physiology of the aorta and other blood vessels.  
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4. Biophysical characterisation of medin 
aggregation 
4.1. Introduction 
Despite the ubiquitous nature of aortic medial amyloid, remarkably little is known 
about how medin aggregates into amyloid fibrils. Preliminary information on the 
kinetics and morphology of synthetic medin was presented in chapter 2. The aim of 
this chapter is to characterise the aggregation of medin in greater detail using a range 
of biophysical techniques and recombinantly prepared peptide.  
Previous biophysical studies carried out on medin have identified that the C-terminus 
with the sequence NH2-NFGSVQFV-COOH, is highly amyloidogenic in isolation 
and shares similarity with fragments of the islet amyloid polypeptide (IAPP) 
(Haggqvist et al., 1999, Reches and Gazit, 2004). The region NH2-NFGSV-COOH 
was identified as the minimum motif for amyloid formation. Additionally, the role of 
the phenylalanine residues in the aggregation process was investigated and when 
substituted for non-aromatic residues, resulted in a reduction of aggregation 
potential. This suggests that the two phenylalanine residues could have an important 
role in the aggregation process, possibly though -stacking interactions (Reches and 
Gazit, 2004) . 
Studies by Larsson et al. (2007) used a variety of synthetic and recombinant 
fragments and full length medin and tested them for their ability to bind Congo Red, 
Thioflavin T and to form fibrillar structures visible by electron microscopy. They 
concluded that the C-terminal 18-19 residues comprised the amyloid promoting 
region and that full length medin aggregated after approximately 30 hours (Larsson 
et al., 2007). They further suggested that the two phenylalanine residues discussed by 
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Reches and Gazit (2004) are not essential for fibril formation of the full length 
protein. This work closely examined the sequence requirements for fibril formation 
but did not investigate the kinetic or structural aspects of medin aggregation. 
Additional work by Madine and Middleton demonstrated that full length synthetic 
medin aggregated over a period of 8 days and the fluorescence intensity, size of 
aggregates and toxicity of the resultant species could all be modulated by the 
addition of inhibitor compounds or glycosaminoglycans (Madine and Middleton, 
2010). Similar to the work conducted by Larsson et al. (2007) the studies by Madine 
and Middleton (2009) did not aim to characterise the aggregation of medin in detail, 
rather, investigate the modulation of medin aggregation. Both studies have used ThT 
as the primary technique to investigate medin aggregation. Furthermore, these 
studies have principally been done on synthetically produced medin often in the 
presence of organic solvents which do not accurately represent the physiological 
environment. 
Here, a range of biophysical techniques are used to study the aggregation of 
recombinant medin. They can be broadly divided into techniques that provide 
information on the mechanism and kinetics of aggregation and the structure and 
morphology of aggregates.  
Arguably the primary technique used to study amyloid kinetics is the thioflavin T 
(ThT) assay. ThT is a cationic benzothiazole dye that shows an increase in 
fluorescence upon amyloid binding (Vassar and Culling, 1959). In the free form, ThT 
has excitation and emission values of 385 nm and 445 nm respectively. However, 
binding to amyloid gives rise to a new excitation maximum at 450 nm, and enhanced 
emission at 482 nm (Levine, 1993). The specificity of ThT for amyloid has led it to 
be considered as a standard technique for the study of amyloid aggregation growth 
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kinetics (Naiki et al., 1989). Although medin has been studied using the ThT assay 
previously the conditions under which it was examined are highly variable and 
further work is warranted to establish reproducible data under physiologically 
relevant conditions.  
Dynamic light scattering (DLS) can be used to monitor the size of particles over the 
aggregation period (Gast and Modler, 2005, Goldburg, 1999). The combination of 
ThT and DLS has successfully been used to gain information about the kinetics and 
mechanism of poly Q peptides (Streets et al., 2013). 
Intrinsic fluorescence (IF) is a technique that exploits the fluorescent properties of 
certain amino acids: namely Trp, Tyr and Phe. The maximum emission fluorescence 
of these amino acids is sensitive to the local environment and can provide 
information about structural changes during aggregation. IF is often used to probe 
protein folding and dynamics (Huiyuan, 2009) and has been used to study the 
aggregation process in many different amyloid systems (Maji et al., 2005, 
Munishkina and Fink, 2007, Amaro et al., 2011). IF is used here to monitor changes 
in the tryptophan environment over the aggregation time course. 
Circular dichroism is a spectroscopic technique that can be used to study the 
secondary structure of proteins and peptides (Huiyuan, 2009). CD is an averaging 
technique and provides information about the conformational state of all the 
molecules within a given sample (Whitmore and Wallace, 2008). Quantitative 
analysis of the secondary structure elements can be achieved by deconvolution of 
experimental spectra using libraries of known structures (Whitmore and Wallace, 
2008). CD can be used to monitor the changes in secondary structure associated with 
aggregation and amyloid formation. For example, CD analysis identified the 
presence of -helical intermediates present during A amyloidogenesis (Kirkitadze 
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et al., 2001). Furthermore CD can be used to identify structural changes associated 
with pathogenic mutations (Adachi et al., 2013). Here, CD is used to monitor 
amyloid formation over time and thus provides both structural and kinetic 
information. 
The morphology of amyloid aggregates can be studied by transmission electron 
microscopy (Gras et al., 2011). This technique is commonly used to study amyloid 
fibrils and intermediate species in the amyloid pathway and can provide information 
about structural features of different amyloid assemblies (Petkova et al., 2005a, 
Fändrich, 2012). 
The dynamic process of amyloid fibril formation and the non-crystalline nature of 
fibrillar protein aggregates make these proteins difficult to study and characterise. It 
is therefore necessary to use a range of relatively low-resolution techniques in 
combination to obtain information about the kinetic and structural properties of 
amyloid proteins which can assist in the development of effective diagnostics and 
therapeutics.  
The aim of this work was to use a range of techniques to examine the aggregation 
kinetics and structural characteristics of full-length recombinant medin under 
physiological conditions. Moreover, this work aimed to use different experimental 
conditions to learn more about the inhibitory compounds described by Madine and 
Middleton (2009) and in doing so investigate their effect on recombinant medin in 
aqueous conditions. 
 
 
 
 
 105 
 
4.2. Materials and methods 
4.2.1. Aggregation kinetics studied by Thioflavin T 
ThT assays were carried out on a Flexstation 3 microplate reader (Molecular Devices 
Ltd.). Experiments were carried out in 96-well blackwalled, clear bottomed 
microplates (Nunc) with data recorded using bottom read mode. The use of a plate 
reader during this assay enables many more points to be sampled compared to the 
method described in section 2.2.4.1. ThT solution was injected into the protein 
samples (20 M peptide concentration in aggregation buffer) at the start of the read, 
to a final ThT concentration of 20 M in aggregation buffer (Appendix 1). The wells 
were mixed with two cycles of trituration prior to recording data. Fluorescent 
measurements, representing the average of 6 flashes, were recorded every 5 minutes 
throughout the duration of the experiments, with the photomulitpler tube sensitivity 
set to medium. The dye was excited at 450 nm and the emission signal recorded at 
485 nm with a cutoff of 475 nm. Unless otherwise stated, the assay was conducted at 
30 °C with no agitation. The resulting data was then analysed and the lag time and 
fluorescence intensity were recorded. Kinetics were analysed from the data using the 
equation 4.1 (Alvarez-Martinez et al., 2011): 
     
 
   
    
 
        4.1 
 
where, y is the polymerisation, y0 is the starting fluorescence, a is the difference 
between y0 and the fluorescence maximum, t is time, Ti is the inflection point of the 
sigmoidal, and the slope 1/ is the rate of polymerisation (Figure 4.1).  The lag 
time can be calculated using equation 4.2: 
                   4.2 
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Figure 4.1 Schematic of an amyloid growth curve, illustrating the different 
kinetic points. Kinetic parameters were obtained by fitting equation      
 
   
    
 
 and the lag time was calculated using the equation            . 
 
4.2.2. Aggregation kinetics by intrinsic fluorescence 
The vast majority of proteins contain amino acids that are intrinsically fluorescent: 
namely phenylalanine, tyrosine and tryptophan. The intrinsic fluorescence (IF) of 
these amino acids, particularly tryptophan, are heavily influenced by their local 
environment. This property can be exploited to investigate the tertiary or quarternary 
structure of proteins (Vivian and Callis, 2001, Andrews and Forster, 1972, Lakowicz, 
2006). Solvent-exposed tryptophan residues usually give a fluorescence spectrum 
with a maximum at 355 nm, whereas tryptophan residues buried in the hydrophobic 
core have blue shifted emission spectra in the range of 309-335 nm. In this study, 
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intrinsic fluorescence of the tryptophan residues at positions 11 and 21 was used to 
monitor aggregation by observing the shift in the spectrum from solvent-exposed, to 
buried in the aggregated form. Intrinsic fluorescence measurements were carried out 
on a Cary Eclipse Varian fluorescence spectrometer operating on a 20 M medin 
solution in aggregation buffer (Appendix 1) at 30 °C. Tryptophan residues were 
excited at 279 nm and the emission spectra recorded between 300 nm and 400 nm 
with a band pass of 5 nm. The fluorescence maxima at 355 nm and 335 nm were 
recorded, normalised and plotted as a function of time. 
4.2.3. Determination of aggregate size distribution by dynamic light scattering 
DLS measurements were carried out on a Zetasizer nano instrument (Malvern 
instruments) on both freshly prepared and aggregated 20 M medin samples in 
aggregation buffer. Each experiment was carried out in a 3 mm quartz cuvette at 25 
°C and results are presented as average values. 
4.2.4. Secondary structure analysis by circular dichroism 
Circular dichrosim (CD) spectroscopy is a technique that can be used to study the 
secondary structure of proteins and peptides. Circularly polarised light is generated 
when two linearly polarised states become out of phase with one another and rotates 
along an ellipsoidal path (Panels A and B, Figure 4.2). Circularly polarised light can 
be either left- (LCP) or right-handed (RCP); CD measures the difference in 
absorption of LCP and RCP. CD is measured in ellipticity where the ratio of the 
minor to major axis of the ellipse is the tangent of the angle (and OR is the optical 
rotation (Panel C, Figure 4.2).  
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Figure 4.2 Schematic of linearly polarised light (A), circularly polarised light 
(B). The origin of ellipticity values, where the ratio of the minor to major axis of 
the ellipse is the tangent of the angle (and OR is the optical rotation (C.) 
 
CD is used here to examine the secondary structure of peptides and their stability 
over time. Each pure secondary structure element gives a signature spectrum in far –
UV CD (Figure 4.3). The secondary structure content of spectra can be analysed 
using various fitting algorithms such as CONTILL and CDSSTR (Van Stokkum, 
1990, Sreerama, 2000, Manavalan, 1987) and using a basis set of spectra of 
appropriate proteins.  
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Figure 4.3 Typical CD spectra of pure secondary structure elements. 
 
Changes in secondary structure of medin during aggregation were monitored using 
far-UV synchrotron radiation circular dichroism (SRCD). Experiments were carried 
out at beam line B23 at Diamond light source (Oxford, U.K.). Freshly prepared 
medin was incubated at a concentration of 200 M, at 30 °C, in the cuvette (121.000-
QS Hellma, Southend-on-Sea, U.K.) for the duration of the time course. Single scans 
were recorded every two hours between 180 and 190 nm, using a slit width of 0.5 
mm, 0.5 cm path length and a scan rate of 1 nm/sec, over 44 hours. The baseline was 
subtracted prior to secondary structure analysis. Analysis was carried out using Olis
®
 
GolbalWorks software. Data at each time point was subject to two fitting methods, 
CONTILL and CDSSTR, using either basis sets 8 or 11 (Van Stokkum, 1990, 
Sreerama, 2000, Manavalan, 1987). The best fit, as determined by the normalised 
spectral fit standard deviation, was selected and the percentage -helix, -sheet, turn 
and random coil content recorded.  
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4.2.5. Analysis of morphology by transmission electron microscopy 
Morphologies of the insoluble medin aggregates were visualised using transmission 
electron microscopy (TEM). Peptide suspensions (10 L) were loaded onto carbon 
coated copper grids held between tweezers. Excess solution was removed by placing 
the grid perpendicular to blotting paper. The grid was then inverted onto a droplet of 
dH20 to wash of excess peptide aggregates. The grid was blotted again before being 
inverted onto a droplet of 4 % uranyl acetate to negatively stain the aggregates. 
Excess stain was removed by blotting before allow the grid to air dry prior to 
visualisation. The grids were observed using a Technai 10 electron microscope 
operating at 100 kV. 
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4.3. Results 
4.3.1. Aggregation kinetics of medin 
The primary aim of this section of work was to establish the aggregation 
characteristics of recombinant wild type medin, to enhance understanding of this 
ubiquitous protein and provide reproducible conditions for future testing of inhibitors 
of medin aggregation. 
4.3.1.1. Investigating the concentration dependence of medin aggregation 
Initially the ThT binding assay was used to see if our recombinant medin was 
capable of binding ThT and to monitor the aggregation over time. These 
measurements were carried out in triplicate an example of three replicate data sets is 
shown in Figure 4.4. Each curve was fitted using the equation described in section 
4.2.1. and information about the lag time, rate constant and overall fluorescence 
intensity collated.  
 
Figure 4.4 Three replicate ThT data sets for medin incubated at 200 M in 
aggregation buffer. Data were recorded on a fluoromax spectrometer at 30 °C 
under quiescent conditions. 
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Figure 4.5 The effect of protein concentration upon medin aggregation 
measured by thioflavin T fluorescence. Data were recorded on a fluoromax 
spectrometer at 30 °C under quiescent conditions at the following medin 
concentrations: 200, 40 and 20 M (A, B and C respectively). The red line 
represent the fit using the following equation:      
 
   
    
 
 .The adjusted R2 
values indicating the goodness of fit for each curve are reported on the right 
hand side. Data represent mean data for 3 replicates. 
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Different concentrations of medin, (10, 20, 40, and 200 M) were incubated with 
ThT and monitored over time. All conditions gave rise to a characteristic rise in 
fluorescence intensity over time (Figure 4.5). Data were then processed as described 
in section 4.2.1, with the lag time, rate constant and fluorescence intensity calculated 
and plotted against concentration (Figure 4.6). Fluorescence intensity appears to 
correlate with concentration as expected (Panel A, Figure 4.6). The rate constant 
values also correlate with concentration (Panel B, Figure 4.6). These data indicate 
that wild type medin aggregates after approximately 33 hours under the conditions 
used here (Panel C, Figure 4.6). This is consistent with previous studies on 
recombinant medin which suggested a lag time of approximately 30 hours (Larsson 
et al., 2007). It is also consistent with previous data carried out on synthetically 
produced medin. Madine et al. showed that synthetic medin incubated at 0.25 mM 
concentration with agitation, demonstrated a dramatic increase in fluorescence 
intensity after three days. The ThT assay was carried out at discrete time points, (0, 3 
and 8 days) so we are unable to determine if the nucleation point is comparable 
(Madine and Middleton, 2010). They also showed that there was a further smaller 
increase in fluorescence intensity after 8 days of incubation; however it was not 
possible to assess recombinant medin over such a long time course in the plate 
reader. Overall, the lag time does not significantly change with concentration which 
is surprising, it may be due to the specific conditions of the assay and further work 
would be required to investigate this. 
These experiments were also used to identify the optimal concentration of medin for 
future experiments; 20 M was selected as it gave a good compromise between the 
amount of material required and the observed fluorescence intensity under these 
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conditions. Furthermore, it is comparable with conditions used to study other 
amyloid proteins using this technique (Schubert et al., 1995, Cribbs et al., 2000). 
 
Figure 4.6 Analysis of the effect of protein concentration on fluorescence 
intensity (A), lag time (B) and rate constant (C). Values were extracted from 
fitting exponential curves to the data and recording the value at the base of the 
exponential phase, the maximum fluorescence intensity and the calculated rate 
constants for each condition. Data represent mean and standard error values 
for 3 replicates.  
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Interestingly, there are also more subtle differences that occur within the lag time. At 
200 mM concentration there is a small hump followed by a dip that precedes the 
exponential increase and they are reproducible. This is also seen at lower 
concentrations to a lesser degree. It is not clear what these changes represent; it is 
possible that they indicate the formation of oligomers or other intermediates but 
further investigation is required to confirm this. 
Furthermore there is variation in the data after the exponential phase, and in the 
steady state, these changes varied between individual repeats unlike the humps 
preceding the exponential phase. In particular there are small humps visible at 20 and 
200 M after approximately 50 hours. Again, it is not clear what is causing these 
differences and further investigation is required. 
4.3.1.2. Investigating the effect of agitation on medin aggregation 
It has previously been shown that agitation during fibril formation can significantly 
reduced lag time by expediating nucleation (Xue et al., 2008, Nielsen et al., 2001, 
Petkova et al., 2005b). In order to investigate whether medin also exhibited the same 
phenomenon a 20 M solution was monitored over time. Conditions were identical 
except for the addition of orbital shaking, for 250 seconds between reads. 
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Figure 4.7 The effect of agitation upon medin aggregation measured by 
thioflavin T fluorescence. Data were recorded on a Fluoromax spectrometer at 
30 °C on a 20 M medin solution in aggregation buffer. The agitated sample 
was subjected to orbital shaking for 250 s between reads. Data are 
representative means of three replicates. 
 
This data showed that aggregation kinetics of medin could be changed by the 
addition of agitation (Figure 4.7). The lag time was reduced from 33 hours to 25 
hours suggesting that the agitation did increase the rate of nucleation (Figure 4.8, 
panel B). Additionally, agitation significantly affected rate but not the fluorescence 
intensity (Figure 4.8 panels A and C). This conforms to the hypothesis of agitation 
expediating nucleation.  
Moreover, the addition of agitation also greatly exaggerated the dip observed before 
the exponential increase in fluorescence but the reason behind this remains unknown 
and demands further scrutiny.  
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Figure 4.8 Analysis of the effect of agitation on fluorescence intensity (A), lag 
time (B) and rate constant (C). Values were extracted from fitting exponential 
curves to the data and recording the value at the base of the exponential phase, 
the maximum fluorescence intensity and the calculated rate constants for each 
condition. Data represent mean and standard error values of 3 replicates.  
 
4.3.1.3. Kinetic analysis by intrinsic tryptophan fluorescence 
Intrinsic fluorescence measurements were carried out to investigate the effect of 
aggregation on the aromatic residues within medin, particularly tryptophan residues. 
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It also acts as an independent method to assess the aggregation kinetics of medin 
under different experimental conditions. These data show that the tryptophan 
residues within medin are initially solvent exposed with a maximum fluorescence at 
355 nm. However, over time, the maximum shifts to 335 nm which is consistent with 
the tryptophan residues becoming buried and less solvent exposed (Figure 4.9).  
 
 
 
Figure 4.9 Changes in intrinsic tryptophan fluorescence over time at 30 °C, at a 
protein concentration of 20 M. Tryptophan residues were excited at 279 nm 
and emission spectra were recorded from 300-400 nm. Data were collected 
every 15 minutes for 50 hours, raw data shown in (A) and initial and final 
spectra shown in (B).  
 
The data were then further analysed to establish the point at which the tryptophan 
residues change from solvent exposed to a buried environment, by plotting the 
change in fluorescence intensities at 355 nm and the wavelength at which the 
maximum fluorescence was observed at each time point. Figure 4.10, panel A shows 
the percentage decrease in fluorescence at 355 nm compared with the increase in 
fluorescence intensity observed during the ThT measurements, over time. The 
intrinsic fluorescence measurements are in good agreement with the ThT findings 
under quiescent conditions, suggesting that the change observed in the tryptophan 
residue environments occurs at the same time as the ThT fluorescence increases, 
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approximately 33 hours after the start of incubation (Figure 4.10 panel A). Panel B 
shows the change in maximum wavelength over time and illustrates the conversion 
from 355 to 335 nm that coincides with the increase in fluorescence intensity and 
ThT fluorescence (Figure 4.10). 
 
Figure 4.10 Percentage decrease in tryptophan fluorescence at 355 nm as a 
function of time (squares) compared to percentage increase in thioflavin T 
fluorescence over time (dashed line) (A). Change in maximum wavelength as a 
function of time (B.) 
4.3.1.4. Dynamic light scattering 
Dynamic light scattering it a technique that provides information about the size 
distribution of particles in solution. DLS was used here to monitor changes in 
particle size pre- and post aggregation. As can be seen in Figure 4.11, at 0 hours the 
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particle size is consistent with monomeric peptide species in a compact 
conformation, whereas after 48 hours much larger higher aggregates have formed. 
These data indicate, like the ThT and IF measurements, that aggregation occurs 
within 48 hours under quiescent conditions in physiological buffer. 
 
Figure 4.11 Dynamic light scattering data for medin (20 M in aggregation 
buffer) at 0 and 48 hours. Data recorded using a Zetasizer nano instrument 
operating at 25 °C; data shows an increase in particle size over time. 
 
4.3.2. Structure and morphology of medin aggregates 
4.3.2.1. Circular dichroism 
The stability of medin, at the early stages of aggregation, was analysed by CD. A 
medin sample was repeatedly exposed to single scans of UV radiation over a 
prolonged period (Figure 4.12). This experiment both acted as a control for the CD 
analysis shown above and as a means to test the stability of medin. The data show no 
signs of degradation over 25 scans, suggesting that medin is stable to radiation and 
that the results shown above in Figure 4.15 are a result of aggregation not 
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degradation. Thus, medin could be scanned repeatedly over a period of time and any 
changes in the spectrum could be attributed to time-dependent structural transition 
not radiation damage. 
 
Figure 4.12 Analysis of medin stability in response to UV radiation. Data were 
recorded over 25 scans at 30 °C on medin (200 M, in CD buffer) using far-UV 
synchrotron radiation circular dichroism at beam line B23 at Diamond light 
source. Numbers represent number of repeated exposures to UV. 
 
Far UV - CD analysis of medin was carried out over time to investigate any changes 
in secondary structure that accompany aggregation. Experiments were carried out 
using far-UV synchrotron radiation circular dichroism (SRCD). The sample was 
incubated in the cuvette at 30 °C and scanned every two hours to monitor changes 
over the aggregation time course identified from ThT measurements. Spectra 
obtained at 0 hours and 44 hours were compared and show a shift towards more -
sheet (Figure 4.13).  
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Figure 4.13 CD spectra for medin comparing start and end points (0 and 44 
hours). Data were recorded at 30 °C on medin (200 M, in CD buffer) using far-
UV synchrotron radiation circular dichroism at beam line B23 at Diamond light 
source. 
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Figure 4.14 CD spectra for medin (black) with fits (red) and residuals (above) at 
0,6,12,18,24,30,36 and 42 hours,  A,B,C,D,E,F,G and H respectively. 
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The secondary structure content present at each scan was calculated using CONTIN 
or CDSSTR secondary structure fitting software and percentage values extracted and 
plotted over time (Figure 4.15). Throughout the time course there is a reduction in 
the percentage of -helix and an increase in the percentage of -sheet and -turn 
(Figure 4.15) in line with previous studies on amyloid formation (Gross, 2000). At 
50 hours, there is approximately 65 % -sheet/turn present and virtually no -helix 
remaining (Figure 4.15). The amount of random coil present remained relatively 
constant throughout. 
 
 
Figure 4.15 Secondary structure analysis of medin over 44 hour time course. CD 
data were analysed using, CONTIN or CDSSTR secondary structure fitting 
software, percentage values recorded, and plotted over time. Asterisk indicate 
standard deviation values for the fits of over 0.1.  
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4.3.2.2. Electron microscopy 
Negative stain electron microscopy was used to examine the morphology of medin 
aggregates formed at 20 M concentration in aggregation buffer (Appendix 1) under 
quiescent conditions. As can be seen in Figure 4.16, medin forms dense networks of 
long, straight fibrils under these conditions. They are generally un-branched and 
approximately 500 nm in length.  
 
Figure 4.16 Negatively stained electron microscopy images of medin fibrils 
formed under quiescent conditions, at 30 °C, at a medin concentration of 20 M 
in aggregation buffer. Scale bars represent 500 nm.  
 
4.3.3. Conditions for future characterisation 
In order to test the modulation of medin aggregation by inhibitory compounds or co-
localising factors it was necessary to select a set of conditions for future assays. A 
peptide concentration of 20 M was chosen as it gave reproducible ThT data, 
without using too much material. Also, it was decided to conduct ThT assays without 
agitation, as these data gave more reproducible results and had a longer lag time in 
which to observe any potential affects.  
4.3.4. Affect of inhibitors on medin aggregation 
It is yet unknown what affect medin has on the physiology of the arteries in which it 
is found or whether it is pathogenic as suspected for other amyloid proteins.  It has 
been suggested that oligomeric medin may cause damage to the elastic structures of 
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the arteries and render them more prone to rupture (Peng et al., 2007). If this is found 
to be the case it may be possible to target medin therapeutically. One strategy for 
inhibition of medin aggregation is to use modified peptides designed to bind to the 
aggregation prone regions of the target peptide, also known as the self recognition 
element (SRE). This approach has been successfully used to inhibit other amyloid 
proteins such as -synuclein, amyloid- and amylin (Madine et al., 2008b, 
Madine et al., 2009b). This work employs the use of a -sheet breaking residue, -
alanine or 3-aminopropanoic acid (A), to disrupt the hydrogen bonding pattern that 
stabilises the cross- structure within aggregates, and prevent further association of 
peptides.  
Previous work by Madine et al. (2009) designed three modified peptides to bind to a 
previously identified SRE at the C-terminus of medin, with the sequence NH2-
NFGSVQFVA-COOH in particular the NH2-FGSV-COOH motif (Madine and 
Middleton, 2010, Larsson et al., 2007). The aim of this work was to test two of these 
inhibitors F(A)S and (A)SV and a third novel peptide Y(A)S using the plate 
reader ThT assay developed throughout this work (Table 4.1). Only one of the two 
modified peptides, designed by Madine and Middleton (2010), with the sequence 
F(A)S, was capable of preventing the formation of large aggregates. The other, with 
the sequences (A)SV, did not prevent the formation of large aggregates.  
Previously the peptides were analysed by ThT fluorescence on incubated samples 
that were frozen at discrete time points and defrosted prior to analysis (Madine and 
Middleton, 2010). Given the improved capabilities of ThT assays carried on the plate 
reader, the aim was to investigate the effect the peptides had on the three parameters 
discussed above, lag time, fluorescence intensity and rate.  
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It is thought that -stacking interactions may play a role in the aggregation process 
(Gazit, 2002). The inclusion of aromatic residues within the peptide sequences may 
therefore improve binding to the SRE and ameliorate the efficacy of inhibition. The 
third new peptide was designed based on the success of F(A)S by swapping the 
phenylalanine residue for a second aromatic residue, tyrosine to give (YAS). 
Table 4.1 Summary of peptide inhibitors designed against the motif, FGS at the 
C-terminus of medin using -alanine to extend the backbone and prevent 
hydrogen bonding. 
 
Amino acid 
composition 
Structure Mr (Da) 
F(A)S 
 
323.34 
Y(A)S 
 
 
339.34 
(A)SV 
 
275.30 
4.3.4.1. -sheet breaking inhibitors 
Each of these modified peptides (Table 4.1) was incubated with a 20 M solution of 
medin and analysed by ThT to see if they have the same effect on the aggregation 
kinetics of medin as previously described. Moreover, to investigate whether the 
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exchange of a phenylalanine residue to a tyrosine is as effective as F(A)S. The 
inhibitors were added two concentrations, both equimolar and in five times excess. 
 
Figure 4.17 Three replicate ThT data sets for medin +F(A)S (equimolar) 
incubated at 20 M in aggregation buffer. Data were recorded on a fluoromax 
spectrometer at 30 °C under quiescent conditions. 
 
Data shown in Figure 4.17 represent three replicate data sets for medin in the 
presence of equimolar F(A)S. The lag time and rate in particular are quite 
consistent but there is more variability in the maximum fluorescence intensity.  
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Figure 4.18  The effect of inhibitor peptides at equimolar concentration upon 
medin aggregation measured using thioflavin T assay. Medin alone (A), F(A)S 
(B), (A)SV (C) and Y(A)S (D). Data were recorded on a fluoromax 
spectrometer at 30 °C on a 20 M medin solution in aggregation buffer. The red 
line represents the fit using the following equation:      
 
   
    
 
 .The 
adjusted R
2
 values indicating the goodness of fit for each curve are reported on 
the right hand side. Data represent mean data for 3 replicates. 
  
Data initially suggest that all three inhibitors have an effect on the aggregation 
kinetics of medin by altering the fluorescence intensity, reducing the lag time and 
increasing the rate (Figure 4.18). Individual analysis of the lag time, fluorescence 
intensity and rate constants however,  show that when compared to medin alone, the 
increased rate and reduced lag time are significant at the p=0.05 level (Figure 4.19). 
These inhibitors appear to actually accelerate medin aggregation by reducing the lag 
time however the presence of inhibitors reduced the rate.   
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Figure 4.19 The effect of inhibitor peptides at equimolar concentration upon 
medin aggregation measured using thioflavin T assay. Data comparing 
fluorescence intensity (A) lag time (B) and rate of elongation (C). Asterisk 
indicate statistical significance at the p=0.05 level. 
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Further experiments were carried out to investigate the effect of incubating medin 
with a five times excess concentration of the inhibitor peptides. Unlike the ThT 
results at equimolar concentration, medin incubated with inhibitors at a five times 
excess concentration showed no significant changes to any of the parameters 
measured (Figure 4.20 and 4.21). 
 
 
Figure 4.20 The effect of inhibitor peptides at five times excess (100 M) 
concentration upon medin aggregation measured using thioflavin T assay. 
Medin alone (A), F(A)S (B), (A)SV (C) and Y(A)S (D). Data was recorded 
on a fluoromax spectrometer at 30 °C under quiescent conditions with a medin 
concentration of 20 M.  The red line represents the fit using the following 
equation:      
 
   
    
 
 .The adjusted R2 values indicating the goodness of fit 
for each curve are reported on the right hand side. Data represent mean data 
for 3 replicates. 
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Figure 4.21 The effect of inhibitor peptides at five times excess (100 M) 
concentration upon medin aggregation measured using thioflavin T assay. Data 
comparing fluorescence intensity (A) lag time (B) and rate of elongation (C).  
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4.4. Discussion 
There is currently very little known about the aggregation kinetics, structure and 
morphology of medin. Studies of the properties of medin are highly justified given 
its prevalence and the reported links with aortic aneurysm and dissection (Peng et al., 
2007). The aim of this work was to increase understanding of the aggregation 
process of full length recombinant medin under physiologically relevant conditions. 
This information can then be used to investigate the effect of mutations, co-localising 
factors and small molecules on the aggregation kinetics of full length medin. 
The thioflavin T fluorescence assay (Levine, 1999) is often used to monitor the 
aggregation of amyloid proteins and it is used here to obtain aggregation profiles for 
full length medin under a variety of conditions. Thioflavin T analysis of the effect of 
increasing peptide concentration upon medin aggregation was consistent with 
previous theories about nucleation-dependant amyloid growth (Cabriolu et al., 2010). 
Increasing concentration is directly proportional to observed fluorescence intensity 
and to a lesser degree the rate constant (Figure 4.6). There was also an observed 
reduction in lag time, however this was less pronounced than expected. This may 
represent the conditions under which the assay was conducted and further work 
needs to be carried out to accurately determine the relationship between lag time and 
concentration. The affect of agitation upon medin aggregation was also investigated. 
Agitation reduced the lag time by approximately a third (Figure 4.8) is consistent 
with previous studies on the effect of agitation. These studies on 2-microglobulin 
demonstrated that agitation reduced the lag time preceding the exponential phase 
(Sasahara et al., 2008). It is likely that this reduction is a result of increased 
fragmentation and thus increased nucleation rate. It may be that agitation is required 
 134 
 
in order to observe greater concentration dependence within lag times. It is also 
interesting to consider the environment in which medin is located in vivo. Aortic 
medial amyloid is most commonly found in close association with the elastic 
structures of the arteries, a highly dynamic environment. The pressure and forces at 
this location may have a role in the mechanism of aggregation. The preliminary 
results shown here agree with previous theories about the role of agitation and given 
the location of medin deposition, warrant further investigation.  
Following kinetic analysis using the classical ThT assay, different aspects of medin 
aggregation were investigated using a range of biophysical techniques.  Moreover, 
these different techniques can collectively build a reliable picture of medin 
aggregation. 
Intrinsic fluorescence data was collected to investigate the role of tryptophan 
residues during the aggregation of medin. This data shows a clear switch in 
tryptophan environment from solvent exposed to buried over the time course of 
aggregation (Figure 4.9) This switch also coincides with the increase in fluorescence 
observed in the ThT measurements (Panel A, Figure 4.10). Results are consistent 
with a change in tryptophan environment associated with aggregation. It may be that 
the tryptophan resididues form stabilising -stacking interactions although, given the 
time course, it is unlikely that contributions from these residues are the drivers 
behind medin aggregation. With such a driver one would expect the switch in 
environments to precede the increase in ThT fluorescence. The exchange of 
tryptophan environment from solvent exposed to buried is in agreement with the 
models proposed by Sawaya et al. (2007) of closely packed inter-digitated steric-
zippers. It is not possible, from these experiments, to specify the class of steric zipper 
but they are consistent with a dry steric-zipper interface between -sheets. 
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Dynamic light scattering measurements indicated that medin is present in a compact 
monomeric form at the onset of the time course, and after 48 hours only much larger, 
presumably aggregated medin remains (Figure 4.11).  
Taken together these data strongly suggest that at a 20 M concentration medin 
aggregates after approximately 33 hours. Not only do these quite different methods 
all suggest a lag time of 33 hours, this is also in agreement with data published by 
Larsson et al (2006) on recombinant medin. However, these finding are not 
consistent with data published by Madine and Middleton (2009) who observed that 
full length synthetic medin required 8 days to aggregate. It is likely that this is a 
result of the different conditions used to aggregate medin. It has previously been 
shown that synthetically produced amyloid proteins aggregate slower than 
recombinant peptides, probably as a result of residual contaminants from the 
synthesis (Finder et al., 2010). Furthermore, in the previous study, medin was 
aggregated at 25 °C whereas these data were collected on medin samples incubated 
at 30 °C. 
Secondary structure analysis of medin by circular dichroism suggested a 
rearrangement in secondary structure over the observed time course from -helix to 
sheet (Figure 4.15) suggestive of amyloid formation (Tomaselli et al., 2006). The 
transition from -helical conformations to -sheet rich structures is thought to play a 
role in the infectivity of prion proteins (Pan et al., 1993). It may be that secondary 
structure transitions trigger the aggregation of amyloid proteins via a similar 
mechanism. This is supported by the comparison of CD data to the ThT data. The 
conversion from -helix to -sheet coincides with the increase in ThT fluorescence 
associated with the dye binding to the cross- structure of the aggregates. 
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Electron microscopy of the aggregated samples showed the presence on dense 
fibrillar networks of similar dimensions and morphology to other amyloid forming 
proteins (Figure 4.16). Although these images clearly show the presence of fibrillar 
aggregates, it is not possible to detect any specific detail about the structure of the 
fibrils as has been shown with other amyloid proteins such as A(Paravastu et al., 
2008).  
Although this work has gone a long way to improve our understanding of how medin 
aggregates, it should be stressed that these data relate only to the assay conditions 
used here and further work must be carried out to fully understand process under a 
variety of conditions. 
Initial work on tripeptides, hypothesised to inhibit medin aggregation, was also 
reported. The efficacy of two previously designed peptides and a third novel inhibitor 
were tested on medin under the conditions established here. Unfortunately the effects 
of the two previously designed inhibitors were not accurately mirrored here. This is 
likely to be consequence of several factors, namely differences in the assay, such as: 
time course, temperature, peptide concentration and peptide preparation method. 
On the contrary at equimolar concentration the tripeptides appear to accelerate medin 
aggregation (Figure 4.18 and 4.19).  
Further work needs to be done to fully characterise the effects of these short peptides 
upon recombinant medin under more physiological conditions. Furthermore, it also 
very important to ensure that the peptides do not contribute to the formation of medin 
aggregates. Cell based toxicity assays must also be included in further work to 
investigate the toxicity of medin aggregates and the effect of tripeptide addition. 
Previous cytotoxicty assays conducted on synthetic medin demonstrated that medin 
incubated for 0, 1 and 3 days had a cytotoxic effect on bovine endothelial cells 
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however following 7 days incubation medin aggregates were no longer toxic 
(Madine and Middleton, 2010). 
Overall, the results described here have begun to characterise the aggregation process 
of medin and provide a benchmark for future work detailed in later chapters.  
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5. Toward a structural model for medin fibrils 
5.1.  Introduction 
As established in previous chapters, in order to design effective modulators of 
amyloid formation it is useful to identify the aggregation prone regions of an 
anyloidogenic peptide. There are several computational methods available to assist in 
this identification and the role of predicted regions can then be tested experimentally 
through a variety of molecular biology and biophysical techniques. It is important to 
identify key interactions such as hydrogen bond networks, salt bridges and aromatic 
interactions within this region that can be subsequently targeted therapeutically.  
5.1.1. Stabilising interactions within amyloid fibrils 
There are many different stabilising interactions that are thought to contribute to the 
formation and stability of amyloid fibrils in general. As discussed in chapter 1, 
hydrogen bonds formed from the backbone amine groups are the primary stabilising 
interaction common to all amyloid fibrils. In addition π-stacking of aromatic residues 
and salt bridges have also been shown to be important (Tu and Raleigh, 2013, 
Petkova et al., 2002).  
Several studies have reported on the role of π-stacking interactions within amyloid 
structures with different conclusions. π-stacking is described as an attractive non-
covalent interaction between aromatic groups, such as those found in phenylalanine, 
tyrosine and tryptophan. Some indicate that aromatic residues are very important for 
amyloid formation, (Gazit, 2002, Jones et al., 2003, Tu and Raleigh, 2013) although 
there is some debate as to whether this is merely due to the hydrophobic nature of 
these residues rather than π-stacking interactions themselves (Bemporad et al., 2006, 
Larsson et al., 2007, Lakshmanan et al., 2013). Several studies have discussed the 
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role of -stacking interactions within medin specifically. Early investigations on the 
C-terminal region of medin by Gazit et al, (2002) suggested that phenylalanines at 
positions 43 and 48 are important for amyloid formation, however later studies by 
Larsson et al. (2007) showed that substitution of these residues for alanines did not 
disrupt fibril formation.  
There is also accumulating evidence that salt bridges, between the side-chains of  
acidic and basic residues, may play an important role in amyloidogenesis or in the 
stabilisation of the resulting pre-fibrillar and fibrillar aggregates. The salt bridges are 
non-covalent interactions that contribute to protein stability They are most 
commonly formed between the anionic carboxylate (RCOO
-
) of either aspartic acid 
or glutamic  acid and the cationic ammonium (RNH3
+
) from lysine or the 
guanidinium (RNHC(NH2)2
+
) of arginine. 
Salt bridges have been shown to be present in several amyloid-like assemblies such 
as A(Petkova et al., 2002), Het-S (Wasmer et al., 2008, Gendoo and Harrison, 
2011) and prion fibrils (Yau and Sharpe, 2012). These ionic interactions can be inter- 
and/or intra-molecular and can form between side chain groups or the terminal 
groups. Examples of the variety of salt bridge interactions within fibrils are shown in 
Figure 5.1. Panel A, Figure 5.1 shows a single molecule of the HET-s protein from 
Podospora anserine forming a left-handed -solenoid structure, stabilised by three 
intra-molecular salt bridges (Wasmer et al., 2008). Fibrils formed from a fragment of 
the mammalian prion protein (PrP), with face-to-face packing of opposite sheets in 
an anti-parallel arrangement that is stabilised by a salt bridge between the N- and C-
termini (Panel B, Figure 5.1) (Yau and Sharpe, 2012). A1-40 fibrils, when grown 
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under agitated conditions, are stabilised by inter-molecular salt bridges (Panel C, 
Figure 5.1). 
 
 
Figure 5.1 Examples of different salt bridge interactions stabilising fibrils 
structures: intra-molecular salt bridges in Het-S (PDB ID: 2RNM) (A), a salt 
bridge formed between the termini of a fragment of PrP (B) (Yau and Sharpe, 
2012) and inter-molecular salt bridges formed in A1-40 fibrils (PDB ID: 2LMO) 
(C). All viewed down the fibril long axis (top) and expanded regions shown 
below. 
 
It is not known what stabilising interactions are present within medin fibrils. There is 
some information available about the role of aromatic residues within medin 
assemblies (Reches and Gazit, 2004, Larsson et al., 2007, Davies et al., 2012, 
Madine et al., 2009a) but it is not known if salt bridges play a role in stabilising 
medin fibrils. The latter interactions could occur in principle because medin has two 
lysine and two arginine residues and one glutamate and three aspartate residues. 
5.1.2. Similarities between medin and other amyloid proteins 
There is a large amount of data on the kinetic, morphological and structural 
characteristics of many different amyloid proteins. This information can be used to 
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guide and inform studies on less well characterised amyloid-forming proteins such as 
medin. There is also a large amount of interest in identifying any common 
amyloidogenic motifs or ‘self recognition elements’ that could be targeted 
therapeutically. One strategy to assist in structural studies is to model the unknown 
fibril structure on a known amyloid structure and then develop and refine the model 
with experimentally-derived restraints. The best models are generated from templates 
that have highest sequence identity and are of a similar size. Two well characterised 
amyloid proteins, A and IAPP, were considered to be possible templates. They are a 
relatively similar in size to medin, (4.5 kDa and 3.9 kDa respectively) and structural 
models for the fibrils of both proteins are available. Interestingly however they have 
a broadly similar fibril structure comprising a single hairpin, despite the low 
sequence identity (23 %) between them (Figure 5.2).  
 
Figure 5.2 Aligned single subunits of A (red), extracted from PDB entry 2LMO 
and amylin (green) fibrils (PDB files from R.Tycko, Bethesda). Alignment was 
carried out in PyMol V 0.9.  
 
In order to select the optimal template, sequence alignment of medin with both A1-
40 and IAPP was performed. As expected, there was low overall sequence identity, 13 
% between medin and IAPP and 16 % between medin and A1-40. Local sequence 
alignment between the three proteins revealed only 16 % identity between medin and 
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amylin over a 19 amino acid overlap whereas there was 38 % sequence identity 
between medin and A1-40 over a 16 amino acid overlap.  
 
 
 
 
Figure 5.3 Sequence alignment between medin and A. Asterisks indicate 
conserved residues, colons indicate strongly similar residues and full stops 
indicate weakly similar residues. Residues highlighted in red indicate 
amyloidogenic regions predicted by Zygreggator (Tartaglia and Vendruscolo, 
2008). Blue box highlights an area of particular similarity. 
 
A1-40 was selected as a template for modelling medin fibrils due to the higher 
sequence identity between medin and A1-40. Furthermore, there is a particular area 
of conservation between residues 25 and 30 of medin with the sequence NH2-
DLGSSK-COOH. In A, residues D23 and K28 (corresponding to D25 and K30 in 
medin) lie within the turn and form an inter-molecular salt bridge (Paravastu et al., 
2008). The remarkable similarity between the sequences between residues 25-30 led 
to the hypothesis that medin may also contain a salt bridge at that location that may 
drive or stabilise aggregation. 
5.1.2.1. Salt bridge in A1-40: D23 and K28 
A combination of limited proteolysis and solution state NMR have shown that 
residues 21-30 in both A1-40 and A1-42 are protease resistant and likely comprise 
the amyloidogenic region of A (Lazo et al., 2005). Molecular dynamics techniques 
coupled with solution-state NMR experiments suggest that this fragment is stabilised 
by a salt bridge between the side chain groups of D23 and K28 (Fawzi et al., 2008). 
Solid-state NMR measurements on full length A1-40 fibrils proved that, in some 
morphologies, fibrils were indeed stabilised by an inter-molecular salt bridge 
 
    RLDKQGNFNAWVAGSYGNDQWLQVDLGSSK-EVTGIITQGARNFGSVQFVA 50 
--DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV-----V---- 40 
       * : ..::     : :  ::  *:**.*  : *::. *.     *  
 
Medin
A1-40
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between residues D23 and K28 (Figure 5.1, panel C), (Petkova et al., 2005b, Petkova 
et al., 2002). Further studies have confirmed that the region encompassing the 
D23/K28 salt bridge is critical to the kinetic and structural elements of A 
aggregation. Kinetic studies on A1-40 with a -lactam bridge between D23 and K28 
indicated that cross-linking at the turn region i.e. simulating the salt-bridge 
interaction, eliminated the lag phase and showed a reduced critical concentration for 
fibril formation, measured by thioflavin T fluorescence. Furthermore these cross-
linked peptides were capable of acting as seeds for wild type A1-40, suggesting 
structural similarity (Sciarretta et al., 2005). In addition to cross-linking, mutation 
experiments promoted turn formation within -sheets through systematic 
replacement of amino-acid pairs within the turn region with D-PG, an effective turn 
nucleator. These mutations led to significantly accelerated fibrillogenesis when 
measured by thioflavin T fluorescence (Doran et al., 2012a). Together this data 
suggests that turn formation is a rate limiting step in A fibril formation. 
Various molecular dynamics experiments have also emphasised the importance of 
D23 and K28 to the geometry and mechanical properties of A fibrils (Cruz et al., 
2012, Berhanu and Hansmann, 2012b). 
5.1.3. A Iowa mutant 
In addition to the structural importance of D23, it has been shown that a mis-sense 
mutation of this residue to an asparagine in amyloid precursor protein gives rise to a 
severe cerebral amyloid angiopathy (CAA), widespread neurofibrillary tangles and 
unusually extensive deposition of A plaques. This mutation was first identified in a 
family in Iowa suffering from familial Alzheimer’s disease (Grabowski et al., 2001). 
Several studies have begun to characterise the kinetic and pathological properties of 
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D23N. Incubation of D23N with human smooth muscle cells showed increased fibril 
formation and pathogenicity when compared with wild type A(Van Nostrand et al., 
2001). Transgenic mice carrying the D23N mutation displayed enhanced 
accumulation of A fibrils in the vasculature of the brain, which strongly stained 
with thioflavin S. There was further evidence of micro-haemorrhage close to the 
plaques. Transport studies also indicated that D23N was more readily retained in the 
brain that WT A(Davis et al., 2004). 
Structural characterisation of D23N, by EM, XRFD and solid state NMR indicate a 
heterogenous mixture of in-register parallel -sheet structures, similar to WT A1-40 
and, surprisingly, anti-parallel -sheet structures. To date, all previous amyloid 
structural models, where the peptide contains more than one hydrophobic region, are 
composed of in-register parallel -sheets (Tycko, 2011). Anti-parallel arrangements 
have been observed, but were restricted to fragments or short peptides (Tycko et al., 
2009). These two structures have different kinetic properties; the anti-parallel 
structures have a higher nucleation rate but lower elongation rate than their parallel 
counterparts. 
These anti-parallel fibrils are thermodynamically meta-stable and over time convert 
to parallel structures. Both the parallel and anti-parallel arrangements exhibited toxic 
effects upon incubation with rat embryonic hippocampal neurons (Qiang et al., 
2012). It is thought the anti-parallel structures represent a toxic intermediate in the 
aggregation pathway which may contribute to the observed enhanced pathology. 
Seeded growth allowed the isolation and characterisation of the anti-parallel fibril 
structure (Qiang et al., 2012). 
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Figure 5.4 Model of anti-parallel D23N fibrils generated from solid-state NMR 
restraints, viewed perpendicular to the fibril long axis from the side (A.) and 
end (B.), highlighting the anti-parallel arrangement of the -sheets. Loops were 
smoothed in PyMol to improve clarity. 
 
Together the clinical, cellular and biophysical data suggest that the aspartic acid at 
position 23 is critical to the kinetic and structural properties of A which in turn, 
manifests in the differences in the clinical pathologies observed.  
5.1.4. Objectives 
The objective of this chapter is to conduct detailed structural analysis of medin 
drawing on the sequential similarity with Afor which fibril structural models are 
available. In particular, the focus is on a possible stabilising salt bridge. This 
hypothesis will be tested by a combination of computational modelling supported by 
experimental measurements using solid state NMR and site directed mutagenesis. 
 146 
 
5.2. Materials and methods 
5.2.1. Overall strategy 
Computational methods have been developed to highlight key amyloidogenic regions 
and interactions that can be tested experimentally (Buchete et al., 2005, Nelson and 
Eisenberg, 2006, Lee et al., 2007). The methods described here were used both to 
identify similarities between amyloid proteins and find stabilising interactions. These 
could then be targeted and investigated by both biophysical and structural methods 
and potentially targeted by inhibitors. Figure 5.5 outlines the overall strategy and the 
two parallel strands of investigation. Initially, sequential and amyloidogenic 
similarities between medin and A were identified using bioinformatics tools. This 
highlighted the region between residues 25 and 30 of medin with the possibility of a 
stabilising salt bridge between both residues. The kinetic and structural impact of 
substituting these residues was also investigated using a range of biophysical 
techniques. 
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Figure 5.5 Schematic illustration of the overall experimental strategy detailing 
the parallel strands of investigation, both structural modelling, direct distance 
measurement using solid-state NMR and mutant characterisation. 
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5.2.1.1. Sequence analysis 
As discussed in previous chapters, medin shares sequence similarity with 
amyloidogenic motifs observed in other amyloid proteins such as IAPP and 
A(section 2.1). Global and local sequence alignment of  human medin against 
human A1-40 and IAPP was performed using LAlign server (Huang and Miller, 
1991) LAlign was used as it provides both a global sequence identity output and 
highlights areas of local similarity, which is ideal for identifying possible 
amyloidogenic motifs that may be missed with global alignments. The alignment was 
carried out using the BLOSUM50 matrix with a gap open penalty of -12 and a gap 
extension penalty of -2 with a threshold of 10. Residues 1-9 of A are considered to 
be unstructured and were omitted from the modelling calculations (Petkova et al., 
2002). Similarly, the additional 10 residues at the C-terminus of medin were 
removed due to the lack of template structure. 
5.2.1.2. Modelling 
Given the sequence similarities between medin and A, structural models of medin 
protofilaments were generated using four A structural models deposited within the 
protein databank (PDB), (PDB IDs: 2LMN, 2LMO, 2LMP and 2LMQ) derived from 
solid-state NMR measurements. Both single and multi-chain modelling were carried 
out using Modeller V9.11 on truncated (residues 10-40) medin (Eswar et al., 2007). 
Input scripts are shown in appendix 4. 
5.2.1.3. Model validation and distance measurements 
An ensemble of 20 models was generated for each template and the best model of 
each selected, based on the lowest molecular pdf score (molpdf), which is a standard 
MODELLER scoring function and is simply a sum of all the restraints (Eswar et al., 
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2007). WHAT IF scores were then calculated for each model and compared with 
those for the template models (Vriend, 1990). WHAT IF calculates an overall RMSD 
score to indicate how all residues within the peptide are packed. Chimera software is 
an integrated programme for the analysis and visualisation of molecular structures, 
here it was used to identify steric clashes within the models (Yang et al., 2012). 
Visualisation of models and distances between residues were calculated in PyMOL 
molecular graphics system version 1.5.0.4 (Schrödinger LLC.).  
5.2.2. Solid state NMR studies 
5.2.2.1. Preparation of medin for NMR studies. 
Uniformly 
13
C and 
15
N isotopically labelled recombinant medin was incubated at a 
concentration of 200 M in aggregation buffer (Appendix 1) for 3 weeks with 
agitation at 25 °C. The resultant fibrils were harvested by centrifugation at 21,000 g 
for 1 hour to generate a tightly packed pellet before being transferred to a zirconium  
3.2 mm rotor with a Kel-F cap (Bruker, U.K.). 
Synthetically produced medin was purchased from Protein peptide research 
(Cambridge, U.K.) with selective isotope labels. The sequence was designed to 
include: three uniformly 
13
C and 
15
N labelled amino acids A13, D25 and K30 (Figure 
5.6). A13 was labelled for experiments intended to determine the strand alignment 
within the fibrils, but time was not available to perform the NMR measurements. 
 
 
Figure 5.6 Labelling scheme for full length wild type medin. Asterisks indicate 
the presence of isotope labels. Residues highlighted in red are uniformly labelled 
13
C and 
15
N. 
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Lyophilised synthetic medin was initially dissolved in hexofluoroisopropanol (HFiP), 
bath sonicated for 10 minutes and then the HFiP removed under a stream of nitrogen. 
The samples were then placed on the high vacuum overnight to remove the last 
remaining traces of HFiP. This process was repeated three times prior to 
resuspension in 10 % dimethylsulphoxide (DMSO), 90 % H2O for aggregation. The 
synthetic peptide was highly insoluble and required dissolution in 100 % DMSO and 
subsequent dilution with H20 to reduce the percentage of DMSO.  Medin was 
incubated at a concentration of 200 M with agitation at room temperature for up to 
21 days. The peptide suspension was then centrifuged at 21,000 g for 1 hour to 
generate a tightly packed pellet before being transferred to a zirconium  4 mm rotor 
with a Kel-F cap (Bruker, U.K.) in preparation for NMR studies. 
5.2.2.2. One-dimensional spectra of isotopically labelled recombinant medin 
One-dimensional 
13
C and 
15
N cross-polarization magic-angle spinning spectra were 
obtained on a Bruker 850 MHz wide-bore solid-state NMR spectrometer at the 
national solid-state NMR facility (Warwick Univeristy). The experimental 
parameters were: 14 kHz sample rotation, 1-ms Hartmann-Hahn contact time, 100 
kHz proton decoupling and a 1.5-s recycle delay.  
5.2.2.3. Two-dimensional DARR spectra of isotopically labelled recombinant 
medin. 
DARR NMR experiments were performed using a Bruker 850 wide bore 
spectrometer operating at a static magnetic field of 20 T and using a Bruker 3.2 mm 
triple resonance probe head in double resonance mode. Samples were maintained at -
23°C with a sample rotation frequency of 14 kHz ± 1 Hz. Experiments utilized a 1H 
90° excitation pulse length of 2.5 s, Hartmann-Hahn cross polarization over a 1-ms 
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contact time, 3 s 13C 90° pulses, SPINAL proton decoupling at 100 kHz and a 1.5 s 
recycle delay. The proton field was reduced to 14 kHz during the DARR mixing time 
of 10 ms. Phase-sensitive spectra were obtained using time-proportional phase 
incrementation with 420 points in the indirect dimension. The spectrum at each t1 
increment was the result of accumulating between 300 and 1024 transients. 
5.2.2.4. Simulated spectra 
Simulated DARR spectra were used to assess the secondary structure content of the 
experimental DARR spectra. This process comprised two stages, firstly 
13
C 
resonance frequencies were collated and subsequently these chemicals shift values 
were used to simulate DARR spectra using a custom C program written by Prof. D. 
A. Middleton. 
Chemical shift values were calculated using the online sever SHIFTX2 (Han et al., 
2011). This sever uses pre-calculated empirically derived chemical shift 
hypersurfaces to predict chemical shift values for user defined molecular model. 
These hypersurfaces encompass information about dihedral angels, side-chain 
orientations, secondary structure and nearest neighbour effect and are generated from 
known protein structures. Chemical shift values for two medin models were 
generated using SHIFTX2, the medin fibril model generated in section 5.3.1.2, and a 
linear medin model.  
A C program developed by Prof. D. A. Middleton used the derived chemical shift 
values to generate simulated DARR spectra. Time domain signals were simulated as 
512 x 512 matrices and complex Fourier transformation was performed in two 
dimensions to obtain the frequency domain spectra. For the simulated DARR spectra, 
only short-range couplings between directly bonded spins were considered, and long-
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range couplings were neglected to simplify the simulated spectra. Each FID in the t2 
dimension was modulated therefore by no more than three frequencies in t1 (i.e., 
depending on the number of bonded carbon atoms), which restricted the number of 
cross-peaks. 
The simulated spectra for the two models were also compared to simulated spectra 
for purely random coil and -helical conformations. These spectra were generated 
using
  13
C resonance frequencies taken directly from standard chemical shift values 
for -helix and random coil (Ulrich et al., 2008). 
5.2.2.5. Heteronuclear distance measurements using frequency selective 
REDOR  
Frequency selective REDOR (FSR) experiments were performed on hydrated fibrils 
using a Bruker Avance 400 spectrometer operating at a magnetic field of 9.3 Tesla. 
Samples were packed into a 4-mm zirconium rotor and rotated at the magic angle 
while maintaining the spinning rate automatically to within ± 1 Hz. All experiments 
utilized cross-polarization with an initial 4.0-µs 
1
H 90° excitation pulse, 1-ms 
Hartmann–Hahn contact time at a matched 1H field of 65 kHz, TPPM proton 
decoupling (Bennett et al., 1995) at a field of 85 kHz following cross-polarization 
and a 1-s recycle delay. Frequency-selective 
13
C-observed REDOR measurements 
with 
15
N dephasing were conducted using the pulse sequence described by (Jaroniec 
et al., 2001). The MAS frequency was 7400 Hz.  To observe 
13
C dephasing a train of 
82 or 122 non-selective 4 s  pulses was applied at the 15N frequency every half 
rotor cycle, corresponding to total dephasing times of 5.5 ms and 8.2 ms, 
respectively.   Frequency-selective 883 ms Gaussian pulses (defined by 1000 points 
and truncated at 1% of the maximum amplitude), were applied in the centre of the 
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dephasing period.  The frequencies of the Gaussian pulses were centred on the amide 
13
C and lysine -15N resonance frequencies in order to selectively re-couple the 
nuclear spins resonating at these frequencies.  A second, control measurement was 
also performed at each dephasing time, omitting all 
15
N irradiation so as to observe 
the loss of 
13
C coherence resulting from processes not related to 
13
C-
15
N re-coupling. 
Spectra were obtained by averaging 8 blocks, each accumulated from 20,480 
transients and alternating experiments with 
15
N irradiation and experiments without 
15
N irradiation, so as to adjust for any drift in probe tuning during the long 
acquisition time. The extent of dephasing resulting from 
13
C-
15
N dipolar coupling 
(SD) was quantified as the peak intensity observed with 
15
N irradiation divided by the 
intensity observed in the absence of 
15
N irradiation.  SD was translated into a 
13
C-
15
N 
distance and using a C program written specifically for that purpose (by Prof. D A 
Middleton). 
5.2.3. Mutagenesis 
5.2.3.1. Generation of D25N and K30I mutants by site-directed ligase 
independent mutagenesis (SLIM). 
In order to investigate the effect of certain residues on the structure and aggregation 
properties of medin, two mutant proteins were generated using the SLIM method 
(Chiu et al., 2004). Two residues within wild type medin were selected for mutation; 
the aspartic acid at position 25 was substituted for an asparagine (D25N) therefore 
neutralising the charge. The lysine at position 30 was substituted for an isolucine 
(K30I) again neutralising the charge and introducing an additional hydrophobic 
residue (Figure 5.7). 
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Figure 5.7 Sequence of medin in single letter amino acid code highlighting the 
two single point substitution mutation sites.  
 
 
This method of mutation uses inverse PCR to amplify the template using 4 primers, 
two long primers that have tails encoding the mutation and two short primers (Figure 
5.8). Amplification of the template by the four primers results in four PCR products; 
after denaturation and re-annealing 16 hybrid species are formed of which two are 
capable of spontaneous circularisation and thus successful cloning (Figure 5.8). An 
agarose gel was used to check the amplification of the target was successful prior to 
denaturation and annealing. Upon completion the mixture was transformed into XL1 
blue cells. The plasmid was isolated and sequenced as described previously 
(Appendix 2). 
  
 155 
 
 
Figure 5.8 Schematic of SLIM protocol, adapted from (Chiu et al., 2004). 
Initially an inverse PCR reaction performed with modified primers, generates 4 
products. Denaturation and re-annealing of these products results in 16 possible 
pairings. Two of these pairings are capable of spontaneous circularisation via 
the tail regions resulting in the mutated plasmid. This example details the 
primers used to generate D25N medin mutant. 
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5.2.3.2. Expression of mutants 
Mutant proteins were expressed under the same conditions as wild type medin 
detailed in section 3.2.1.8. In brief, plasmids were transformed into BL21 cells, 
grown overnight and subsequently used to inoculate 2 L of LB. Cells were induced at 
an O.D. 600 between 0.7 and 1, with IPTG at a final concentration of 1 mM. Cells 
were harvested by centrifugation and then lysed by sonication. Proteins were purified 
using a 5 ml HisTrap™ column (G.E.Healthcare), desalted, and then cleaved using 
SUMO protease, produced in-house. The resultant cleavage mixture was then passed 
back down the 5 ml HisTrap™ column to remove any un-cleaved protein and the 
protease.  
5.2.4. Characterisation of mutants 
In order to investigate the affect of the substitutions upon medin aggregation, a 
variety of biophysical techniques were used and the data compared to that collected 
for wild type medin. 
5.2.4.1. Kinetic analysis by thioflavin T assay and intrinsic fluorescence. 
Both assays were carried out on the mutants under the same conditions as the wild 
type, described in section 4.2.1. In brief, mutant peptides were incubated in 
aggregation buffer at a concentration of 20 M in the presence of ThT (20 mM) 
(Appendix 1). ThT assays were carried out on a Flexstation 3 microplate reader 
(Molecular Devices Ltd.) using 96-well black-walled, clear bottomed microplates 
(Nunc) with data recorded using bottom read mode.  
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5.2.4.2. Structure and morphology analysis by CD and electron microscopy. 
Far- UV CD was used to identify any changes in secondary structure that arose as a 
result of the substitutions. TEM was carried out to see if there were any visible 
differences in morphology following 48 hour incubation. Both were done under the 
same conditions as wild type medin described in section4.2.4. In brief, the mutant 
peptides were incubated at a concentration of 200 M, at 30 °C, in the cuvette 
(121.000-QS Hellma, Southend-on-Sea, U.K.) for the duration of the time course. 
Experiments were carried out at beam line B23 at Diamond light source (Oxford, 
U.K.).  Single scans were recorded every two hours between 190 and 240 nm, using 
a slit width of 0.5 mm, 0.5 cm path length and a scan rate of 1 nm/sec, over 44 hours. 
Analysis was carried out using Olis
®
 GolbalWorks software. Data at each time point 
was subject to two fitting methods, CONTILL and CDSSTR, using either basis sets 8 
or 11 (Van Stokkum, 1990, Sreerama, 2000, Manavalan, 1987). The best fit, as 
determined by the normalised spectral fit standard deviation, was selected and the 
percentage -helix, -sheet, turn and random coil content recorded.  
5.3. Results 
5.3.1. Models 
Molecular modelling based on A fibril models was carried out to visualise any 
possible turn and to guide elements of the experimental design such as isotope 
labelling schemes and solid-state NMR pulse sequences.  
5.3.1.1. A1-40 template 
Four Afibrilmodels were used as templates representing two different polymorphs 
of Awith 2- and 3-fold symmetry. Previous structural studies used synthetic 
isotopically labelled Aaggregated under two different conditions, with and 
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without agitation. Subsequently, multiple rounds of seeding were used to generate 
two different homogeneous morphologies (Paravastu et al., 2008, Petkova et al., 
2005b). The aggregates were then studied, primarily by solid state NMR, and models 
generated from the resultant restraints (Paravastu et al., 2008, Petkova et al., 2002). 
Four models have been deposited in the PDB with the following Ids: 2LMO, 2LMN, 
2LMP and 2LMQ. Patavastu et al. represented each polymorph as two models 
corresponding to positive (2LMN and 2LMP) and negative stagger (2LMO and 
LMQ). Stagger is used to describe the degree to which each strand is displaced along 
the fibril long axis from C- to N-terminus (Figure 5.9). Solid state NMR data on 
Asuggest a stagger of ± 2, whereby the C terminal -stand of each molecule is 
displaced by 7.2 Å, the equivalent of 1.5 times the inter-strand spacing. Paravastu et 
al. (2008) are however unable to distinguish between the two (Petkova et al., 2002). 
Residues 1-9 of A1-40 are considered to be unstructured and are therefore not 
included in the models (Petkova et al., 2002).  
 
 
Figure 5.9 Schematic example of stagger along a fibril axis.  Images show 
examples of negative staggers of -1 and -2 respectively. 
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A common feature of these models is the tertiary structure of a single A molecule, a 
single hairpin, which given the sequence similarity at this region, may also represent 
the tertiary structure of medin.  
These models represent two examples of different polymorphs generated from the 
same primary sequence, and are used here as templates for modelling the tertiary 
structure of medin. The quarternary packing within the A1-40 fibrils and the two- 
and three-fold molecular symmetries (Figure 5.5) of the two morphologies were 
disregarded in the modelling. 
5.3.1.2. Medin models 
Four medin models were generated using Modeller version 9.11(Eswar et al., 2007) 
for the truncated medin 10-40 sequence. Truncated medin was used to match the 
length of the template model. The best model from each ensemble of 20 was selected 
based on the lowest molpdf score and shown in Figure 5.5. These models gave 
comparable WHAT IF scores, indicating that the side chain groups are similarly well 
packed and a similar number of steric clashes calculated by Chimera, to the template 
models.  
The models show several possible stabilising interactions within medin fibrils. There 
are 9 hydrophobic residues within the proposed amyloid core. It is likely that these 
residues form hydrophobic interactions that stabilise the structure. In particular W21 
and I35 are on opposite sides of the turn and with their side chains oriented inwardly 
(Panel D Figure 5.10). The phenylalanine residues at positions 8, 43 and 48 are 
outside the core of the proposed fibril but may form -stacking interactions that may 
stabilise the termini. The turn region in the medin model encompasses residues 25-30 
and has an appropriate geometry to permit a salt bridge between D25 and K30. Given 
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the remarkable conservation at these positions, the salt bridge hypothesis was tested 
experimentally. 
The models were visualised in PyMOL (V1.5.0.4) and the distances between C of 
D25 and N of K30 measured. Models based on 2LMO and 2LMN (two-fold 
symmetry) exhibited many close intermolecular distances between D25 and K30, 
several less than 4 Å and, therefore, capable of forming ionic interactions (Kumar 
and Nussinov, 2002) (Figure 5.10). Generally, models based on 2LMP and 2LMQ 
(three-fold symmetry) gave distances greater than 6 Å (data not shown). 
 161 
 
 
Figure 5.10 Closer analysis of model medin using 2LMN as a template (A-C). 
Images show possible intermolecular salt bridge interactions with distances 
between Lys NandAsp C shown in black. Lysine residues shown in red, 
aspartate in blue. Schematic to demonstrate the location of hydrophobic 
residues (red) within the model (D). 
 
5.3.2. Structural studies of wild type recombinant medin by solid state NMR 
Chapter 3 described the development of a procedure to produce full-length, 
uniformly 
13
C and 
15
N labelled medin. The uniformly labelled protein enabled two-
W21 
I35/36 
V24 
D25 
V32 
K30 
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dimensional solid-state NMR experiments to examine the global conformation of 
medin in a fibrillar preparation as the first step to test the structural models 
generated.  
5.3.2.1. One-dimensional solid-state NMR  
Proton decoupled 
13
C and 
15
N spectra were collected for full length recombinant 
medin. The data show that medin was successfully isotopically labelled with both 
13
C 
and 
15
N. Characteristic chemical shifts were annotated according to the Wang and 
Jardetzky (2002) (Figure 5.11). Quaternary carbon atoms are located between 165-
180 ppm, aromatic carbon atoms between 105-135 ppm and the aliphatic carbon 
atoms between 10-70 ppm. There is a small peak at approximately 160 ppm 
corresponding to the guanidinium of arginine. (Wang and Jardetzky, 2002).  
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Figure 5.11 Annotated one dimensional solid-state NMR spectra of uniformly 
13
C and 
15
N labelled medin fibrils.  Data was collected on a Bruker 850 MHz 
wide-bore spectrometer operating at a static magnetic field of 20 T Proton de-
coupled 
13
C spectrum obtained after 1024 scans (A) Proton de-coupled 
15
N 
spectrum obtained after 20480 scans (B). 
A. 
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5.3.2.2. DARR spectrum and simulated spectra 
Dipolar assisted rotational resonance spectra of full length uniformly 
13
C, 
15
N 
labelled medin fibrils were collected on the 850 MHz facility at the University of 
Warwick. The two-dimensional DARR spectrum correlates 
13
C spins through dipolar 
couplings.  As seen in the one-dimensional experiments, the peaks in the DARR 
spectrum are very broad with a large amount of overlap (Figure 5.12), suggesting 
that the sample is highly heterogeneous. Some cross-peaks could be assigned using 
chemical shift data available for other amyloid proteins (Petkova et al., 2005b) but 
full de novo sequential assignment of the spectrum was not possible. 
 
Figure 5.12 DARR spectrum for uniformly 
13
C/
15
N labelled recombinant medin 
following incubation at 25 °C at a concentration of 200 M in aggregation 
buffer. Data was collected on a Bruker 850 MHz wide-bore spectrometer 
operating at a static magnetic field of 20 T with a sample temperature of 23 °C 
and a spinning rate of 14 KHz.   
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Further multidimensional 
13
C-
13
C and 
13
C-
15
N measurements at high field would be 
necessary to assist the spectral assignment needed for a full structure determination, 
but these were not possible in the time available.  Instead, a different approach was 
taken in which 
13
C chemical shifts were calculated from the medin model shown in 
Figure 5.10. These shifts were then used to simulate a DARR spectrum to compare 
with the experimental spectrum. 
13
C chemical shifts for C, C and amide carbonyl 
sites are sensitive to the backbone  and  angles defining secondary structure. 
Similarity in the experimental and simulated spectra, as judged by the overlap of 
cross-peaks, would therefore suggest that the model broadly comprised the correct 
secondary structural elements.   
DARR spectra were generated from the hairpin model of medin shown in Figure 
5.10, using the online server SHIFTX2 which generates 
13
C chemical shifts values 
from protein structures (Han et al., 2011) and a program to convert the values into a 
pseudo 2D spectrum. The experimental data (blue) are in good agreement with the 
simulated spectrum (black, Figure 5.13, 5.14 and 5.15) and overlap in the vast 
majority of the spectrum. This suggests that medin fibrils have a predominantly -
sheet conformation, and share some structural similarity with the proposed model. A 
second spectrum was simulated for a model of medin in a continuous -sheet 
conformation lacking the hairpin (red, Figure 5.13, 5.14 and 5.15). Although there is 
again overlap of many cross-peaks, on visual inspection, the match for the linear 
model appears to be not as close as for the hairpin model. The chemical shift 
predictions are not accurate enough to distinguish between these two models 
however. 
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Further simulated spectra were generated from average chemical shift values for 
medin in random coil and complete -helical structures (Appendix 3), taken from the 
BMRB (Ulrich et al., 2008). In these cases the overlap with the experimental spectra 
was substantially poorer than for the models above, suggesting that these structural 
elements do not feature highly in the medin fibrils.  
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Figure 5.13 Spectra showing Cchemical shifts for recombinant medin (blue) 
overlaid with corresponding simulated spectra calculated for medin model 
based on A template (black, panel A) and a linear model (red, panel C). The 
assigned simulated spectra for the medin model based on A template and the 
linear model are shown in panels B and D respectively. 
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Figure 5.14 Carbonyl region of recombinant medin DARR spectrum. Simulated 
spectra for models based on A (black, panel A) and a linear medin model (red, 
panel B).  
 
 
Figure 5.15 Expanded region of recombinant medin DARR spectrum showing 
the differences between simulated spectra for models based on A (black, panel 
A) and a linear medin model (red, panel B). 
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5.3.3. Testing the salt bridge hypothesis using solid state NMR frequency 
selective REDOR experiments. 
In order to investigate the hypothesis of a salt bridge within medin fibrils, a second 
synthetic peptide was produced which contained selective isotope labels including 
13
C/
15
N D25 and K30 (for full details see section 5.2.2.1). This hypothesis was 
testing using frequency selective REDOR experiments. This technique allows the 
detection of 
13
C-
15
N dipole-dipole couplings between a selected spin pair, in this case 
D25 C and K30 N Initially a reference spectrum is collected using standard cross-
polarisation pulse sequence with a° pulse on the observed nucleus (black lines, 
Figure 5.16). The second spectrum is obtained by the addition of a second set of ° 
pulses on the dipolar coupled spin which results in a drop in signal intensity S 
which is related to the internuclear distance between the two spins (red lines, Figure 
5.16).  
   
 
  
           
 
  
                  
  
 
 
  
 
 
 
   can be simulated for different values of the dipolar coupling constant   until a 
good fit is achieved. The dipolar coupling constant can then be used to calculate an 
inter-nuclear distance using equation 2.3. In order to obtain an accurate internuclear 
distance multiple experiments but be conducted at a variety of dephasing times. Due 
to the length of the experiments and the loss of intensity at longer dephasing times it 
was not possible to obtain a precise internuclear distance. However, the limit of 
13
C-
15
N dipolar coupling is approximately 5 Å.  Dephasing observed at the two mixing 
times could only occur if these is nuclei (D25 C and K30 Nwere within 5 Å and 
may therefore permit salt bridge formation. 
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Figure 5.16 Frequency selective REDOR spectra for full length synthetic medin 
at two different mixing times, 5.5 ms (A) and 8.2 ms (B). Data was collected on a 
Bruker Avance 400 spectrometer operating at a magnetic field of 9.3 T. 
Reference spectra are shown in black and spectra with additional de-phasing 
are shown in red. The loss in signal intensity is indicative of an internuclar 
distance of less than 5 Å. 
 
5.3.4. Mutagenesis 
Modelling and NMR data suggest that a salt bridge is feasible. A method of testing 
this experimentally is to create mutants that are prohibitive to salt bridge formation 
and any effects they may have on the kinetic and morphological properties of medin.  
5.3.4.1. Cloning 
Two mutants, D25N and K30I were generated using the SLIM method and 
confirmed by sequencing (Appendix 2). The medin sequence was amplified using 
two long tailed primers (containing the mutation) and two short primers (Appendix 
2). The efficacy of the process can be verified by agarose gel electrophoresis. As 
anticipated the gel shows two strong bands that correspond to the correct number of 
base pairs.  The control reaction (lane 2, Figure 5.17), containing the template with 
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no primers present, is blank indicating that the bands seen in lanes 3 and 4 are 
products of the PCR reaction not the template DNA (Figure 5.17). 
 
 
Figure 5.17 Agarose gel electrophoresis of the mutant PCR products. Lane 1. 1 
Kbp DNA ladder (NEB). Lane 2. Control PCR reaction with no mutagenesis 
primers. Lane 3. PCR amplification product from pimers containing D25N 
mutation. Lane 4. PCR amplification product from pimers containing K30I 
mutation.  
 
Sequencing of the resultant plasmids showed the presence of the single point 
mutations, confirming successful cloning (Appendix 2). The mutant proteins were 
then successfully expressed and purified using the protocol described for medin, in 
the same vector.  
5.3.4.2. Mutant expression 
D25N and K30I were successfully expressed in E.coli giving yields of 1.5 and 3 mg 
of pure protein per litre of culture media. Purification of the mutants followed the 
protocol established in section 3.2.1.8. The fusion protein was isolated from the 
crude extract by Ni
2+
 affinity chromatography (Lane 1, Figure 5.18). D25N 
expressed better than K30I giving a higher yield of fusion protein (Panel A, Lane 1 
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Figure 5.18) The affinity tag was cleaved from both proteins using SUMO protease. 
K30I was fully cleaved (Panel B, Lane 2 Figure 5.18), it does not seem however that 
D25N was fully cleaved (Panel A, Lane 2 Figure 5.18). Given the increased yield of 
D25N it may be that insufficient protease was added. Following cleavage the mutants 
were isolated from the cleavage mixture using reverse affinity purification.  
 
 
Figure 5.18 15 % SDS PAGE gel images of D25N (A.) and K30I (B.) purification 
and cleavage steps. Lane 1. Eluted from HisTrap™, Lane 2. Cleavage mixture, 
Lane 3. Reverse HisTrap flow through, Lane 4. SeeBlue® plus 2 protein 
standard (Invitrogen) 
 
As described in section 3.2.3.1, WT medin was difficult to visualise using standard 
electrophoresis and staining methods. The same problems were observed for both 
mutant peptides. D25N can be seen in lane 2 (Panel A, Figure 5.18) but it is running 
on the dye front. Furthermore, following reverse affinity purification, despite 
showing significant absorbance at 280 nm, there is nothing visible on the gel (Lane 
3, Panel A, Figure 5.18). The reverse affinity purification dilutes the protein fraction 
approximately 10-fold. This dilution goes some way to explaining the lack of a 
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visible protein band in the flow through (Panel A, Figure 5.18. K30I is not visible in 
either lane (Panel B, Figure 5.19) the lower expression and resultant purification 
yields may explain why it not visible despite a positive absorbance reading at 280 
nm.  
The initial expression yield of these mutants was sufficient for the work described 
here; therefore, the expression, purification and visualisation did not undergo any 
optimisation. 
5.3.5. Aggregation kinetics of mutant peptides D25N and K30I. 
5.3.5.1. ThT analysis 
ThT fluorescence of the mutant peptides was carried out to assess the effect of the 
point mutations on the aggregation kinetics of medin. The peptides were analysed 
under the same conditions as the wild type peptide (section 4.2.1) and three 
properties compared: the end point fluorescence intensity, lag time and elongation 
rate constants. Neither of the mutations had a large effect on the aggregation of 
medin but there are some statistically significant differences. D25N had a faster rate 
constant than WT medin (Figure 5.19and 5.20). Conversely, K30I had reduced lag 
time compared with WT medin (Figure 5.19and 5.20). There is a relatively small 
increase in fluorescence intensity after approximately 15 hours, followed by a small 
decrease. This change precedes the main increase in fluorescence and may represent 
the formation of oligomers. Interestingly the largest ‘hump’ is seen for D25N which 
ultimately results in the lowest overall increase in fluorescence intensity (Panel 
B,Figure 5.20). This may suggest the formation of off-pathway oligomeric species. 
This indicates that the mutations do not prevent the formation of amyloid according 
to the ThT assay. 
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Figure 5.19 Aggregation of mutants compared to wild type medin analysed by 
thioflavin T fluorescence. WT medin, D25N and K30I are shown in panels A-C 
respectively.  Data were recorded on a fluoromax spectrometer at 30 °C on a 20 
M protein solution in aggregation buffer. The red line represent the fit using 
the following equation:      
 
   
    
 
 .The adjusted R2 values indicating the 
goodness of fit for each curve are reported on the right hand side. Data 
represent mean data for 3 replicates. 
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Figure 5.20 Analysis of the effect of mutations on fluorescence intensity (A), lag 
time (B) and rate constant (C). Values were extracted from fitting exponential 
curves to the data and calculating the lag phase, the maximum fluorescence 
intensity and the calculated rate constants for each condition. Data represent 
mean and standard error values for 4 replicates. Asterisk represent statistical 
significance where p=0.05. 
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5.3.5.2. Aggregation kinetic of mutants using intrinsic fluorescence 
Intrinsic fluorescence (IF) measurements were carried out on the two mutant peptides 
to investigate the effect of the mutations on the tryptophan environment.  
Surprisingly, D25N demonstrated an increasing maximum fluorescence at 355 nm 
over time, consistent with increasingly solvent exposed tryptophan residues. There is 
also no change in the emission wavelength, suggesting no change in the local 
environment. This is in contrast to wild type medin, for which a time-dependant 
decrease in florescence suggests a switch from solvent exposed tryptophan residues, 
to buried within the hydrophobic core as discussed in section 4.3.1.3.  
 
Figure 5.21 Changes in intrinsic tryptophan fluorescence of D25N over time at 
30 °C, at a protein concentration of 20 M. Tryptophan residues were excited at 
279 nm and emission spectra were recorded from 300-400 nm. Data were 
collected every 15 minutes for 50 hours, raw data shown in (A) and initial and 
final spectra shown in (B).  
 
K30I demonstrates a decrease in fluorescence maximum at 355 nm suggesting that 
the tryptophan residues are less solvent exposed (Figure 5.22). This may be a result 
of precipitation, the aggregation profile obtained from ThT measurements gave the 
highest overall fluorescence suggesting the greatest overall amount of aggregation 
(Figure 5.19). K30I, unlike wild type medin, does not undergo the same switch from 
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solvent exposed to buried within the hydrophobic core. This implies an alternative 
aggregation mechanism. 
 
Figure 5.22 Changes in intrinsic tryptophan fluorescence of K30I over time at 
30 °C, at a protein concentration of 20 M. Tryptophan residues were excited at 
279 nm and emission spectra were recorded from 300-400 nm. Data were 
collected every 15 minutes for 50 hours, raw data shown in (A) and initial and 
final spectra shown in (B).  
 
5.3.6. Structure and morphology of mutants 
Although the kinetic analysis by ThT indicated that the mutations had little effect on 
the aggregation potential of medin, it is possible that these mutations have alternative 
aggregate structures. Accordingly, the secondary structure content and the 
morphology of the aggregates were examined by circular dichroism and electron 
microscopy respectively. 
5.3.6.1. Monitoring secondary structure of D25N over time 
Circular dichroism was used to monitor the secondary structure content of freshly 
prepared mutants, over a period of 44 hours, at 2 hourly intervals. Experiments were 
carried out on Beamline 23 at Diamond light source under the same conditions as for 
wild type medin (see section 4.2.4 for details).  
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Figure 5.23 CD spectra for D25N comparing start and end points (0 and 44 
hours). Data were recorded at 30 °C on medin (200 M, in CD buffer) using far-
UV synchrotron radiation circular dichroism at beam line B23 at Diamond light 
source. 
 
Circular dichroism data for D25N shows that it has a predominantly helical structure 
(Figure 5.23 and 5.24), approximately 60 % when estimated using CONTILL and 
CDSTRR fitting methods. The amount of -helix present remains relatively constant 
throughout the time course (Figure 5.25). There is a slight shift towards -sheet near 
the end of the time course, from approximately 10 % to 30 % (Figure 5.25). This 
shift occurs at the same time as the fluorescence intensity begins to increase in ThT 
measurements; after 25 hours (Figure 5.19).  Overall, D25N has more -helix than 
WT medin throughout the time course. There is small conversion to -sheet, 
approximately 20%, but it is not as pronounced as the conversion seen in WT medin 
(65 %).  
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Figure 5.24 Circular dichroism spectra of D25N (200 M, in CD buffer) at 
different time points: 0, 6 12, 18, 24, 30, 34 and 44 hours, A-H respectively. 
Experimental data shown in black and secondary structure fits in red. Residual 
data from the fits are shown above each data set. Data were recorded at 30 °C 
using far-UV synchrotron radiation circular dichroism at beam line B23 at 
Diamond light source.  
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Collectively the ThT, IF and CD data show that D25N has a distinct aggregation 
pathway to wild type medin. This indicates that D25 has a key role in 
amyloidogenesis. The preliminary ‘hump’ seen in the ThT, and the large degree of 
-helix observed in the CD may suggest the formation of oligomeric species. This is 
also consistent with the solvent availability of the Trp residues within D25N 
suggesting that the species are soluble. These may be off-pathway stable oligomeric 
species or they may go on to form fibrillar aggregates.  The increase in ThT observed 
at 30 hours and the conformational change seen in CD at the same point implies that 
there is a change in aggregate structure at this point. The increase in ThT and the 
conformational change for D25N however is less pronounced than for wild type 
medin which may suggest that only some of the population undergoes further 
aggregation. 
 
Figure 5.25 Secondary structure analysis of D25N over 44 hour time course. CD 
data were analysed using, CONTIN or CDSSTR secondary structure fitting 
software, percentage values for -helix (black), -sheet/turn (red), extracted and 
plotted over time. 
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5.3.6.2. Investigating the stability of D25N in response to UV radiation 
To ensure the secondary structure analysis reported changes in the protein 
conformations rather than degradation, UV stability experiments were carried out. 
This experiment further provided us with information about the general stability of 
the peptide. These data show that D25N is stable in response to UV radiation for a 
total exposure time of 32.5 minutes (Figure 5.26). Secondary structure experiments 
were carried out for a total UV exposure time of 28.6 minutes, therefore any changes 
observed are a result of secondary structure changes not degradation.  
 
Figure 5.26 Analysis of D25N stability in response to UV radiation, key refers to 
scan number. Data were recorded over 25 scans at 30 °C on medin (200 M, in 
CD buffer) using far-UV synchrotron radiation circular dichroism at beam line 
B23 at Diamond light source. 
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5.3.6.3. Monitoring the secondary structure of K30I over time. 
The secondary structure content of K30I was also investigated over 44 hours. Spectra 
shown in Figure 5.27 and 5.28 do not demonstrate any significant change in 
secondary structure over time. There is a loss in intensity after 44 hours but the two 
spectra are virtually superimposable (Figure 5.27). This is confirmed when the data 
is analysed using secondary structure fitting algorithms (CDSSTR and CONTIN) ( 
Figure 5.29). The amount of each secondary structure element remains constant 
throughout the time course, approximately 25 % -helix, 40 % -sheet/turn and 35 
% random coil ( 
Figure 5.29). 
 
Figure 5.27 CD spectra for K30I comparing start and end points (0 and 44 
hours). Data were recorded at 30 °C on medin (200 M, in CD buffer) using far-
UV synchrotron radiation circular dichroism at beam line B23 at Diamond light 
source. 
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The end point data for K30I has a higher signal to noise ratio and a lower starting 
intensity than both D25N and wild type medin suggesting that some of the peptide 
has precipitated (Figure 5.27). Unlike D25N and wild type medin, the aggregation 
seen with K30I is not associated with a change in secondary structure that could be 
measured using this technique. K30I, like D25N, appears to have a distinct 
aggregation pathway to wild type medin, again suggesting a key role for K30 within 
amyloidogenesis.  
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Figure 5.28 Circular dichroism spectra of K30I (200 M, in CD buffer) at 
different time points: 0, 6 12, 18, 24, 30, 34 and 44 hours, A-H respectively. 
Experimental data shown in black and secondary structure fit in red. Residual 
data from the fits are shown above each data set. Data were recorded at 30 °C 
using far-UV synchrotron radiation circular dichroism at beam line B23 at 
Diamond light source. 
 185 
 
 
 
Figure 5.29 Secondary structure analysis of K30I over a time course of 44 hours. 
CD data were analysed using, CONTIN or CDSSTR secondary structure fitting 
software, percentage values extracted and plotted over time. Asterisks indicate 
standard deviation values for the fits of over 0.1.  
 
5.3.6.4. Investigating the stability of K30I in response to UV radiation 
As with D25N, it was necessary to check the stability of K30I in response to UV 
radiation. K30I was less stable than D25N following exposure to UV radiation over 
32.5 minutes but this was sufficient stable to assess secondary structure over time 
(28.6 minutes) (Figure 5.30). 
 186 
 
 
Figure 5.30 Analysis of K30I stability in response to UV radiation, key refers to 
scan number. Data were recorded over 25 scans at 30 °C on medin (200 M, in 
CD buffer) using far-UV synchrotron radiation circular dichroism at beam line 
B23 at Diamond light source. 
 
5.3.7. Morphology of mutant aggregates studied by transmission electron 
microscopy. 
Negative stain electron microscopy was used to examine the morphology of D25N 
and K30I at the end of the aggregation time course, after 44 hours. There were no 
fibrillar aggregates visible in the D25N sample (Figure 5.31). There is however a 
large number of small, ‘doughnut’-shaped assemblies, approximately 50 nm in 
diameter (Figure 5.31). This correlates with the hypothesised formation of stable 
oligomers. The subsequent increase in ThT fluorescence seen at 30 hours (Figure 
5.19) may be due to a change in oligomer conformation or the association of 
oligomers into larger assemblies visible in the electron micrograph (Panel A, Figure 
5.31).  
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By contrast K30I showed the presence of long, thin fibres (Figure 5.31), however 
they do not appear to form the dense networks seen for wild-type medin (Figure 
4.16). The presence of large fibrils correlates with the reduction in signal observed in 
the CD data as the fibrils fall out of solution (Figure 5.27). This also accounts for the 
large increase in fluorescence intensity observed in the ThT assay (Panel C, Figure 
5.20). In addition to the fibrils, there are some small oligomer-like aggregates visible 
with the same dimensions as those observed for D25N (Figure 5.31).  
 
Figure 5.31 Negatively stained electron microscopy images of D25N (A) and 
K30I (B) formed under quiescent conditions, at 30 °C, at a peptide 
concentration of 20 M in aggregation buffer. Zoomed in sections indicated by 
boxes are shown below. 
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5.4. Discussion 
The recent advances in biophysical techniques have led to huge increase in the 
number of known protein structures deposited within the Protein Data Bank. The 
number of depositions however still accounts for only a small portion of all known 
proteins and the number of solved amyloid protein structures is even fewer. 
Currently, A1-40 is the only full length amyloid protein with deposited fibril models 
in the PDB. Using known structures it is possible to infer information about proteins 
yet to be solved (Furnham et al., 2013). Molecular modelling is a powerful tool to 
guide experimental design. A good example of the uses of molecular modelling is in 
drug/inhibitor design whereby small molecule ligands are modelled in target binding 
sites of proteins. The results then guide the experimental work (Favia et al., 2013). 
Conventionally, homology modelling requires a high degree of sequence similarity; 
however, the low number of amyloid proteins deposited within the PDB and the 
diversity of amyloid forming proteins makes this challenging. Despite this problem it 
has been shown that amyloid proteins with low sequence identity, such as IAPP and 
A, form fibrils that share many structural similarities (Figure 5.2).  
The structure of medin is unknown; therefore, a molecular modelling approach was 
used to identify key features that could be tested experimentally. There are molecular 
fibril models available for IAPP and A1-40 either in the PDB or in the literature. 
Sequence alignment between medin and IAPP and A, revealed closer similarity 
with A with both a global and local alignment, therefore A was chosen as the 
template for modelling medin fibrils. 
Although the overall sequence alignment of medin with A1-40 was low, a high level 
of similarity was identified between residues 25 and 30 of medin, which encompass 
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the turn region of A1-40. Modelling, suggests that it may be possible for ionic 
interactions to occur in medin if such a turn existed. Despite the lack of experimental 
evidence for a turn in medin, all amyloid structures composed of peptides over 
approximately 20 amino acids in length include some form of turn (Iwata et al., 
2006, Petkova et al., 2005a, Luca et al., 2007).  These models are limited by the 
relatively low sequence identity. Furthermore, the models represent a truncated form 
of medin due to the lack of template in these regions. Given these limitations, it was 
important to test this hypothesis experimentally. This took two forms, direct 
measurements using solid state NMR and mutagenesis studies.  
5.4.1. Solid state NMR measurements of medin 
Initial structural studies of recombinant medin fibrils demonstrate a high degree of 
heterogeneity within the sample. There an increasing body of evidence to suggest 
that there is a large diversity of structural conformations within amyloid deposits 
(Pedersen et al., 2010). Multiple strains, have not only been seen for prion proteins 
(Tanaka et al., 2004) but, IAPP (Dzwolak et al., 2004), 2 microglobulin (Yamaguchi 
et al., 2005) and APetkova et al., 2005a. Certain strains or variants can be 
selected for through the process of seeding (Kim et al., 2007, Yamaguchi et al., 2005, 
Qiang et al., 2011). It has been shown numerous times that the presence of a 
‘structural template’ in the form of a seed can propagate and select for a specific 
morphology or structure (Petkova et al., 2005a). 
In previous studies on A1-40, the solid-state NMR line-widths for un-seeded fibrils 
were too large to obtain site specific information (Petkova et al., 2005a). In order to 
overcome the problem of sample heterogeneity, the fibrils were subjected to multiple 
rounds of seeding to generate a homogenous population of fibrils prior to structural 
 190 
 
analysis. This improved the line-widths and led to site-specific information, which in 
turn led to molecular models (Petkova et al., 2005b).  This could be a possible 
strategy to improve the line-widths and thus resolution of medin data however it was 
beyond the scope of this work. Despite the overlaps within the DARR spectrum 
comparison with simulated spectra revealed that it best resembled the simulated 
spectra for the hairpin model (Figure 5.13,5.14 and 5.15).  
An alternative method to obtain site specific information is to use a synthetic peptide 
to simplify the NMR experiments. Frequency selective REDOR experiments showed 
that the inter-nuclear distance between D25 C and K30 Nwas less than 5 Å. It is 
therefore likely that medin fibrils are stabilised by a salt bridge between D25 and 
K30 as seen in A(Petkova et al., 2002).  
5.4.2. Mutagenesis studies 
An additional means of testing the hypothesis of a salt bridge is to generate mutants 
that prevent the formation of a potential salt bridge between D25 and K30. Two 
mutants were generated in this work, D25N and K30I. 
In order to investigate the role of these residues within medin aggregation, D25N and 
K30I were subject to kinetic, structural and morphological characterisation to 
observe any differences to wild type medin. 
5.4.2.1. Characterisation of D25N 
Kinetic and structural analysis of D25N indicated that is has a distinct aggregation 
pathway to wild type medin. Collectively the data suggest the formation of 
oligomeric species.  ThT, IF and CD measurements indicate the presence of 
aggregates that are capable of binding ThT, are likely to be soluble in solution and 
have a predominantly -helical conformation that undergo and slight shift towards -
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sheet. Previous studies have described -helical oligomeric species that are capable 
of later converting to amyloid fibrils (Zhao et al., 2012, Jayaraman et al., 2012). It is 
possible that the D25N mutation initially favours oligomer formation and there is a 
partial conversion to -sheet later on, possibly coinciding with oligomer association. 
Electron micrographs of D25N following incubation do not show fibrillar structures, 
they did however, reveal the presence of small, spherical, concave structures similar 
in appearance to previously described oligomeric species (Figure 5.31) (Ahmed et 
al., 2010, Fändrich, 2012).  
Oligomeric amyloid species are thought to have a key role in the pathology of the 
amyloidoses. It would be interesting to assess the toxicity of the species formed by 
D25N to see if they also possess cytotoxic capabilities. The Iowa mutant of A forms 
fibrils however, it is more toxic that WT A(Van Nostrand et al., 2001). If D25N is 
more prone to oligomer formation it may be that it too is more toxic than its WT 
counterpart. 
5.4.3. Characterisation of K30I 
ThT analysis, intrinsic fluorescence data, CD measurements are all consistent with 
rapid conversion to large aggregates (Figure 5.19, 5.22 and 5.27). TEM visualisation 
confirms the presence of a large quantity of long, slender fibrils (Figure 5.31). 
Generally, K30I was less stable than both D25N and WT medin, illustrated by the 
increase degradation in response to UV exposure (Figure 5.30). It has been shown 
previously that instability greatly accelerates fibril formation (Ionescu-Zanetti et al., 
1999) and likely explains the increased number of fibrillar aggregates observed by 
TEM. It is probable that the increased hydrophobicity of the K30I mutant drives 
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fibrils formation. In summary, substituting K30 for isoleucine increases the overall 
aggregation potential of medin 
Both D25N and K30I have different kinetic, structural and morphological properties 
when compared with WT medin. These results indicate that both D25 and K30 have 
a role in the aggregation of WT medin. Mutations have often been shown to alter 
protein structure, this is exemplified by the number of amyloid diseases arising from 
single point mutations such as hereditary forms of TTR (Ericzon et al., 2003) and 
rarer conditions such as gelsolin related amyloidosis (Solomon et al., 2012). The 
changes observed here may be no more than a result of altering the intrinsic 
properties of the protein. However, collectively, the similarity with A, the NMR 
data and the mutation characterisation may support the hypothesis of a stabilising salt 
bridge between these residues.  
In conclusion, data presented here are consistent with the presence of a salt bridge 
within medin fibrils. This provides further evidence that ionic interactions could be a 
common stabilising feature of amyloid structures. This could provide a common 
therapeutic strategy for targeting amyloid assemblies.  
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6. Expression and purification of SMA for 
structural studies 
6.1. Introduction 
6.1.1. Immunoglobulin light chain amyloidosis  
Immunoglobulin light chains are involved in a variety of protein deposition diseases, 
including AL amyloidosis. AL amyloidosis is the most common and severe form of 
systemic amyloidosis. Patients with AL amyloidosis have a very poor prognosis with 
a median survival time of 40 months following diagnosis (Wechalekar et al., 2008). 
Approximately 90 % of patients with AL amyloidosis have signs of pathological 
heart involvement, and approximately 50 % of patients are in heart failure at the time 
of diagnosis (Desport et al., 2012). In total, approximately 75 % of deaths in patients 
with AL amyloidosis are attributed to cardiac involvement, namely heart failure and 
arrhythmia (Desport et al., 2012).   Furthermore, subsequent treatment options are 
very limited (Lachmann et al., 2003). This is in part due to the extremely high level 
of heterogeneity; no patient diagnosed to date has had the same proteins within 
deposits as another patient (Enqvist et al., 2009). It has been shown previously in 
many studies that single point mutations or truncations can convert native non-
amyloidogenic proteins into pathogenic amyloid (Van Nostrand et al., 2001, Steward 
et al., 2008). In the case of AL amyloidosis, it is highly unlikely that a single position 
or truncation can be responsible due to the diversity of light chains found amongst 
patients. This has led researchers to explore model systems in an attempt to learn 
more about this devastating disease. 
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6.1.2. SMA as a model system 
As described in section 1.6.4.1, Stevens et al (1997) isolated three immunoglobulin 
light chains from patients which could act as a model system for AL amyloidosis. 
Two of these proteins, REC and SMA were extracted from the urine and lymph 
nodes respectively, from patients with amyloid deposits. The third protein, LEN was 
isolated from the urine of a patient with multiple myeloma with no apparent amyloid 
deposits. This allowed Stevens et al. and others to study the differences between 
these homologous proteins in an attempt to identify pathogenic features that could be 
targeted therapeutically. 
6.1.3. Previous characterisation  
Various studies have investigated the biophysical and morphological properties of 
LEN, REC and in particular SMA (Khurana et al., 2003). The aggregation 
characteristics of SMA have been studied over a wide range of pH values (Ionescu-
Zanetti et al., 1999). Results have shown that fibril formation is favoured by 
destabilising environmental conditions such as low pH ( pH 2) or in the presence of 
denaturants (Khurana et al., 2001). This work led to the identification of two partially 
folded intermediate conformations, IN and IU. IN is a relatively native-like 
conformation whereas IU was less structured (Khurana et al., 2001).  Structural 
investigation into these intermediate species revealed that IN led to amorphous 
aggregation (Route 1, Figure 6.1) whereas IU readily formed fibrils (Route 2, Figure 
6.1) (Qin et al., 2007). The data collected on SMA was also compared with data for 
the non-amyloidogenic light chain LEN (Khurana et al., 2003). This showed that 
LEN was more stable at all pH values and despite the presence of intermediate 
species, were very short lived and populated at much lower levels. It was, therefore, 
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proposed that the presence of long-lived, partially folded intermediate species, 
greatly contributed the amyloidogenicity of SMA.  
 
 
Figure 6.1 Proposed models of SMA (and light chain in general) amyloid 
formation. The monomer can form a native-like partially folded intermediate 
that preferentially forms amorphous aggregates (3.) and a more unfolded 
intermediate that preferentially forms fibrils (2.) (Qin et al., 2007). A third 
model suggests that light chain dimers are able to stack with a 90 ° rotation, 
forming protofibrils and ultimately fibrils (1.) (Stevens et al., 1995a). 
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Morphological analysis of SMA at a range of pH values studied by TEM, atomic 
force microscopy (AFM) and in the presence of different surfaces has shown that it is 
capable of forming a wide range of morphologies. At low pH large numbers of fibrils 
are formed rapidly, at slightly acidic pH amorphous aggregation predominates with 
very few fibrils observed and at physiological pH large amyloid-like fibrils are seen 
(Ionescu-Zanetti et al., 1999). Fibril growth has been shown to accelerate in the 
presence of surfaces (Zhu et al., 2002) or lipid membranes (Meng et al., 2008) 
however they did not seem to alter the morphology. 
6.1.4. Structural information 
There does not appear to be any link between the sequential differences between 
amyloidogenic and non-amyloidogenic proteins. The possibility of intermediate 
species and the range of observed morphologies emphasise the need for detailed 
structural information. In 1997, Huang et al solved the structure of the non-
amyloidogenic LEN using X-ray crystallography (Figure 6.2) (Huang et al., 1997). It 
has a very similar structure to other variable light chain domains with a typical 
immunoglobulin fold, a 2-layer -sandwich with between 7 and 9 anti-parallel -
strands (Figure 6.2) (Bork et al., 1994).  
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Figure 6.2 Dimer structure of LEN (PDB ID: 1LVE) solved by X-ray 
crystallography. Figure adapted from Huang et al (1997) with each monomer 
individually coloured and visualised in PyMOL. 
 
LEN, like other immunoglobulin light chains forms a dimer. In their native states 
SMA and REC also form dimers; it is thought that increased dimer stability may 
contribute to amyloid formation (Stevens et al., 1995b). A model proposed by 
Stevens et al (1995), suggested that fibril formation is initiated by dimers stacking on 
top of one another, each rotated 90° around the fibril long axis (Route 2, Figure 6.1). 
Although the structure of LEN can be used to map differences in sequence to 
possible structural changes, there remains a need for detailed structural information 
of the pathogenic light chain aggregates. 
Large fibrillar aggregates are unsuitable for crystallisation due to the inherent nature 
of the fibres and the lack of long range order. Furthermore, they are not amenable to 
study by solution state NMR due to their insoluble nature and size. The most 
appropriate technique is currently solid state NMR. This technique enables the study 
of large insoluble aggregates and can provide structural information about aggregate 
architecture. This in turn could reveal diagnostic information about the differences 
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between amyloidogenic and non-amyloidogenic light chains or guide therapeutic 
strategies. 
The principal aim of the work described in this chapter is to develop an expression 
protocol for the production of isotopically (
13
C, 
15
N) labelled SMA, which is an 
essential precursor to detailed solid-state NMR analysis. Methodology is described 
for the production of SMA aggregates and preliminary solid-state NMR are 
presented which demonstrate the feasibility of investigating the structure of these 
protein aggregates using a mixture of 
13
C and 
15
N isotope labels. 
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6.2. Materials and methods 
6.2.1. Vector – pKIV007 
The vector containing SMA was transformed into E.coli JM83 cells and supplied as 
an agar stab from Dr. Fred Stevens (Argonne national laboratory, U.S.A.) An 
overnight culture was inoculated using the stab and the plasmid extracted using a 
mini prep kit (Qiagen). The vector was then transformed into XL1 blue and BL21 
(DE3) E.coli strains to build up vector stocks and carry out expression trails 
respectively.  
The pKIV007 vector was designed in Dr. Fred Stevens’ lab and is based on the 
p40ASK vector and contains ampicillin antibiotic resistance. It contains no affinity 
tags (Stevens et al., 1995b). 
6.2.2. Expression and purification of pKIV007 
Expression trials and growth conditions for pKIV007 were the same as carried out 
for medin. In brief, the vector was transformed into E.coli BL21 (DE3) competent 
cells. A single colony was then selected and grown in 50 ml of Luria broth (LB) 
(Appendix 1) containing antibiotic overnight at 37 °C. This culture was then spun 
down at 3000 x g and used to inoculate 2 L of LB. The culture was incubated at 37 
°C until an OD600 = 0.8 was reached. Expression of the fusion protein was induced by 
the addition of IPTG to a final concentration of 1 mM. Cell growth was then allowed 
to continue 30 °C for 3 hours prior to harvest by centrifugation. All the samples were 
then lysed by sonication and then centrifuged at 19000 x g, the supernatant and pellet 
were collected for analysis by SDS-PAGE. 
The resuspended cells were subjected to a single freeze-thaw cycle prior to 2 French 
press cycles in the presence of DNase at a final concentration of 20 ng/ml and a 
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cOmplete EDTA-free protease inhibitor cocktail tablet (Roche applied sciences). The 
lysed cells were then centrifuged at 19000 x g to remove the cell debris and the 
supernatant filtered through a 0.22 µm Acrodisc
TM
. All purification columns were 
run on an AKTA protein purification system (GE Healthcare) at a flow rate of 2 
ml/min unless otherwise stated. Samples were loaded via the peristaltic pump at a 
flow rate of 2 ml/min. 
6.2.2.1. Anion exchange chromatography 
In order to isolate SMA from the crude extract a combination of anion and cation 
exchange chromatography was performed.  
A HighTrap Q FF column (GE Healthcare) was equilibrated with 3 CV of IE A 
buffer (Appendix 1), 3 CV of IE B buffer followed by a further 3 CV of IE A buffer. 
The high PI of SMA (8.9) prevented binding to the column and the flow through was 
therefore collected for further purification.  
The flow through was then buffer exchanged using a HiPrep 26/10 desalting column 
(GE Healthcare). The column was equilibrated with 2 CV IE C buffer and the sample 
loaded onto the column. The desalted protein was collected in 2 ml fractions and then 
pooled prior to cation exchange. 
Cation exchange chromatography was used to separate SMA from other proteins 
with a high PI. A HighTrap SP FF column (GE Healthcare) was equilibrated with 3 
CV of IE C buffer (Appendix 1), 3 CV of IE D buffer followed by a further 3 CV of 
IE C buffer. The desalted protein was again loaded onto the column. The proteins 
were separated and eluted in three steps: 15 % gradient over 5 CV, a further 5 CV at 
15 % followed by a gradient from 15-100 % over 10 CV. 
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6.2.2.2. Size exclusion chromatography 
The final purification step was size exclusion chromatography. A Superdex 10/300 
gel filtration column (GE Healthcare) was equilibrated with 3 CV of GF buffer.  
Separation was carried out at a flow rate of 1 ml/min and 2 ml fractions were 
collected. 
6.2.3. Subcloning 
The pKIV007 vector was subcloned into pOPINS in an attempt to improve the 
expression yield and facilitate purification. Subcloning was carried out according to 
Berrow et. al (2009) as described in section 3.2.1.6 using the following primers: 
 
Forward SUMO primer 
GCG AAC AGA TCG GTG CAG ACA TCG TGA TGA CCC AG 
Reverse SUMO primer 
ATG GTC TAG AAA GCT TTA TCA CCH TTT GAG TTC CAG TTT 
 
 
6.2.4. Expression and purification of SUMO-SMA  
As described in section 3.2.1.6 the pOPINS vector introduces a N-terminal his6-tag 
for affinity purification and a SUMO protein to aid solubility. A schematic of the 
SUMO-SMA fusion protein is shown in Figure 6.3. 
 
Figure 6.3 Schematic of the SUMO-SMA construct, red arrow indicates 
cleavage site.  
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6.2.4.1. Expression trials and conditions 
Expression trials of the pOPINS-SMA vector were carried out as described in section 
3.2.1.8. The resultant growth conditions were the same as for pKIV007 except the 
induced culture was allowed to grow overnight prior to harvest instead of 3 hours. 
6.2.4.2. SDS PAGE analysis 
The expression and purification of SMA was analysed by SDS-PAGE using the 
Laemmli method (Laemmli, 1970). Analysis was carried out using 15% 
polyacrylamide gels in a Bio-Rad gel electrophoresis system. 5 l protein samples 
were added to 5 l of 2 x sample buffer, boiled and loaded onto the gel. All gels were 
run at 180 V for 60 minutes and then stained with Coomassie Brilliant Blue G-250 
stain and de-stained with destain solution (Appendix 1). 
6.2.4.3. Tryptic digest and MALDI -MS 
Purified peptide (approx 2 g) was resuspended in 50 mM ammonium bicarbonate 
pH 7.8 containing 2 M urea and digested overnight with 0.1 g trypsin. The resulting 
peptides were cleaned up using C18 Zip Tips (Millipore) in preparation for analysis 
by either MALDI-MS or ES-MS. MALDI-MS analysis was performed using a 
MALDI-TOF instrument (Waters-Micromass) on samples dried on to the target plate 
using a saturated solution of -cyano-4 hydroxycinnaminic acid in 50% acetonitrile  
with 0.1% trifluoroacetic acid.  
6.2.4.4. Intact mass analysis using ES-MS 
For intact mass analysis, freshly prepared purified SMA sample was infused into the 
nano electrospray source of the mass spectrometer (Waters Q-ToF micro), at a flow 
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rate of 150 l/hour, via a gas tight syringe. The positive ion mass spectrum of the 
sample was recorded. 
6.2.5. Characterisation of SMA aggregation under different buffer conditions 
It has previously been reported that SMA aggregates differently under different pH 
conditions. This work investigated the aggregation of SMA at pH 2, pH 5.6 and pH 
7.4, three previously described conditions detailed in Table 6.1.  
 
Table 6.1 Different aggregation conditions for SMA 
pH Buffer components 
Temperature 
(°C) 
2 20 mM HCl 25 
5.6 50 mM sodium acetate, 100 mM NaCl 37 
7.4 20 mM sodium phosphate, 150 mM NaCl 37 
 
6.2.5.1. Secondary structure analysis by circular dichroism 
Changes in secondary structure of SMA at the end of the aggregation time course 
was assessed using far-UV synchrotron radiation circular dichroism (SRCD). 
Experiments were carried out at beam line B23 at Diamond light source (Oxford, 
U.K.). Freshly prepared SMA was incubated at a concentration of 40 M (as 
previously described (Zhu et al., 2002)), at the three different pH conditions. After 14 
days the aggregate suspension was placed in the cuvette (121.000-QS Hellma, 
Southend-on-Sea, U.K.). Four scans were recorded between 180 and 260 nm, using a 
slit width of 0.5 mm, 0.5 cm path length and a scan rate of 1 nm/sec and averaged. 
The baseline was subtracted prior to secondary structure analysis. Analysis was 
carried out using Olis
®
 GolbalWorks software. Data at each time point was subject to 
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two fitting methods, CONTILL and CDSSTR, using either basis sets 8 or 11 (Van 
Stokkum, 1990, Sreerama, 2000, Manavalan, 1987). The best fit, as determined by 
the normalised spectral fit standard deviation, was selected and the percentage -
helix, -sheet, turn and random coil content recorded.  
6.2.5.2.  Morphology analysis by transmission electron microscopy 
Morphologies of the insoluble SMA aggregates formed under the three pH 
conditions were visualised using transmission electron microscopy (TEM). Peptide 
suspensions (10 L) were loaded onto carbon coated copper grids held between 
tweezers. Excess solution was removed by placing the grid perpendicular to blotting 
paper. The grid was then inverted onto a droplet of dH20 to wash off excess peptide 
aggregates. The grid was blotted again before being inverted onto a droplet of 4 % 
uranyl acetate to negatively stain the aggregates. Excess stain was removed by 
blotting before allow the grid to air dry prior to visualisation. The grids were 
observed using a Technai 10 electron microscope operating at 100 kV. 
6.2.6. NMR studies  
6.2.6.1. Preparation of 13C and 15N isotopically labelled SMA mixture 
5 mg of 
13
C and 10 mg of 
15
N isotopically labelled SMA were mixed and incubated 
at a final concentration of 40 M, at 37 °C for 3 weeks with agitation. The resultant 
fibrils were harvested by centrifugation at 21 000 g and transferred to a 3.2 
zirconium solid state NMR rotor with a boron nitrate cap (Bruker U.K.)  
6.2.6.2. Frequency selective REDOR experiment  
Frequency selective REDOR experiments were conducted as described in section 
5.2.2.5. 
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6.2.7. SMA model 
Given the sequence similarities between medin and LEN, models of medin were 
generated using the structure of LEN derived from X-ray crystallography 
measurements (PDB ID: 2LVE). Modelling was carried out using Modeller V9.11 on 
full length SMA (Eswar et al., 2007).  
6.2.7.1. Model validation and distance measurements 
An ensemble of 20 models was generated for each template and the best model of 
each ensemble selected based on the lowest molecular pdf score (molpdf), which is a 
standard MODELLER scoring function and is simply a sum of all the restraints 
(Eswar et al., 2007). WHAT IF scores were then calculated for each model and 
compared with those for the template models (Vriend, 1990). Chimera software was 
used to identify steric clashes within the models (Yang et al., 2012). Visualisation of 
models and distances between residues were calculated in PyMOL molecular 
graphics system version 1.5.0.4 (Schrödinger LLC.). 
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6.3. Results 
6.3.1. Expression and purification of pKIV007 
SMA was initially expressed using the clone and expression procedures described by 
Stevens et al (1997). Where possible, expression and purification conditions, were 
followed, although some changes were necessary to accommodate differences in 
laboratory equipment and E.coli strain availability. As described in section 3.2.2.4, 
the vector was provided as an agar stab in E.coli JM83 cells. These cells were not 
available to buy at the time of this work therefore expression tests were carried out in 
E.coli BL21 (DE3) which are used routinely for protein expression in this laboratory. 
If the protein had over-expressed, a large band would be expected at approximately 
12 kDa. Overall tests showed that there was not a high level of over-expression and 
that the peptide ran slightly above the expected molecular weight upon SDS-PAGE 
analysis. However, the results indicated that the optimal expression conditions for 
SMA within this vector were 5 hours at 18 °C (Panel A, Figure 6.4). Due to the lack 
of affinity tag within this vector, SMA was purified from the crude extract using a 
combination of ion exchange and size exclusion chromatography.  
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Figure 6.4 15 % SDS-PAGE of expression trials of SMA in the pKIV007 vector.  
Where P denoted pellet sample, SN denotes supernatant and ON means 
overnight. 
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6.3.1.1. Ion exchange chromatography purification 
Initially anion exchange chromatography was carried out pH 8. SMA has a pI of 8.5 
and therefore carries an overall positive charge at pH 8 thus did not bind to the 
quaternary ammonium group on the resin of the Q FF column and eluted in the 
column flow though. This step quickly removed a large number of contaminating 
proteins.  
The flow through was successfully desalted into IE C buffer (pH 5.6) (buffer 
composition given in Appendix 1) in preparation for cation exchange 
chromatography. At pH 5.6 SMA has an overall positive charge and therefore binds 
to the negatively charged sulphopropyl group of the resin. SMA was eluted during a 
gradient of NaCl (20 % over 20 CV). SDS-PAGE electrophoresis was performed to 
identify the fractions containing SMA. These were pooled and concentrated prior to 
size exclusion chromatography. 
6.3.1.2. Size exclusion chromatography purification 
Size exclusion chromatography was used to further purify SMA and ensure that there 
were no remaining contaminating proteins as a result of peak overlap. The 
chromatogram shows a large narrow peak eluting after approximately 19 ml 
consistent with a protein of similar size to SMA (Figure 6.5). There is a small 
shoulder that precedes the large peak which may represent a dimer species in line 
with the known dimer properties of immunoglobulin light chains.  
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Figure 6.5 Gel filtration trace chromatogram of S column fractions. Separation 
was carried out on a Superdex 75 10/300 gel filtration column (GE Healthcare) 
in 10 mM NaOAc, pH 5.6  at 2 ml/min. 
 
The overall yield of SMA was very low, less that 1 mg/L of rich culture medium. 
The initial expression yield was low and the large number of purification steps 
resulted in a very low overall yield. The yield is likely to be much lower still when 
expressed in a minimal medium required for isotope labelling, the goal of this work. 
It was thought by sub-cloning into pOPINS might improve the expression yield and 
reduce the number of purification steps required, both by saving time and potential 
losses. 
6.3.2. Sub-cloning of SMA into pOPINS vector 
The SMA sequence was successfully amplified using the vector specific primers and 
confirmed by agarose gel electrophoresis. The SMA gene is 357 bp in size and a 
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large band visible at the appropriate size (Lane 2. Figure 6.6).  The pOPINS vector 
was prepared as described previously (section 3.2.1.6). The In-Fusion™ reaction was 
successfully carried out and a mixture of blue and white colonies was observed. 
Several white colonies were selected, grown and the plasmids purified and sent for 
sequencing. The sequencing data confirmed the insertion of the SMA gene into the 
pOPINS vector (Appendix 2) however there was an additional alanine present in at 
the N-terminus. Due to the location and nature of this residue it was decided not to 
sub-clone again and to continue work with this construct. 
 
Figure 6.6 Agarose gel of amplified SMA gene generated using the pOPINS 
specific primers. Lane 1. 100 bp DNA ladder (NEB), Lane 2, amplified SMA 
gene. 
 
6.3.3. Expression and purification of SMA in pOPINS vector. 
6.3.3.1. Expression tests 
The new vector was subject to expression tests to find the optimal expression 
conditions. The ultimate aim of this work was to develop a protocol for the 
expression and purification of isotopically labelled SMA in preparation for structural 
studies. Expression of isotopically labelled protein requires growth in minimal media 
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with single carbon and nitrogen sources. Consequently it was decided to carry out the 
expression tests in minimal media from the outset. Results in Figure 6.7, clearly 
show that the overall expression is substantially higher than that observed for the 
pKIV007 vector despite the change from enriched to minimal growth media. Optimal 
conditions were observed following an overnight incubation, although there is little 
difference between the three temperatures (Panel B, Figure 6.7). Overnight 
incubation at 30 °C was selected for future growth. 
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Figure 6.7 15 % SDS-PAGE of expression trials of SMA in the pOPINS vector.  
Where P denoted pellet sample, SN denotes supernatant and ON describes 
overnight incubation. 
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6.3.3.2. Purification of SMA  
The overall purification strategy for SMA in the pOPINS vector mirrored the steps 
involved in purifying medin: affinity purification, a desalt step, cleavage of the tag 
and reverse affinity purification. Full details can be found in sections 3.2.2.4 and 
3.2.2.5). Following lysis SMA was isolated from the crude extract using affinity 
purification.  
 
Figure 6.8 Affinity purification chromatogram of the fusion protein isolation. 
Sample was run on a 5 ml HisTrap™ FF column (GE Healthcare) in histrap 
buffer A. Step gradient of histrap buffer B shown in blue (Appendix 1).   
 
This efficiently isolated SMA from the crude extract (Figure 6.8). Fractions from this 
stage were collected and pooled prior to desalting. SDS-PAGE analysis confirmed 
that the tag was then successfully cleaved from SMA using SUMO protease after 3 
hours incubation at 25 °C. Cleaved SMA was then passed back through the His-
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Trap™ column removing any residual contaminants, the protease and the tag (Lane 
2, Figure 6.9). 
 
Figure 6.9 15 % SDS-PAGE analysis of purified SMA. Lane 1. Low molecular 
weight markers (Sigma Aldrich), Lane 2. Purified SMA. 
 
This proved to be a successful purification method for SMA and resulted in an 
improved yield when compared with the pKIV007 vector – approximately 5 mg/L of 
culture. 
6.3.4. Confirmation of SMA  
In order to confirm isolation of the correct protein both tryptic digest and intact mass 
spectrometry analysis were performed.  
Tryptic digest fragments were subject to MALDI mass spectrometry to obtain mass 
data. Digest prediction was performed using MASTCOT peptide mass fingerprint 
(Perkins et al., 1999) and detected 9 possible fragments, 7 of which were obtained 
experimentally suggesting that the purified protein has the correct sequence for SMA 
(Table 6.2).  
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Table 6.2 Tryptic digest fragments of SMA, detailing the sequence, expected 
mass from digest and actual masses obtained from MALDI. 
Fragment sequence 
Expected 
mass 
MALDI 
ADIVMTQSPDSLAVSLGER 1988.9 1990 
ATINCK 649.3 649.0 
SSQSVLYSSNNR 1341.6 1341.7 
NYLAWYQQK 1213.6 1213.6 
LGQPPK 639.3 638.2 
LLIYWASTR 1122.6 1122.7 
ESGVPDR 759.3 759.0 
FSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSHPQTFGQGTK 4578.0 N/A 
LELK 502.3 - 
 
MS-MS data for the intact protein shows a large peak at 12804 Da, the exact 
expected mass of SMA (+ alanine), confirming purification of the correct protein 
(Figure 6.10). 
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Figure 6.10 MS-MS data of purified protein peak, showing a large peak at 12804 Da, consistent with the correct mass for SMA. 
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6.3.5. Characterisation of SMA aggregation under different buffer conditions 
The aggregation of SMA has previously been studied at a wide range of pH values 
primarily using ThT and AFM (Ionescu-Zanetti et al., 1999, Meng et al., 2008). In 
order to ensure that the SMA produced in the pOPINS vector exhibited similar 
properties, it was characterised under three previously described conditions (Ionescu-
Zanetti et al., 1999) detailed in Table 6.1. This was done with a view to identifying 
conditions to produce aggregates with defined morphology and in sufficient (mg) 
quantities for NMR analysis. 
6.3.5.1. Secondary structure and stability analysis by circular dichroism 
It has been proposed that the stability of early folding intermediates play a key role in 
determining the propensity of SMA, and immunoglobulin light chains in general, to 
self-assemble and the nature of the resultant aggregates (Qin et al., 2007).  It was 
therefore decided to assess the stability of SMA in response to UV radiation under 
the three different buffer conditions. UV radiation can alter protein structure through 
ionising radiation. The primary photochemical process splits the water and the 
fragments can then attack the amide bond resulting in cleavage of the polypeptide 
chain (Johnson et al., 2011). Secondly, it has been suggested that UV radiation, can 
heat the internal water molecules within a protein resulting in conformational change 
and unfolding (Wallace, 2009).  SMA was relatively unstable in response to UV 
radiation under all three conditions. At pH 7.4 SMA seemed the most unstable with a 
large amount of degeneration in the signal (Figure 6.12). UV is merely a model for 
destabilising conditions but it is interesting that SMA is the most unstable at 
physiologically relevant pH conditions.  
 218 
 
 
Figure 6.11  Analysis of SMA stability at pH2 (A.), pH 5.6 (B.) and pH 7.4 (C.) 
in response to UV radiation. Data were recorded over 25 scans at 30 °C on 
freshly prepared SMA (40 M, in pH2 buffer) using far-UV synchrotron 
radiation circular dichroism at beam line B23 at Diamond light source. 
Numbers represent number of repeated exposures to UV beam. 
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CD analysis of the secondary structure of freshly prepared SMA at the three pH 
values showed that different incubation conditions altered the secondary structure 
content (Figure 6.12). At pH 2, secondary structure analysis software reported 100 % 
-helix (Figure 6.13). At pH 5.6 there was a mixture of secondary structure elements 
with a slight preference for -helix (approximately 50 %) (Figure 6.13). At pH 7.4, 
there is much less -helix but approximately 40 % -sheet (Figure 6.13).  
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Figure 6.12 CD spectra for freshly prepared SMA at pH 2, 5.6 and 7.4 (A, B and 
C respectively). Experimental data shown in black, fit in red, residuals are 
shown above. 
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Figure 6.13 Secondary structure comparison of SMA under three different 
buffer conditions, calculated by CDSSTR or CONTILL algorithms. 
 
6.3.5.2. Morphology analysis by transmission electron microscopy 
Analysis of aggregates, formed from SMA following incubation at 30 °C with 
agitation, under three different pH conditions by transmission electron microscopy 
showed very different morphologies. At pH 2, a sparse deposition of small curly 
fibrillar species are seen similar to previously described protofibril species (Flach et 
al., 2012, Kumar et al., 2007) (Panel A, Figure 6.14). By contrast, a very large 
number of amorphous aggregates were formed a pH 5.6. These species were granular 
and quite uniform in size (Panel B, Figure 6.14) At pH 7.4 large twisted fibrils are 
formed with typical amyloid-like dimensions (Panel C, Figure 6.14). At pH 7.4 small 
uniform spherical aggregates are observed similar to oligomer species described in 
several studies (Fändrich, 2012).   
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Figure 6.14 Negatively stained electron microscopy images of SMA aggregates 
formed under different conditions: pH 2, pH 5.6 and pH 7.4 (A, B and C 
respectively). Higher magnification images of boxed areas shown on the right. 
All scale bars represent 1000 nm. 
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6.3.6. NMR experiments 
The final stage of this work was to investigate the feasibility of obtaining solid-state 
NMR information from 
13
C and 
15
N labelled SMA aggregates. It was necessary to 
design a suitable NMR experiment for this purpose, taking into account the amount 
of material produced, the available access to a high-field spectrometer (necessary to 
obtain the highest sensitivity and resolution) and the remaining time and resources 
available for the project. With these considerations in mind, it was decided that 
aggregates produced at pH 5.6 should be examined, as this condition gave rise to the 
highest yield of material.  In addition, the amount of access available on the 850 
MHz National High Field Solid-state NMR spectrometer at the University of 
Warwick (7 days) limited the number and type of experiments that could be 
performed.    
Consequently, it was decided that an experiment on aggregates formed from a 
mixture of uniformly 
15
N labelled SMA and uniformly 
13
C labelled SMA would be 
performed.  By using an appropriate heteronuclear dipolar recoupling experiment (in 
this case frequency-selective REDOR), it would, in principle, be possible to detect 
intermolecular contacts between residues at the interfaces of protein monomers in the 
aggregates.  Two batches of SMA, one with uniform 
13
C labels and a second with 
uniform 
15
N labels were successfully expressed and purified, then mixed and allowed 
to aggregate at pH 5.6 (Figure 6.15). In these aggregates 50 % of the interfacial sites 
between monomers correspond to interactions between a 
15
N labelled monomer and a 
13
C labelled monomer.  
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Figure 6.15 Schematic illustrating the process of forming SMA aggregates with 
mixed isotope labels.  
 
Frequency selective REDOR experiments allow the selective measurement of 
specific inter-atomic distances from uniformly labelled solids. Two experiments are 
carried out: a 
13
C spectrum of the carbonyl region (~170 ppm) is observed after a 
dephasing period in which rotationally synchronous radiofrequency pulses are 
applied at a selective 
15
N frequency (i.e., in the backbone amide frequency range at 
around 120 ppm or at a specific side chain 
15
N frequency). A second, control 
13
C 
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spectrum of the carbonyl region is obtained without pulses applied at the 
15
N 
frequency. If the first spectrum shows diminished intensity compared to the control 
spectrum, then this indicates coupling between the selective 
15
N sites and carbonyl 
13
C sites. For 
13
C-
15
N, such a dephasing is consistent with intermolecular 
13
C-
15
N 
distances of less than 4.5 Å.      
Here the 
15
N dephasing frequency was set to recouple dipolar interactions between 
side-chain nitrogen atoms of lysine and arginine, and carbon atoms of all backbone 
and side chain carbonyl groups.  
 
Figure 6.16 Frequency selective REDOR experiment of mixed aggregates 
formed at pH 5.6 from singly labelled 
13
C and 
15
N SMA. There is a decrease in 
signal between spectra with (black) and without dephasing (red) on the 
15
N 
channel consistent with an intermolecular distance of less than 5 Å.  
 
The REDOR spectra show that a small (approximately 10 %) dephasing occurs when 
the 
15
N pulses are applied (Figure 6.16) providing evidence of close inter-molecular 
contacts (< 5 Å) 
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This preliminary result demonstrates that it is possible to detect couplings between 
backbone and side chain carbonyl groups and K/R amino groups of SMA aggregates. 
Furthermore, the results provide initial constraints on the molecular organisation of 
SMA molecules within the aggregates. 
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6.4. Discussion 
Initial expression and purification of SMA in the pKIV007 vector resulted in low 
protein yield and was therefore unsuitable for the production of large quantities of 
isotopically labelled protein required for ssNMR analysis.  
Sub-cloning of SMA into the pOPINS vector led to increased protein yield and 
reduced purification time. This enabled the production of 
13
C and 
15
N isotopically 
labelled protein in preparation for ssNMR studies.  
Secondary structure and morphological analysis was carried out on recombinantly 
produced SMA at three different pH values. Earlier studies on SMA and other 
amyloidogenic light chains have noted that aggregate formation occurs more rapidly 
upon destabilisation, including low pH. Here, this work investigated the effect of UV 
radiation on the stability of SMA at three different pHs. SMA was unstable under all 
three conditions and seemed the most unstable at pH 7.4. This is consistent with 
previous data on the stability of SMA. Khurana et al, (2003) used urea induced 
denaturation to demonstrate that SMA was unstable at a wide range of pH values 
(Khurana et al., 2003). Notably it was much more unstable that LEN, the non-
amyloidogenic immunoglobulin light chain with only 8 residues different to SMA. 
This instability is likely to contribute to the amyloidogenicity of SMA. 
Secondary structure analysis revealed differences in secondary structure content 
between the three conditions (Figure 6.12). This variation is broadly consistent with 
previous data (Figure 6.14). At pH 2, 100 % -helix was observed (Figure 6.13).  
A mixture of secondary structure elements was recorded at pH 5.6 with a slight 
preference for -helix (Figure 6.13). At pH 7.4, there is a predominance of -sheet, 
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consistent with previous reports and in line with the proposed structure of a -
sandwich (Figure 6.13) (Khurana et al., 2003) 
It must be noted that the CD data in general has a high signal to noise ratio which 
may produce artificial variation in the data and thus compromise the accuracy of the 
secondary structure fitting. However, this data is broadly consistent with other 
secondary structure studies on SMA. 
At pH 2, small curly fibrillar species are seen which resemble previously described 
protofibrillar species (Panel A, Figure 6.14) (Lashuel et al., 2003). At pH 5.6 a large 
number of granular amorphous aggregates were formed. This data fits with previous 
descriptions of SMA aggregated at pH 5.6, where amorphous aggregation is 
dominant (Panel B, Figure 6.14) (Khurana et al., 2001). At pH 7.4 fibrils, similar in 
appearance to the ‘braided’ SMA fibrils described by Ionescu-Zanetti et al (1999) 
were formed (Panel C, Figure 6.14). 
In summary, these data are consistent with previously described characteristics of 
SMA under these conditions. Experiments investigating the stability of SMA in 
response to UV radiation support the hypothesis that destabilisation of monomers is 
likely to contribute to amyloidogenicity. 
Initial solid state NMR studies on SMA aggregates demonstrated that a mixed 
labelling scheme was effective for detecting inter-molecular contacts between 
different monomers. FS-REDOR experiments indicated the presence of close inter-
atomic distances (< 5Å) between lys/arg amino groups and carbonyl groups (Figure 
6.16). A model of an SMA dimer generated by homology modelling of LEN is 
shown in Figure 6.17, arginine and lysine side chains are shown as sticks in red. 
These side chains are too far away from any carbonyl groups in the second monomer 
(in blue) to enable detection in the FS-REDOR experiment (Figure 6.17). Previous 
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models regarding fibril formation of SMA have suggested that aggregate formation is 
initiated by dimer formation and the subsequent stacking of dimers, each rotated 90° 
around the fibril long axis (Figure 6.1) (Stevens et al., 1995a).  
 
Figure 6.17 Homology model of SMA dimer generated using Modeller, viewed 
from the side (A) and down the proposed fibril long axis (B). Modelled using the 
non-amyloidogenic light chain LEN (PDB ID: 2LVE) as a template. Lys and arg 
residues shown in red. Model visualised in PyMol.  
 
These data are not consistent with this model of aggregate formation suggesting a 
distinct pathway. NMR experiments were carried out pH 5.6 as this condition gave 
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rise to the highest aggregate yield and therefore it was hoped the best signal to noise 
ratio. This work demonstrates that it is possible to detect inter-molecular contacts 
between monomers. 
Further structural analysis was beyond the scope of this work but the labelling 
scheme and subsequent FS-REDOR experiments could be used to investigate the 
structure of aggregates formed under a wide range of conditions. This could lead to 
site-specific information about the assembly of SMA monomers into the different 
aggregates and intermediates formed by this immunoglobulin light chain. In turn this 
information could be used to modulate aggregation in potential therapeutic strategies. 
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7. Discussion and future work 
The overall aim of this thesis has been to study the amyloidogenic and structural 
properties of medin and SMA in order to enhance the understanding of 
cardiovascular amyloid and to design molecules for use as therapeutics or 
diagnostics. 
7.1. Medin 
Aortic medial amyloid is the most common form of localised amyloid recorded to 
date (Cornwell, 1982, Westermark and Westermark, 2011). At the inception of this 
project, little was known about the aggregation, structural and toxicological 
properties of medin when compared with the information available for other 
amyloidogenic peptides such as A and IAPP. It is thought that medin is excised 
from the precursor protein lactadherin by enzymatic cleavage but hitherto, there is no 
information available about how this process occurs, or about the protease 
responsible (Larsson et al., 2007). Furthermore, it is not known what affect medin 
deposition has on the cells and tissues within arteries. There is some evidence to 
suggest that medin may have a role in aortic aneurysm and dissection, through the 
weakening of the elastic structures within the arteries, however, this data is primarily 
circumstantial (Peng et al., 2007).  
Previous biophysical studies on medin have identified eight residues at the C-
terminus as being highly amyloidogenic in isolation and this region is thought to 
drive aggregation of full length medin (Larsson et al., 2007). Madine et al (2009) 
studied the biophysical properties of this peptide and suggested a structural model for 
the arrangement of this short peptide within fibrils (Madine et al., 2009a). Chapter 2 
aimed to continue efforts to identify other key amyloidogenic regions (self-
 232 
 
recognition elements) of medin that could be targeted therapeutically. Targeting SRE 
of amyloid proteins has previously been shown to be a successful strategy for 
inhibiting amyloid proteins (Hughes et al., 2000, Madine et al., 2008a). 
Amyloidogenic prediction servers have been shown to identify effectively regions of 
amyloidogenic peptides that drive aggregation (Conchillo-Solé et al., 2007, Tartaglia 
and Vendruscolo, 2008). These servers highlighted three potential self recognition 
areas of medin. Consequently, three synthetic peptides were generated, incorporating 
one, two and three predicted regions (Med 42-49, Med 30-50 and Med 1-50 respectively). 
Initial ThT analysis indicated that Med 30-50 and Med 1-50 both gave rise to a 
characteristic increase in fluorescence consistent with cross- sheet structure, and 
TEM analysis indicated that all three peptides had different morphologies.  
Solid-state NMR is a very powerful tool to investigate the structure of amyloid 
assemblies (Heise, 2008, Tycko, 2006b). Here, ssNMR was used to probe the 
structural differences between aggregates derived from the three different peptides. 
Chemical shift information was consistent with a -sheet conformation at all 
positions with the exception of F43 in Med 42-49.  Rotational resonance experiments 
investigated the packing arrangement of the assemblies; a close contact between F42 
and V46 observed in Med 42-49 by Madine et al (2009) was not seen for Med 30-50 and 
Med 1-50. Analysis of F43 ring dynamics indicated that F43 within Med 42-49 fibrils 
are rigid whereas it is increasingly flexible in Med 30-50 and Med 1-50. There is 
ongoing debate about the role of aromatic residues in amyloid assemblies. Results 
from many different studies show that aromatic residues promote aggregation; early 
studies suggest this was mediated through the formation of  stacking interactions 
(Gazit, 2002). However more recently there are a growing number of reports that 
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suggest hydrophobicity, -sheet propensity, and planar geometry play a more 
important role (Berhanu and Hansmann, 2012a, Cukalevski et al., 2012, Doran et al., 
2012b). Reches and Gazit  (2004)  showed that substituting phenylalanine at position 
43 for either alanine or isoleucine in the octapeptide dramatically reduced its 
amyloidogenic potential (Reches and Gazit, 2004). In contrast, previous studies on 
full length medin substituted F43 and 48 for A in the full length peptide. This study 
reported that these substitutions did not affect the amyloidogenicity of medin 
(Larsson et al., 2007). The data presented in chapter 2 are consistent with both 
studies; F43 in Med42-49 was rigid whereas in Med1-50 it was much more flexible. In 
the context of these results, it may be that  stacking does play a role within Med 
42-49 in the absence of other driving forces. In the larger peptides, this interaction is 
probably superseded by a multitude of electrostatic and hydrophobic interactions at 
different points within the sequence. 
In summary, these results suggest that the three peptides have distinct aggregate 
morphologies and at least two of the predicted self-recognition regions are required 
for fibril formation observed in the disease state. This data suggests that the 
prediction servers were able to accurately identify aggregation-prone regions and the 
use of multiple servers generates more accurate predictions.  
This research has also emphasised that short peptides are often not good structural 
models of full length proteins, as it is apparent that Med42-49 has different structural 
properties to Med1-50. Short peptides can often have different strand orientations and 
packing arrangements, for example A16-22 has an anti-parallel sheet arrangement 
whereas A1-40 has a parallel sheet arrangement (Balbach et al., 2000). This has been 
observed for several different amyloid proteins (Balbach et al., 2000, Goldsbury et 
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al., 2000, Jaroniec et al., 2002) and underlines the need to study the full length 
protein to obtain disease relevant results.  
The three regions identified here, NH2-NAWVA-COOH, NH2-VTGII-COOH and 
NH2- FGSV-COOH, could now be used in the rational design of inhibitory peptides, 
as described previously for other amyloid proteins (Madine et al., 2008a, Hughes et 
al., 2000). This strategy aims to inhibit aggregation by preventing the association of 
subsequent monomers to the assembly through the incorporation of -sheet breaking 
residues. Previous studies have designed inhibitors to the highly amyloidogenic C-
terminal region of medin. One inhibitor in particular, F(A)S prevented the 
formation of large aggregates and demonstrated cyto-protective effect in toxicity 
studies (Madine and Middleton, 2010). This same peptide was tested alongside two 
others, Y(A)S and (A)SV in chapter 4. There are several experimental differences 
between the work described and that by Madine et al (2010) namely the use of 
recombinant medin as opposed to synthetic medin, and continual monitoring by ThT, 
in place of discreet time point measurements. The preliminary results shown in 
section 4.3.4.1 suggest that F(A)S and (A)SV had an effect on the aggregation 
kinetics of recombinant medin, significantly extending the lag time. They did not 
however prevent aggregation as seen by Madine et al. (2010). These results, and 
many previous studies, indicate that targeting the SRE of an amyloidogenic peptide 
with peptide inhibitors can be a successful strategy for therapeutic design. However, 
with regards to medin, further characterisation and optimisation of the current 
peptides is required.  
The work in chapter 3 represents the culmination of many optimisation procedures to 
establish a reproducible expression and purification protocol for medin. Moreover, 
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this protocol has been adapted to produce isotopically labelled medin for NMR 
structural studies. Biophysical and structural characterisation of amyloid proteins 
generally requires relatively large quantities of protein. Furthermore, structural 
studies using NMR require the incorporation of isotope labels. A popular method to 
achieve this is the use of a bacterial expression host, most commonly E.coli. One of 
the many challenges of working with amyloidogenic proteins is the transient nature 
of monomeric species and subsequent formation of insoluble aggregates. Some 
studies have used this inherent insolubility as an advantage during purification 
(Finder et al., 2010), whilst others employ the use of solubility tags (Chen et al., 
2012). This work used the latter to express and purify recombinant medin for the first 
time in sufficient quantities for subsequent structural and biophysical 
characterisation. Although the protocol can now be used for the production of medin, 
there are still some areas that could be optimised further, such as cleavage to improve 
yield and visualisation. 
Previous studies on the characteristics of medin aggregation are limited, and have 
almost exclusively, been carried out on synthetically produced medin peptides 
(Madine et al., 2009a, Madine and Middleton, 2010, Gazit et al., 2007). Synthetically 
produced proteins have been shown to have different aggregation properties to their 
recombinant counterparts (Finder et al., 2010). Furthermore, they often require 
dissolution in organic solvents which do not reflect physiological conditions. The 
work described in chapter 4 is, to date, the most comprehensive in vitro 
characterisation of medin aggregation. Kinetic analysis of medin aggregation using 
ThT assay revealed that medin aggregates in a typical nucleation dependent manner, 
demonstrating a characteristic lag phase, followed by a rapid period of elongation 
and growth (Cabriolu et al., 2010). This approach uses continual monitoring 
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throughout the aggregation time course and can therefore give rise to accurate 
measurement of lag times, elongation rate and maximum fluorescence intensity.  It is 
not possible to rule out any contribution from the presence of ThT but control 
experiments indicate that ThT fluorescence does not change over time in the absence 
of medin and it is currently a standard method for studying amyloid kinetics(Levine, 
1999). Recombinant medin exhibits a lag phase of approximately 30 hours, 
supporting previous data obtained by Larsson et al (2007) who recorded a lag phase 
of 33 hours (Larsson et al., 2007). This lag phase was reduced by the introduction of 
agitation, in agreement with previous observations of other amyloid proteins (Nielsen 
et al., 2001, Serio et al., 2000, Collins et al., 2004). This is significantly quicker than 
the data obtained for synthetic medin which did not reach equilibrium after 21 days 
of incubation.  
In the wider context of amyloid aggregation, medin aggregation is relatively rapid 
although it has a longer lag time than similarly sized amyloid peptides A and IAPP. 
Direct comparisons are difficult to make as there is such large range of aggregation 
conditions used in the literature. These include differences between recombinant and 
synthetic peptides (Finder et al., 2010), seeded and unseeded growth (Kim et al., 
2007) denaturing conditions (Platt et al., 2008) and whether proteins are agitated or 
not (Sasahara et al., 2008). 
In addition to the wide variety of conditions used to characterise amyloid proteins 
there exists the complication of co-localising factors. Amyloid deposits within the 
body are invariably found associated with a variety of additional factors which can 
include other proteins, GAGs and proteoglycans (Papy-Garcia et al., 2011). In order 
to better understand disease processes the role of these additional components needs 
to be taken into consideration. The characterisation of medin aggregation shown in 
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chapter 4, under relatively physiological conditions provides a platform for future 
work into the effect of co-localising factors and toxicity studies.  
Many studies within the amyloid field focus on the identification of structural or 
sequential amyloidogenic motifs used in therapeutics and diagnostics as discussed 
previously. As discussed in detail in chapter 5, medin shares some remarkable 
sequential similarities with A, particularly within the turn region of A stabilised 
by asalt bridge. It was therefore hypothesised, that medin may also contain a 
stabilising salt bridge. Mutagenesis studies showed that residues D25 and K30 have 
an important role in the aggregation of medin as their substitution alters the kinetics 
and morphology of medin. TEM analysis of D25N resulted in the formation of 
oligomer-like species whereas K30I produced an increase in the number of fibrils. 
There are many reports on the toxic potential of oligomeric species and it would be 
critical to assess the toxicity of WT, D25N and K30I aggregates. 
In order to investigate the possibility of a salt bridge further, solid state NMR 
experiments were used to measure the inter-nuclear distance between D25 and K30. 
This was initially attempted with uniformly 
13
C/
15
N double labelled recombinant 
medin but the fibrils were too heterogeneous resulting in insufficient resolution to 
identify the resonances for D25 and K30. As discussed in chapter 6, many amyloid 
proteins have been shown to form polymorphic fibrils (Paravastu et al., 2006, 
Madine et al., 2008c). Distinct structural morphologies of some of these proteins 
have been documented, predominantly for A(Petkova et al., 2002, Paravastu et al., 
2008). In order to study these morphologies in isolation, repetitive seeded growth 
was required (Petkova et al., 2005a). Previous studies have required between 12 and 
15 generations of seeded growth to obtain a homogenous morphology (Paravastu et 
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al., 2008). Seeding medin in a similar way was beyond the possibilities of this work 
due to time constraints and availability of high field NMR instrumentation, but is a 
key consideration for future studies. Alternatively, a synthetically prepared medin 
sample with selective isotope labels was prepared to address this aim. Fibrils derived 
from synthetically prepared medin were investigated and revealed an inter-nuclear 
distance between D25 and K30 of less than 5 Å consistent with salt bridge formation. 
As highlighted in the general introduction, salt bridges occur in several other amyloid 
assemblies (Petkova et al., 2002) and may be a key interaction to target 
therapeutically. However as seen with the salt bridge mutations, one must be 
cautious as with all therapeutics, not to generate a more toxic alternative. It is 
generally accepted that oligomeric species are more toxic that mature fibrils (Kayed 
et al., 2003). Targeting salt bridge interactions may destabilise fibril formation but 
promote oligomer formation, which could result in a more severe pathology.  
The remarkable similarity between medin and A may indicate that there are 
common features or motifs within amyloid proteins. Medin has also been shown to 
share similarity with IAPP (Reches and Gazit, 2004). Likewise, there also data that 
investigate the similarities between A and IAPP. There is evidence that A can 
activate IAPP receptors (Fu et al., 2012) and they share structural and sequential 
similarities (Luca et al., 2007). Further analysis of these common regions and 
comparison with additional amyloid proteins could assist in the design of common 
therapeutics and diagnostics. 
7.2. SMA 
Information from the optimisation of medin production was subsequently used to 
optimise the expression and purification of a second cardiovascular amyloid protein 
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– SMA. AL amyloidosis is a rare yet devastating disease. One of the greatest 
research challenges in the study of AL amyloidosis is to elucidate the mechanism 
that causes such a diverse range of immunoglobulin light chains to form fibrillar 
aggregates. There is a high degree of sequence homology between these 
amyloidogenic light chains and it possible therefore that structural differences govern 
their amyloidogenicity. Due to the variety of amyloidogenic light chain fragments a 
model protein SMA is often used in the study of AL amyloidosis. Chapter 7 
discusses the production of isotopically labelled SMA in preparation of structural 
studies by solid state NMR. Furthermore, SSNMR experiments demonstrate that 
isotopically labelled proteins coupled with high field selective NMR experiments can 
provide site-specific information about the structure of light chain aggregates. This 
work acts as a proof of principle and can be used in the study of many different 
amyloidogenic light chains and other amyloid proteins in general.  
The importance of establishing a recombinant expression protocols for amyloid 
proteins is not limited to economic and efficiency factors. Studies concerning other 
amyloid proteins such as A have shown that synthetic and recombinant proteins can 
have different aggregation properties (Finder et al., 2010).  
 
Overall, this work presents the first comprehensive expression and purification 
protocol for the production of medin. This has enabled the characterisation of its 
aggregation under relatively physiological conditions which can be used to assess the 
role of additional co-localising factors or aggregation inhibitors in future studies. 
This work has also highlighted structural similarities between medin and A, 
opening up the debate about common structural motifs/interactions, their role in the 
aggregation process and implications for therapeutic design and diagnostics. In 
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conclusion this work has enhanced our understanding of medin aggregation and 
provided a platform for future studies into both medin and SMA. 
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Appendix 1 
 
Cell growth media and buffers 
 
Luria Betani (LB) 
 
Component  Final amount in 1L (g) 
Tryptone 10 
Yeast Extract 5 
NaCl 10 
 
Terrific Broth (TB) 
 
Solution A – pH 7.4 and autoclaved 
 
Component  Final amount in 900 mL  
Tryptone 12 g 
Yeast Extract 24 g 
Glycerol  4 mL 
 
Solution B – pH 7.4 and filter sterilised and added to solution A. 
 
Component  Final concentration in 100 mL 
(M) 
Na2HPO4 0.17 
KH2PO4 0.72 
 
Minimal media 
 
Solution A – pH 7.2 and autoclaved 
 
Component  Final concentration in 1L (mM) 
Na2HPO4 88 
KH2PO4 55 
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Solution B – filter sterilised and added to solution A. 
 
For isotopically labelled samples 
13
C-glucose and 
15
NH4Cl are used instead. 
 
Component  Final concentration in 1L (mM) 
Glucose 22 
NH4Cl 19 
MgSO4 1 
CaCl2.H2O 0.1 
Kanamycin/Ampicillin 0.3 
Thymine HCl 0.03 
 
Super optimal broth (SOB) 
 
Component Final concentration in 1L 
Tryptone  20 g 
Yeast Extract  1 g 
NaCl 100 mM 
KCl 2.5 mM 
 
Super optimal broth with catabolite repression (SOC) 
 
Component Final concentration in 1L 
Tryptone  20 g 
Yeast Extract  1 g 
NaCl 100 mM 
KCl 2.5 mM 
Glucose 20 mM 
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Luria Betani –Agar 
 
Component  Final amount in 0.5 L (g) 
Tryptone 5 
Yeast Extract 2.5 
NaCl 5 
Agar 7.5 
Kanamycin/ampicillin 0.03 
 
CMB80 buffer 
 
Component  Final concentration in 1L (mM) 
KOAc 10 
CaCl2 80 
MnCl2 20 
MgCl2 10 
Glycerol 10 % v/v 
 
 
SDS-PAGE, Tris-trycine gel and Western blot buffers 
 
10 x SDS-PAGE Running buffer 
 
Component Final concentration in 1L 
Tris HCl 0.25 M 
Glycine 1.9 M 
Sodium dodecyl sulphate (SDS) 35 mM  (1 % v/v) 
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SDS-PAGE Sample buffer  
 
Component  Final concentration in 10 mL  
Tris HCl 50 mM 
Glycerol 10 % v/v 
SDS 70 mM  
Dithiothreitol 0.01 mM 
Bromophenol blue 1.5 mM 
 
SDS-PAGE gel composition  
 
Component Stacking gel 4% (ml) Resolving gel 15 %(ml) 
30 % Acrylamide 1.3 5 
Tris base 1.5 M pH 8.8 2.5 - 
Tris base 0.5 M pH 6.8 - 2.5 
ddH20 6.1  
SDS 0.1 0.1 
TEMED 7.5 l 7.5 l 
Ammonium persulphate (APS) (10%) 75 l 75 l 
 
Tris-Trycine gel buffer – pH 8.45 
 
Component Final concentration in 1L 
Tris base 3 M 
Sodium dodecyl sulphate (SDS) 10 mM  (0.3 % v/v) 
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Tris-Trycine SDS-PAGE gel composition 
 
Component Stacking gel 4% (ml) Resolving gel 15% (ml) 
30 % Acrylamide 1.3 5 
Tris gel buffer 2.5 3.3 
ddH20 6.2 0.7 
Glycerol - 1 
TEMED 7.5 l 7.5 l 
Ammonium persulphate (APS) (10%) 75 l 75 l 
 
5 x Inner cathode buffer – pH 8.25 
 
Component Final concentration in 1L  
Tris base 0.5 M 
Trycine 0.5 M 
SDS 0.5 % 
 
5 x Outer cathode buffer – pH 8.9 
 
Component Final concentration in 1L  
Tris base 1 M 
 
Tris-trycine sample buffer 
 
Component Final concentration in 1L  
Tris base 0.5 M 
Tricine 0.5 M 
SDS 0.5 % 
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Coomassie stain 
 
Component Final concentration in 1L  
Coomassie Blue R250 0.5 % w/v 
Acetic acid 10 % v/v 
Methanol 40 % v/v 
dd H20 50 % v/v 
 
Coomassie destain solution 
 
Component Final concentration in 1L (% 
v/v) 
Acetic acid 10 
Methanol 40 
dd H20 50 
 
10 x Western blot transfer buffer 
 
Component Final concentration in 1L 
Tris HCl 0.25 M 
Glycine 1.9 M 
Sodium dodecyl sulphate (SDS) 7 mM (0.2 % w/v) 
 
1 x Western blot transfer buffer 
 
Component Final concentration in 1L (% 
v/v) 
10 x Transfer buffer 10 
Methanol 20 
dd H20 70 
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10 x Phosphate buffered saline (PBS) – pH 7.4 
 
Component Final concentration in 1L (M) 
NaCl 1.36  
KCl 0.026 
Na2HPO4 0.1 
KH2PO4 0.017 
 
10 x Tris-acetate-EDTA buffer  
 
Component Final concentration in 1L  
Tris base 48.4 g  
Glacial acetic acid 11.4 ml 
EDTA 3.7 g 
 
 Medin purification buffers 
 
Amylose binding buffer - pH 7.4 
 
Component Final concentration in 1L (mM) 
Tris-HCl 50 
NaCl 150 
EDTA 1 
 
Amylose elution buffer – pH 7.4 
 
Component Final concentration in 1L (mM) 
Tris-HCl 50 
NaCl 150 
EDTA 1 
Maltose 50 
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His-Trap A – pH 7.4 
 
Component Final concentration in 1L (mM) 
NaPO4 20 
NaCl 500 
 
His-Trap B – pH 7.4 
 
Component Final concentration in 1L (mM) 
NaPO4 20 
NaCl 500 
Imidazole 500 
 
Aggregation buffer – pH 7.4 
 
Component Final concentration in 1L (mM) 
NaPO4 20 
NaCl 150 
 
 
SMA purification buffers 
 
IE buffer A – pH 8 
 
Component Final concentration in 1L (mM) 
Tris-HCl 50 
NaCl 10 
EDTA 1 
 
 
IE buffer B – pH 8 
 
Component Final concentration in 1L (mM) 
Tris-HCl 50 
NaCl 500 
EDTA 1 
 270 
 
 
IE buffer C– pH 5.6 
 
Component Final concentration in 1L (mM) 
NaAc 50 
NaCl 10 
EDTA 1 
 
IE buffer D– pH 5.6 
 
Component Final concentration in 1L (mM) 
NaAc 50 
NaCl 500 
EDTA 1 
 
Gel filtration buffer –pH 8 
 
Component Final concentration in 1L (mM) 
Tris-HCl 50 
NaCl 150 
EDTA 1 
 
SMA aggregation buffers 
 
pH 2 
 
Component Final concentration in 1L (mM) 
HCl 20 
 
pH 5.6 
 
Component Final concentration in 1L (mM) 
NaAc 50 
NaCl 100 
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pH 7.4 
 
Component Final concentration in 1L (mM) 
NaPhos 20 
NaCl 150 
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Appendix 2 
Site directed ligase independant mutagenesis (SLIM) primers 
D25N 
Forward long:  
GGT TCC TCC ATC GAA GTT ACC GGT ATC ATC ACC  
Forward short:  
C GGT ATC ATC ACC CAG GGT G  
Reverse long:  
GTA ACT TCG ATG GAG GAA CCC AGG TCA AC  
Reverse short:  
CAG GTC AAC CTG CAG CCA CTG  
 
K30I 
Forward long:  
CAG GTT AAC CTG GGT TCC TCC AAA GAA GTT ACC G  
Short forward:  
C AAA GAA GTT ACC GGT ATC ATC ACC  
Reverse long: 
GAG GAA CCC AGG TTA ACC TGC AGC CAC TG  
Reverse short: 
CAG CCA CTG GTC GTT ACC GTA G  
 
Sequencing data 
Sequencing was performed by GATC Biotech (London, U.K.). Following 
amplification in XL1 blue E.Coli cells, plasmids were purified using a mini-plasmid 
prep kit (Sigma Aldrich) and prepared to a concentration of approximately 
Single read sequencing was performed using T7 forward and reverse primers.  
D25N 
Template MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
Sequencing MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
************************************************************ 
 
Template AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGRLDKQGNFNAWV 120 
Sequencing AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGRLDKQGNFNAWV 120 
************************************************************ 
 
Template AGSYGNDQWLQVNLGSSKEVTGIITQGARNFGSVQFVA 158 
Sequencing AGSYGNDQWLQVNLGSSKEVTGIITQGARNFGSVQFVA 158 
************************************** 
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K30I 
 
Template MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
Sequencing MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
************************************************************ 
 
Template AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGRLDKQGNFNAWV 120 
Sequencing AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGRLDKQGNFNAWV 120 
************************************************************ 
 
Template AGSYGNDQWLQVDLGSSIEVTGIITQGARNFGSVQFVA 158 
Sequencing AGSYGNDQWLQVDLGSSIEVTGIITQGARNFGSVQFVA 158 
************************************** 
 
SMA  
Sequencing      MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
SMA             MGSSHHHHHHGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLME 60 
                ************************************************************ 
 
Sequencing      AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGADIVMTQSPDSL 120 
SMA             AFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGG-DIVMTQSPDSL 119 
                ************************************************ *********** 
 
Sequencing      AVSLGERATINCKSSQSVLYSSNNRNYLAWYQQKLGQPPKLLIYWASTRESGVPDRFSGS 180 
SMA             AVSLGERATINCKSSQSVLYSSNNRNYLAWYQQKLGQPPKLLIYWASTRESGVPDRFSGS 179 
                ************************************************************ 
 
Sequencing      GSGTDFTLTISSLQAEDVAVYYCHQYYSHPQTFGQGTKLELKR 223 
SMA             GSGTDFTLTISSLQAEDVAVYYCHQYYSHPQTFGQGTKLELKR 222 
                ******************************************* 
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Appendix 3 
Medin DARR spectra overlaid with simulated spectra for random coil (A) and -
helix (B) conformations. 
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Appendix 4 
Alignment file: 
>P1;2beg 
structureX:2beg:17    :D :42  : :Abeta:: 1.90: 0.19 
LVFFAEDVGSNKGAIIGLMVGGVVIA* 
 
>P1;1med 
sequence:1med:20    : :50   : :medin:: 2.00:-1.00 
DQWLQVDLGSSK-EVTGIITQGARNF*  
 
Input file: 
# Homology modeling by the automodel class 
from modeller import *              # Load standard Modeller 
classes 
from modeller.automodel import *    # Load the automodel class 
 
log.verbose()    # request verbose output 
env = environ()  # create a new MODELLER environment to build 
this model in 
 
# directories for input atom files 
env.io.atom_files_directory = './:../atom_files' 
 
# Read in HETATM records from template PDBs  
env.io.hetatm = False 
 
a = automodel(env, 
              alnfile  = 'med.ali',     # alignment filename 
              knowns   = '2beg',              # codes of the 
templates 
              sequence = '1med')              # code of the 
target 
a.starting_model= 1                 # index of the first model  
a.ending_model  = 6                 # index of the last model 
                                    # (determines how many 
models to calculate) 
a.make()                            # do the actual homology 
modeling 
 
